
Integrated Analysis Plan

Clinical Study Protocol Identification No.	EMR700568-012														
Title	Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE)														
EudraCT Number	2009-017978-21														
Study Phase	Non-Experimental registry														
Investigational Medicinal Product(s)	Cladribine Merck Europe 10 mg tablets Cladribine is an adenosine deaminase-resistant analogue of deoxyadenosine that exerts its effect in MS via prolonged suppression of peripheral lymphocyte counts														
Clinical Study Protocol Version	20 July 2016 / Version 4.0 including amendment No.2														
Integrated Analysis Plan Author	Coordinating Author PPD [redacted] Merck PPD [redacted] Function Author PPD [redacted] PP [redacted] PPD [redacted]														
Integrated Analysis Plan Date and Version	21 November 2018 / Version 1.0														
Integrated Analysis Plan Reviewers	<table><thead><tr><th>Function</th><th>Name</th></tr></thead><tbody><tr><td>PPD [redacted] Merck</td><td>PPD [redacted]</td></tr><tr><td>PPD [redacted] Merck</td><td>PPD [redacted]</td></tr><tr><td>PPD [redacted] Merck</td><td>PPD [redacted]</td></tr><tr><td>PPD [redacted] , PP [redacted]</td><td>PPD [redacted]</td></tr><tr><td>PPD [redacted]</td><td>PPD [redacted]</td></tr><tr><td>PPD [redacted]</td><td>PPD [redacted]</td></tr></tbody></table>	Function	Name	PPD [redacted] Merck	PPD [redacted]	PPD [redacted] Merck	PPD [redacted]	PPD [redacted] Merck	PPD [redacted]	PPD [redacted] , PP [redacted]	PPD [redacted]	PPD [redacted]	PPD [redacted]	PPD [redacted]	PPD [redacted]
Function	Name														
PPD [redacted] Merck	PPD [redacted]														
PPD [redacted] Merck	PPD [redacted]														
PPD [redacted] Merck	PPD [redacted]														
PPD [redacted] , PP [redacted]	PPD [redacted]														
PPD [redacted]	PPD [redacted]														
PPD [redacted]	PPD [redacted]														

This document is the property of Merck KGaA, Darmstadt, Germany, or one of its affiliated companies. It is intended for restricted use only and may not - in full or part - be passed on, reproduced, published or used without express permission of Merck KGaA, Darmstadt, Germany or its affiliate.

Copyright © 2018 by Merck KGaA, Darmstadt, Germany or its affiliate. All rights reserved.

Approval Page

Integrated Analysis Plan: EMR700568-012

Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE)

Merck Responsible

Date

Signature

PPD

Via ELDORADO approval process

[Redacted]

[Redacted]

1 Table of Contents

Integrated Analysis Plan.....	1
Approval Page	2
1 Table of Contents	3
2 List of Abbreviations and Definition of Terms.....	6
3 Modification History.....	7
4 Purpose of the Integrated Analysis Plan	8
5 Objectives and Endpoints.....	8
6 Overview of Planned Analyses	9
6.1 Intermediate Analyses.....	9
6.2 Final Analysis	9
7 Changes to the Planned Analyses in the Clinical Study Protocol.....	10
8 Protocol Deviations and Analysis Populations	12
8.1 Definition of Protocol Deviations and Analysis Sets.....	12
8.2 Definition of Analysis Populations and Subgroups	12
9 General Specifications for Data Analyses.....	13
9.1 Treatment groups	13
9.2 Analysis Period	14
9.3 Identification of patients	14
9.4 Dictionary coding.....	14
9.5 Study Day 1	15
9.6 Registry Day 1	15
9.7 Baseline.....	15
9.8 End of clinical trial.....	15
9.9 Last date in PREMIERE	15
9.10 Last ALC date with value in PREMIERE	15
9.11 Conversion factors	15
9.12 Handling of missing data	16
9.13 Presentation of continuous and qualitative variables.....	16
9.14 Significance level.....	16
9.15 Software(s).....	16
10 Study Participants	16

10.1	Disposition of Participants and Discontinuations	16
10.2	Protocol Deviations	18
11	Demographics and Other Baseline Characteristics	18
11.1	Demographics	18
11.2	Medical History.....	19
12	Previous Medications or Medications/Procedures in PREMIERE	19
12.1	Previous medications	19
12.2	Medications in PREMIERE.....	19
12.2.1	Disease Modifying Drugs in PREMIERE.....	20
12.3	Procedures in PREMIERE.....	20
12.4	Handling of Partial dates for Medications	20
13	Study intervention Compliance and Exposure.....	21
14	Efficacy Analyses.....	21
15	Safety Analyses.....	21
15.1	Primary Endpoints.....	21
15.1.1	Serious Adverse Events Related to Cladribine	21
15.1.2	Blood and Lymphatic System Disorders	22
15.1.3	Neoplasms Benign, Malignant, and Unspecified.....	23
15.1.4	Lymphopenia.....	23
15.2	Secondary Endpoints: Pregnancy.....	26
15.3	Adverse Events.....	27
15.3.1	All Adverse Events	27
15.3.2	Serious Adverse Events.....	27
15.4	Deaths, Other Serious Adverse Events, and Other Significant Adverse Events.....	28
15.4.1	Deaths.....	28
15.5	Adverse Event of Special Interest.....	28
15.5.1	AESI= Infections.....	28
15.5.2	AESI = Malignancies	30
15.6	Handling of Missing or Partial AE Dates (onset, resolution date).....	30
15.7	Clinical Laboratory Evaluation.....	30
15.8	Vital Signs.....	30
15.9	Other Safety or Tolerability Evaluations	30

16	Analyses of Other Endpoints	31
17	References	31
18	Appendices	32
18.1	Pregnancy and neonatal topics (SMQ 20000185).....	32
18.2	Adverse Events Related to Pregnancy	1
18.3	AESI: Opportunistic Infections.....	1
18.4	AESI Herpes Zoster	3
18.5	Malignant or Unspecified Tumours (SMQ 20000091).....	4
18.6	AESI: Malignancies	1

Table of Contents of Table

Table 1	Changes from the planned analyses in the clinical study protocol	10
Table 2	Table header example	13
Table 3	Identification	14
Table 4	Time intervals.....	17
Table 5	List of MS-DMD.....	20
Table 6	NCI-CTCAE Lymphopenia Grade	23
Table 7	Time window for lymphocyte from first cladribine/placebo dose.....	24
Table 8	Time window for lymphocyte from the end of clinical trial.....	25

Table of Contents of Figure

Figure 1	PREMIERE Registry Overview Diagram.....	9
----------	---	---

2 List of Abbreviations and Definition of Terms

AE	Adverse Event
ADR	Adverse Drug Reaction
ATC	Anatomical Therapeutic Chemical classification
CDISC	Clinical Data Interchange Standards Consortium
CI	Confidence Interval
CMQ	Custom MedDRA query
(e)CRF	(electronic) Case Report Form
CSR	Clinical Study Report
CTCAE	Common Terminology Criteria for Adverse Events
EMA	European Medicines Agency
EudraCT	European Union Drug Regulating Authorities Clinical Trials
FDA	Food and Drug Administration
GCP	Good Clinical Practice
GDS	Global Drug Safety
GPP	Good Pharmacoepidemiology Practices
HLGT	High Level Group Term
HLT	High Level Term
IAP	Integrated Analysis Plan
ICH	International Conference on Harmonization
IEC	Independent Ethics Committee
IRB	Independent Review Board
ISS	Integrated Summary of Safety
KM	Kaplan-Meier
LLN	Lower limit of normal
MedDRA	Medical Dictionary for Regulatory Activities
NA	Not Applicable
NCI-CTCAE	National Cancer Institute – Common Terminology Criteria for Adverse Events
P1	Original cladribine clinical trial physician
P2	Usual health care provider
PRP	Principal registry physician

PT	Preferred Term
RRMS	Relapsing-remitting MS
SADR	Serious Adverse Drug Reaction
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SDTM	Study Data Tabulation Model
SMQ	Standard MedDRA query
SOC	System Organ Class
SUSAR	Suspected Unexpected Serious Adverse Reaction
TEAE	Treatment-Emergent Adverse Event
TLF	Tables, Listings, and Figures
WHO-DD	World Health Organization Drug Dictionary

3 Modification History

Unique Identifier for Version	Date of IAP Version	Author	Changes from the Previous Version
NA			

4 Purpose of the Integrated Analysis Plan

The purpose of this IAP (integrated analysis plan) is to document technical and detailed statistical specifications for the final analysis of data collected for protocol EMR700568-012 called PREMIERE. Results of the analyses described in this IAP will be included in the Clinical Study Report (CSR). Additionally, the planned analyses identified in this IAP will be included in regulatory submissions or future manuscripts. Any post-hoc, or unplanned analyses performed to provide results for inclusion in the CSR but not identified in this prospective IAP will be clearly identified in the CSR.

The IAP is based upon section 9 (Data Analysis and Statistics) of the study protocol and protocol amendments and is prepared in compliance with International Conference on Harmonization (ICH) E9 and Guidelines for Good Pharmacoepidemiology Practices (GPP). It describes analyses planned in the protocol and protocol amendments.

5 Objectives and Endpoints

Objectives	Endpoints (Outcome Measures)	Endpoints (Outcome Measures) Timeframe	IAP section
Primary			
<ul style="list-style-type: none"> To quantify and characterize the risk (cumulative incidence) of serious adverse drug reaction (SADR), including malignancies and serious infections To assess time to resolution of lymphopenia among registry participants with persistent lymphopenia To quantify and characterize the risk (cumulative incidence) of AE in the 'Blood and Lymphatic System Disorders' and 'Neoplasms Benign, Malignant, and Unspecified' System Organ Classes (SOCs) 	<ul style="list-style-type: none"> Cumulative incidence of SADR, including malignancies and serious infections Time to resolution of lymphopenia, among registry participants with persistent lymphopenia Cumulative incidence of all AEs in the "Blood and Lymphatic System Disorders" System Organ Class (SOC) and in the "Neoplasms Benign, Malignant, and Unspecified" SOC 	<ul style="list-style-type: none"> AE crude incidence from Registry Day 1 to End of registry Time to resolution of lymphopenia, for participants with ongoing lymphopenia at the end of clinical trial AE crude incidence from Registry Day 1 to End of registry 	<ul style="list-style-type: none"> Section 15.1.1 Section 15.1.4 Section 15.1.2 & 15.1.3
Secondary			
<ul style="list-style-type: none"> To assess pregnancy outcomes, including congenital malformations or other important health conditions in the offspring born to women exposed to oral cladribine 	<ul style="list-style-type: none"> Pregnancy outcomes, including congenital malformations, spontaneous abortion, elective abortion, stillbirth, ectopic pregnancy, molar pregnancy, and other important health conditions in the offspring 	<ul style="list-style-type: none"> Number of patients with pregnancies from Registry Day 1 to End of registry and descriptive statistics of pregnancy outcomes 	<ul style="list-style-type: none"> Section 15.2

6 Overview of Planned Analyses

Summary of PREMIERE registry

The PREMIERE study is an ongoing prospective observational long-term safety registry of patients who have participated in at least one of the 5 cladribine clinical trials (namely CLARITY [25643], CLARITY EXT [27820], ONWARD [26593], ORACLE [28821] and the pantoprazole drug-drug interaction [DDI] phase I study [27967]). These 5 studies are referred throughout this document under the general term "clinical trials".

The original objectives of the PREMIERE registry were to monitor long-term safety events in a clinical trial population to produce long-term safety data in order to better characterize the potential safety risks of oral cladribine, and to build an evidence-based risk minimization strategy. The study was amended with simplification and including restriction to serious adverse drug reactions (SADR), selected AEs (all AEs in the 'Blood and Lymphatic System Disorders' and 'Neoplasms Benign, Malignant, and Unspecified' SOCs) and reduction of frequency of assessments. The duration of follow-up in the registry is up to the end of the registry or 8 years after the subject's first enrolment into a cladribine clinical trial, whichever occurs first. Last patient last visit for the final analysis was on October 25th, 2018.




Figure 1 PREMIERE Registry Overview Diagram

6.1 Intermediate Analyses

Two intermediate safety synoptic reports have been performed while the study was ongoing (REF. CSR items #1 and #2). The data cut-off for the first analysis was 20 February 2015 and the cut-off for the second analysis was 15 May 2017.

6.2 Final Analysis

All final, planned analyses identified in the Clinical Study Protocol and in this IAP will be performed only after the last participant has completed the study (following protocol definition) with all study data in-house, all data queries resolved as much as possible, and the database locked.

7 Changes to the Planned Analyses in the Clinical Study Protocol

As usual, Statistical Analysis Plans are more detailed than relevant sections of the Study Protocols; such additions and refinements are therefore not mentioned in this section. Instead, only true deviations from statements in the study protocol are listed together with a brief rationale.

Table 1 Changes from the planned analyses in the clinical study protocol

Protocol Section: Item	Protocol definition	Changes implemented in the SAP
Section 5.6: Study Cohort	There will be no control/comparison group	"Never exposed to Cladribine" group will be considered as reference for a long-term non-treated population.
Section 9.2.2: Treatment/Analysis periods	<p>The most relevant analysis period will be the cumulative analysis period, which starts from the date of first dose of clinical trial medication to the end of the registry follow-up. In addition of the cumulative period, three treatment periods are identified:</p> <p>a) the initial treatment period, from the date of first dose of clinical trial medication to end of the clinical trial participation; b) the extension treatment period (when subjects elects to enroll in a cladribine extension trial) from the date of first dose of cladribine to the end of extension trial participation, c) and the registry study period (where subjects do not receive any experimentally assigned treatment) from the date of enrollment into the registry to the end of registry participation.</p> <p>The primary analysis will correspond to the cumulative analysis period, which starts from the date of first dose of clinical trial medication to the end of registry follow-up.</p>	<p>The primary analysis will NOT start from the date of first dose of clinical trial medication to the end of registry follow-up. Reporting for the clinical trial period has been presented in each individual study CSR. In the Integrated Summary of Safety (ISS) for the proposed indication of Cladribine in the treatment of adult patients with relapsing forms of Multiple Sclerosis (RMS), long-term data available at the cut-off date of 15 May 2017 has already been presented exhaustively, including all subjects – those enrolled and those not enrolled in PREMIERE.</p> <p>In order to focus on the long-term safety events that were collected during the registry follow-up, the analysis period for the safety analysis population will be the time from the end of clinical trial + 1 day to the last date in PREMIERE registry.</p> <p>In addition, two analysis periods for the lymphocyte analysis population will be defined:</p> <ul style="list-style-type: none"> • The time from first dose of cladribine/placebo* in clinical trials to the last Absolute Lymphocyte Count (ALC) date with a value available in PREMIERE registry

		<ul style="list-style-type: none"> • The time from first ALC date with value in PREMIERE registry to the last ALC date with a value available in PREMIERE registry * A subject who switches treatment from placebo to cladribine in subsequent studies/periods will be considered from first dose of cladribine and the placebo period will not be considered.
Section 9.2.2 Treatment/Analysis periods	Demographic characteristics (e.g., age, sex) at baseline of the registry will be described using descriptive statistics for continuous variables or proportions for categorical variables at entry into the registry. Summaries will be provided by region/country.	Demographic characteristics will not be summarized by region/country. Instead, based on the understanding of the protocol, summary statistics for the number of subjects by country will be provided.
Section 9.2.1 General Considerations	Time to resolution of persistent lymphopenia will be estimated using the life table methodology.	<p>The time to resolution of lymphopenia (duration of lymphopenia episode) has already been presented in the ISS using the product-limit method of Kaplan and Meier. This analysis will not be repeated.</p> <p>The time to resolution of lymphopenia for participants with ongoing lymphopenia at end of clinical trial will be analyzed using descriptive statistics.</p>
Section 9.2.1 General Considerations	The main analysis will be to estimate cumulative incidence rates using life-table methodology.	<p>The main analysis of adverse events will be done on the period from the end of clinical trial + 1 day to the last date in PREMIERE registry. The life-table methodology will not be used. Rather, the crude incidence will be presented with the corresponding 95% confidence interval.</p> <p>The time to first event from the first dose of cladribine has already been presented in the ISS following the Kaplan-Meier methodology for AESI infections and malignancies. Therefore, it will not be repeated here.</p>

Section 10.2 Subject information and informed consent	Subjects who refuse to enroll in the registry will be asked to sign consent (see CRF: Data Release Participant only) for use of their clinical trial data to compare registry non-participants with registry participants in terms of demographics, cancer risk factors and severity of MS.	Comparison of registry participant's vs non-registry participants will not be performed due to very strong sample size imbalance between the 2 groups. Indeed as the registry target population was of 2175 subjects, 1161 patients enrolled as full participants and 22 refused and signed the data release consent form only.
---	---	---

8 Protocol Deviations and Analysis Populations

8.1 Definition of Protocol Deviations and Analysis Sets

Important protocol deviations are protocol deviations that might significantly affect the completeness, accuracy, and/or reliability of the study data or that might significantly affect a participant's rights, safety, or well-being.

For this study, important protocol deviations will be identified and confirmed at the protocol deviation review meetings.

8.2 Definition of Analysis Populations and Subgroups

The registry target population includes all subjects who participated in Sponsor oral cladribine Phase I to III clinical trials in MS associated with a protocol approved prior to the time of submission of the marketing application and completed (last patient, last visit) after November 2008. This corresponds to five clinical trials (protocol number/study name):

- 25643/CLARITY
- 26593/ONWARD
- 27820/CLARITY EXTENSION
- 27967/Pantoprazole DDI
- 28821/ORACLE MS

Subjects will be analyzed according to their actual exposure to oral cladribine. There will be no per-protocol analysis population excluding patients with protocol deviations.

Safety Analysis Population (SAF)

The Safety Analysis Population will consist of all subjects from studies CLARITY, CLARITY EXT, ORACLE MS and ONWARD who are enrolled in the PREMIERE registry as full participants.

Lymphocyte Analysis Population

The lymphocyte analysis population consists of all subjects from SAF with at least one absolute lymphocyte count (ALC) value in PREMIERE, with an associated ALC date after the end of clinical trial.

DDI Safety Set

The **DDI** Safety Set will include all subjects from the Pantoprazole DDI study who are enrolled in the PREMIERE registry as full participants. In this study, subjects received two single doses of 10 mg cladribine separated by a wash-out of at least 10 days and two 40 mg doses of pantoprazole on two consecutive days. Data from the DDI Safety Set will be presented in listings only.

9 General Specifications for Data Analyses

9.1 Treatment groups

Analyses will be performed on the "as treated principle", where patients are allocated to the treatment group that they actually received in the clinical trial studies (which may be different from the study treatment to which they were randomized to).

Patients are assigned to the following treatment groups according to their actual treatment in one of the studies CLARITY alone, ONWARD, CLARITY/CLARITY EXTENSION, ORACLE MS, Pantoprazole DDI.

- **Never exposed to cladribine:** if a subject has taken only placebo (or placebo +IFN-β) in studies, then her/his data becomes part of the "Never exposed to cladribine" treatment group. A subject who switches treatment from placebo to cladribine in subsequent studies/periods **will not** be considered in this group.
- **Exposed to cladribine:** patients with at least one dose of cladribine. Subjects who were on placebo during the clinical trial and switched to cladribine in the extension study will contribute to the treatment group "Exposed to cladribine" from the moment they initiate cladribine.

An example of the header for table outputs is presented below.

Table 2 Table header example

	Never exposed to Cladribine (N=XXXX)	Exposed to Cladribine (N=XXXX)	Total (N=XXXX)
Safety Analysis Population	xxx (100.0)	xxx (100.0)	xxx (100.0)

9.2 Analysis Period

Analysis period for Safety Analysis Population and the DDI Safety Set

The analysis period for SAF and the DDI Safety Set is the time from the end of clinical trial + 1 day to the last date in PREMIERE.

Analysis period for Lymphocyte Analysis Population

Two analysis periods for lymphocyte analysis population are defined:

1. The time from first dose of cladribine/placebo* in clinical trials to the last absolute lymphocyte count (ALC) date with a value available in PREMIERE registry.
2. The time from first ALC date with a value in PREMIERE registry to the last ALC date with a value available in PREMIERE registry.

*** A subject who switches treatment from placebo to cladribine in subsequent studies/periods will be considered from first dose of cladribine and the placebo period will not be considered.**

9.3 Identification of patients

Patients are identified by their unique subject number taken from the subject ID in their first study. Other variables are created to distinguish their previous trial origin.

Table 3 Identification

Unique Subject Identifier (USUBJID)	First Previous Study Identifier	Last Previous Study Identifier (if diff)	Previous Clinical Trial
PPD [REDACTED]	PPD		CLARITY only
PPD [REDACTED]	PPD		ONWARD
PPD [REDACTED]	PPD	PPD	CLARITY/CLARITY EXTENSION
PPD [REDACTED]	PPD		Pantoprazole DDI
PPD [REDACTED]	PPD		ORACLE MS

9.4 Dictionary coding

The Adverse events (AEs) and Medical History will be coded to MedDRA version 21.0. Concomitant medications will be upgraded with WHO Drug Dictionary version March 2018 (WHODRUG B2 MARCH2018).

9.5 Study Day 1

Study Day 1 is the day of start of first study drug intervention (placebo or cladribine). For patients in the sequence placebo-cladribine, the placebo period is ignored and Study Day 1 is at the start of cladribine. The day before is Study Day -1 (no Study Day 0 is defined).

9.6 Registry Day 1

Registry Day 1 is defined as the end of clinical trial +1 day. The day before is Registry Day -1 (no Registry Day 0 is defined).

9.7 Baseline

Baseline is defined as registry baseline, which is the last assessment prior to or at Registry Day 1.

Unless specified, the demographics at baseline will be computed considering the last assessment prior to or at Registry Day 1.

9.8 End of clinical trial

The end of the clinical trial is defined as the last date of data collection from the last cladribine clinical trials.

9.9 Last date in PREMIERE

Last date in PREMIERE is the last date from any datasets including death and AE start date.

Programming rule to cover possible unclean data:

For subjects who died, last date in PREMIERE is the date of death and all data collected after date of death are ignored.

9.10 Last ALC date with value in PREMIERE

Last ALC date with an associated value (value not missing) in the PREMIERE registry is considered.

Programming rule to cover possible unclean data:

The last ALC date with value in PREMIERE is defined as the last ALC date with value after the end of clinical trial.

9.11 Conversion factors

Unless specified, the following conversion factors will be used to convert days into months or years:

- 1 year = 12 months = 365.25 days

9.12 Handling of missing data

Several attempts are to be made to contact subjects and to limit missing data (see protocol section 9.3.1). There will be no imputation for missing data.

9.13 Presentation of continuous and qualitative variables

Continuous and qualitative variables:

Continuous variables will be summarized using descriptive statistics, i.e.

- number of subjects (N),
- number of subjects with non-missing values,
- mean, standard deviation,
- median, 25th Percentile - 75th Percentile (Q1-Q3),
- minimum, and maximum.

Qualitative variables:

Qualitative variables will be summarized by counts and percentages. Unless otherwise stated, the calculation of proportions will be based on the number of subjects in the analysis set of interest. Therefore, counts of missing observations will be included in the denominator and presented as a separate category.

9.14 Significance level

There are no plans for any statistical inference. This study will adhere to the Guidelines for Good Pharmacoepidemiology Practices (GPP). Accordingly, data evaluations and interpretations will be based on point estimates and 95% confidence intervals (CI) for the evaluation of the statistical precision around the point estimate.

9.15 Software(s)

Analyses will be performed using SAS® Software version 9.4 or higher.

10 Study Participants

The subsections in this section describe the specifications for reporting participant disposition and study discontinuations.

10.1 Disposition of Participants and Discontinuations

Number of subjects screened (*full participant + data release participant*), number of subject enrolled (*full participant*), number of subjects in the SAF and in the DDI Safety Set will be presented by treatment group (never exposed to cladribine and exposed to cladribine) and total.

The number of subjects in the Lymphocyte Analysis Population will be summarized based on the SAF.

Study status will be summarized on the SAF by treatment group and total, presented as

- Completed or
- Discontinued.

Reason for study discontinuation will be summarized. Percentages will be presented with respect to the number of full participants.

Programming rule

Programming rule to cover potential unclean data: Patients who died will be set to study status "Discontinued", with reason ="Death".

Time since end of clinical trial, time since first dose will be summarized in weeks as a continuous variable and in cumulative intervals and in time intervals with the following categories:

Table 4 Time intervals

Cumulative intervals	Time intervals
Less than 12 weeks	1 to 84 days (12 weeks)
At least 12 weeks	85 to 168 days (24 weeks)
At least 24 weeks	169 to 252 days (36 weeks)
At least 36 weeks	253 to 336 days (48 weeks, 1y)
At least 48 weeks, 1y	337 to 420 days (60 weeks)
At least 60 weeks	421 to 504 days (72 weeks)
At least 72 weeks	505 to 588 days (84 weeks)
At least 84 weeks, 2y,	589 to 672 days (96 weeks, 2y)
At least 96 weeks, 3y,	673 to 1008 days (144 weeks, 3y)
Etc.	Etc.

Patient-year will be computed as the sum per group of the time since end of the clinical trial, in years. Patient-year will be presented per treatment group and total.

Reporting on study status will be done for SAF.

████████████████████
████████████████████

████████████████████
████████████████████

The disposition table will be repeated by

- CLARITY only
- CLARITY/CLARITY EXTENSION
- ORACLE MS
- ONWARD

10.2 Protocol Deviations

Important protocol deviations will be summarized by type of deviation. In addition, a listing of PREMIERE important protocol deviations will be provided.

Programming Note

Information will be taken from SDTM.DV dataset.

11 Demographics and Other Baseline Characteristics

Summaries will be presented on SAF by treatment group and total.

11.1 Demographics

The following variables will be presented. Variables with * are computed prior to first clinical trial study.

- Age at baseline (Registry Day 1), years and in categories (<= 40 y, >40 y)
- Sex (male, female)*
- Race*
- Region: America US, America non-US**, Western Europe, Australia, Eastern Europe, Russia, ROW*

**America non-US includes Canada and all countries from South America.

- Previous clinical trial: CLARITY only, ONWARD, CLARITY/CLARITY EXTENSION, ORACLE MS.
- Time since last Cladribine/Placebo dose (weeks)
- Total cumulative dose (mg/kg): summary statistics and in categories 0, >0-3.5, >3.5-5.25, >5.25-7.0, >7.0-8.75, >8.75.

11.2 Medical History

No reporting will be done.

12 Previous Medications or Medications/Procedures in PREMIERE

Medications in PREMIERE will be presented by Category, Therapeutic group (ATC level 2) and Preferred Name, per treatment group and total, using crude incidence:

Crude incidence, in % = (number of subjects with at least one medication / total number of subjects) * 100.

The following categories as reported in the CRF will be presented:

- MS-Related Immunomodulators and Immunosuppressants
programming note CM.CMSPID = 101-199
- MS-Related Symptomatic Medications, including pain control
programming note CM.CMSPID = 201-299
- MS-Related Antidepressants
programming note CM.CMSPID = 301-399
- OTHER MS- AND NON-MS-RELATED
programming note CM.CMSPID = 401-499

12.1 Previous medications

Reporting of previous medications was done previously in each initial study CSR. No reporting will be done for the PREMIERE CSR.

12.2 Medications in PREMIERE

Reporting will be done for SAF.

Medications in PREMIERE are medications (other than cladribine or placebo medications) which are taken by subjects at any time after (>) the end of clinical trial.

Data collection will be derived from PREMIERE dataset Concomitant Medication panel (SDTM.CM). Specifically, medications used during pregnancy collected for female partner of male patients will not be included (SDTM.CM CMCAT = “over the counter medications”, “prescription medications”).

12.2.1 Disease Modifying Drugs in PREMIERE

MS-disease modifying drugs (DMDs) drugs are defined by **custom selection** based on all concomitant medication collected.

Table 5 List of MS-DMD

Preferred Term (WHODD)
ALEMTUZUMAB
BETASERON /01229701/
DIMETHYL FUMARATE
FINGOLIMOD
FINGOLIMOD HYDROCHLORIDE
FUMARIC ACID
GLATIRAMER ACETATE
INTERFERON BETA
INTERFERON BETA-1A
INTERFERON BETA-1B
MITOXANTRONE
MITOXANTRONE HYDROCHLORIDE
NATALIZUMAB
PEGINTERFERON BETA-1A
RITUXIMAB
TERIFLUNOMIDE

Note: the final list of medications may be revised after database lock. Any changes from the list above will be described in the CSR.

12.3 Procedures in PREMIERE

Procedures are not coded in PREMIERE. No reporting will be done.

12.4 Handling of Partial dates for Medications

Missing and partial dates will be imputed considering the fact that medication may be considered as medication taken concomitantly to PREMIERE registry.

- Start missing day will be imputed to be 1 and start missing month will be imputed to be January.
- End missing day will be imputed to be the last day of the month. End missing month will be imputed to the last month of the year. In case of death, imputation rules will assure that no end dates are imputed after death.
- No imputation for complete start date and end date missing (day, month and year), and therefore medication will be ignored.

- If start date is completely missing (i.e. day, month, year missing) and end date is known or partially known then the start date will be imputed to be the Registry Day 1 minus one day if prior to end date, otherwise equal to end date.
- Complete end date missing (day, month and year) and partial or complete start date then will be imputed to be the last study assessment date.

13 Study intervention Compliance and Exposure

Not Applicable (please see section 7).

14 Efficacy Analyses

Not Applicable.

15 Safety Analyses

15.1 Primary Endpoints

15.1.1 Serious Adverse Events Related to Cladribine

Reporting will be done for SAF.

The objective is “to quantify and characterize the risk (cumulative incidence) of SADR, including malignancies and serious infections”.

Definition

The primary endpoint will be selected considering any serious adverse event characterized as Probable or Possible in the relationship to cladribine. Malignancies and serious infections will be considered in this endpoint only if the characteristics “serious” and “related” (“probable” or “possible”) are applicable.

Following protocol section 8.5.1.2, “an adverse drug reaction (ADR) is a response to a medicinal product which is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the restoration, correction, or modification or physiological functions. Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility”.

The treating physician or other relevant concerned health care provider are asked to assess the relationship of the AEs to cladribine using the following definition, similar in all studies:

- Probable: A causal relationship is clinically/biologically highly plausible, and there is a correlation between the onset of the SAE and administration of cladribine, and between withdrawal of cladribine and resolution of the SAE.

- Possible: A causal relationship is clinically/biologically plausible and there is a correlation between the onset of the SAE and administration of cladribine.
- Unlikely: A causal relationship is improbable, and another documented cause of the SAE is most plausible.
- Unrelated: A causal relationship can be definitively excluded, and another documented cause of the SAE is most plausible.

The following statistics will be presented:

- Patient-year is the sum of the time since the end of clinical trial, expressed in years. Display with 1 decimal.
- m is the number of unique events. A unique event is a unique Preferred Term and date of onset per subject.
- n is the number of subjects with at least one event
- N is the total number of subjects in the treatment group
- AE (%) is the crude incidence. Display with 1 decimal.
 - $AE(\%) = (\text{number of subjects with at least one event} / \text{total number of subjects}) * 100$
- 95% Confidence Interval (CI) for the crude incidence within group for patients with at least one AE. The 95% Confidence Interval of the AE will be computed using the exact Clopper-Pearson confidence interval formula for binomial proportions (REF. Clopper item #3).

Statistics description

The following statistics per treatment group and total will be presented:

- Summary: Patient-years will be provided in the summary table. In addition, number of unique event, number of patients with at least one AE, crude incidence (%), 95% CI of the crude incidence. All these statistics will be repeated for AE leading to death and serious AE.

Note: SADR is a serious AE by definition. Therefore, only SADR and SADR leading to death will be presented.

- By SOC/ HLGT/ HLT/PT: Number of patients with the AE and crude incidence (%) will be presented by system organ class (SOC), High Level Group Term (HLGT), High Level Term (HLT), and preferred term (PT).

15.1.2 Blood and Lymphatic System Disorders

Reporting will be done for SAF.

Any adverse event preferred term belonging to the MedDRA SOC="Blood and Lymphatic System Disorders" will be selected.

Statistics as presented for section 15.1.1, Serious Adverse Events Related to Cladribine, will be repeated.

15.1.3 Neoplasms Benign, Malignant, and Unspecified

Reporting will be done for SAF.

Any adverse event preferred term belonging to the MedDRA SOC="Neoplasms Benign, Malignant, and Unspecified" will be selected.

Analyses as presented for SOC="Blood and Lymphatic System Disorders" will be repeated.

15.1.4 Lymphopenia

Unless specified, reporting will be done for the Lymphocyte Analysis Population.

Evolution of absolute lymphocyte count (ALC) and specifically lymphopenia is of primary interest for treatment with cladribine.

ALC will be tabulated by grade using the NCI-CTCAE version v3.0, and lymphopenia grades are defined as follows:

Table 6 NCI-CTCAE Lymphopenia Grade

Laboratory Toxicity	Grade 1	Grade 2	Grade 3	Grade 4
ALC Decreased	<LLN – 800/mm ³ <LLN – 0.8 x 10 ⁹ /L	<800 – 500/mm ³ <0.8 – 0.5 x 10 ⁹ /L	<500 - 200/mm ³ <0.5 – 0.2 x 10 ⁹ /L	<200/mm ³ < 0.2 x 10 ⁹ /L

Change from first cladribine/placebo dose

Data collected from first cladribine/placebo dose [Study Day 1] to the last ALC value in PREMIERE will be presented and summarized on a continuous manner (change from Study Day 1 and absolute value) and by grade, over time.

ALC Study Baseline is defined by the latest ALC value prior or equal to first cladribine/placebo dose [Study Day 1].

Over-time target point will be presented using visit window computed relative to Study Day 1, as presented below.

In case multiple samples are collected in the same window, the value closest to the target day will be used for analysis, where the target day is the middle of the time window. If there are two values with the same time before and after the target day, the earlier (first) value will be used for analysis.

Table 7 Time window for lymphocyte from first cladribine/placebo dose

Evaluation	Target point (day)	Interval for analysis (Day)
ALC Study Baseline	Study Day 1	Last value prior to or equal to Study Day 1
Week 2	14	[2 ; 23]
Week 5	35	[24 ; 47]
Week 9	63	[48 ; 77]
Week 13	91	[78 ; 103]
Week 16	112	[104 ; 130]
Week 24	168	[131 ; 203]
Week 36	252	[204 ; 287]
Week 44	308	[288 ; 329]
Week 48	336	[330 ; 350]
Week 52	364	[351 ; 376]
Week 55	385	[377 ; 399]
Week 60	420	[400 ; 461]
Week 72	504	[462 ; 546]
Week 84	588	[547 ; 630]
Week 96	672	[631 ; 686]
Week 101	707	[687 ; 721]
Week 105	735	[722 ; 784]
Week 120	840	[785 ; 924]
Week 144	1008	[925 ; 1092]
Week 168	1176	[1093 ; 1260]
Week 192	1344	[1261 ; 1428]
Week 216	1512	[1429 ; 1596]
<i>And every 24 weeks.... If needed</i>		

Change from the end of clinical trial

A summary table of ALC similar to change from first cladribine/placebo dose will be presented.

Data collected from last value from the end of clinical trial to the last ALC value in PREMIERE will be presented and summarized on a continuous manner (absolute value only) and by grade, over time.

ALC Registry Baseline is defined as the first ALC date with a value on or after the end of clinical trial +1 day [Registry Day 1].

Programming rule to cover possible unclean data:

If first ALC date in PREMIERE is before the end of clinical trial, ALC Registry Baseline is defined as the first ALC value in PREMIERE on or after the end of clinical trial + 1 day.

A new set of time window are presented below using visit window computed relative to ALC Registry Baseline.

If more than 1 value is available for a particular time window for the same subject, the first value in the time window will be considered.

Table 8 Time window for lymphocyte from the end of clinical trial

<i>Evaluation</i>	<i>Interval for analysis (day)</i>
Last value from last clinical trial	
ALC Registry Baseline	First ALC date with value in PREMIERE registry
Week 12	[2 - 98]
Week 24	[99 - 182]
Week 36	[183 - 266]
Week 48, 1y	[267 - 350]
Week 60	[351 - 434]
Week 72	[435 - 518]
Week 84	[519 - 602]
Week 96, y2	[603 - 700]
Week 144, y3	[701 - 1036]
<i>Etc.</i>	[1037 - weekN*7+4*7]

Lymphopenia grade and MS-DMD

Best and Worst ALC grades will be presented in relation to use of MS-DMD medication. For subjects with MS-DMD medications reported at least once after end of clinical trial, the best and worst ALC grade will be selected on or after (\geq) the first MS-DMD.

The Worst and the Best grade will be summarized overall and by treatment group. Subjects who are not taking MS-DMD from the end of clinical trial +1 day to the end of PREMIERE will be excluded from the analysis.

Resolution of lymphopenia computed with observed ALC value

Subjects who complete or drop out at the end of the clinical trial with an unresolved lymphopenia will be presented, together with their outcome in PREMIERE registry. The outcome can be resolved or unresolved.

An unresolved lymphopenia is defined for a subject who left the end of a clinical trial without returning to normal or grade 1 ALC value after an episode of grade 3 or 4 lymphopenia. A grade 3 or 4 lymphopenia episode is defined by a start/end date. Start= ALC \geq grade 3, post baseline, End = following normal (grade 0) or grade 1.

The duration (in months) of the resolved episodes (out of the unresolved at end of clinical trial period) will be summarized. In addition, use of MS-DMDs prior to resolution will be presented.

Resolution of lymphopenia computed using CRF tick box

Reporting will be done for SAF. This is an exception, to include the largest possible information available.

The number of subjects with declared Grade 3 or 4 lymphopenia at end of clinical trial [CRF Tick box], will be summarized together with their outcome in PREMIERE. The outcome in PREMIERE will be computed from those with at least one grade 0/1 in PREMIERE or with a CRF "resolution date".

Presentation per treatment group and total will be done.

Resolution of lymphopenia based on observed ALC value versus CRF tick box

A 2-by-2 table of number of subjects with and without resolution of lymphopenia at the end of clinical trial based on ALC value versus CRF Tick box will be presented.

In addition, a listing will be generated for subjects with unresolved lymphopenia at the end of clinical trial according to ALC grade, but with the CRF Tick box = "Resolved". The following variables will be displayed: Subject ID, cumulative dose of cladribine, previous clinical trial, treatment group (see section 9.1), all ALC values in PREMIERE with grade and date and tick box for resolved with date of resolved if available.

15.2 Secondary Endpoints: Pregnancy

Reporting will be done for SAF.

Data collection for pregnancy, pregnancy outcomes, including congenital malformations, spontaneous abortion, elective abortion, stillbirth, ectopic pregnancy, molar pregnancy, and other important health conditions in the offspring is a secondary endpoint of the PREMIERE registry with its dedicated questionnaire.

The number of subjects with pregnancy, treatment status at start of pregnancy, number of pregnancy and outcomes will be presented by treatment group together and split by female subjects and for male participant pregnancy of partner.

Treatment status at start of pregnancy will be summarized as follows:

- ≤ 6 months after end of treatment: defined as start of pregnancy \leq last dose + 183 days
- > 6 months after end of treatment: defined as start of pregnancy $>$ last dose + 183 days

For start of pregnancy, the first date of the last menstrual period will be used. If this date is missing or partial, the estimated delivery date will be considered (minus 280 days for duration of pregnancy). If that estimated delivery date is also missing, the date of baby birth and gestational age at birth will be considered.

Descriptive statistics will be presented for the time (in days) from last dose to start of pregnancy for subjects who started pregnancy \leq 6 months after end of treatment.

Mode of delivery, major delivery complication (y, n), infant child status (alive, deceased) and birth defects (y, n) will be presented.

A listing of AE related to pregnancy and a listing of pregnancy details will be presented.

All datasets with event collection of pregnancy, dedicated CRF pages or AE reporting or any other datasets will be considered as source of information. When information is taken from AE panels, all PTs from MedDRA SMQ (SMQ 20000185) labelled “SMQ 20000185 Pregnancy and neonatal topics” are identified (see Appendix 18.1). The obtained list is reviewed, and a decision is made for which events qualify as Pregnancies. These classifications are documented with reasons in Appendix 18.2 and read into the programs for calculations.

Note: the final list of AEs related to pregnancy may be revised after database lock. Any changes from the list above will be described in the CSR.

15.3 Adverse Events

Reporting will be done for SAF.

Adverse events are events that are reported with a start date on or after the end of clinical trial + 1 day [Registry Day 1].

AEs collected in PREMIERE either from AEs CRF Pages (AE dataset) or New Diagnoses CRF Pages (CE dataset) will be included.

Seriousness is not collected for events in the New Diagnoses CRF Pages. Seriousness will not be imputed and therefore these diagnoses will not be included in serious or non-serious AE tables.

15.3.1 All Adverse Events

All adverse events will be summarized following statistics described in section 15.1.1.

Clinical trial.gov and EudraCT -requirements

In addition, a summary table will be provided for non-serious adverse events by SOC and PT per treatment group excluding SAEs applying

- frequency threshold of 5% based on crude incidence in either group

15.3.2 Serious Adverse Events

Serious adverse events will be presented following statistics described in section 15.1.1

Clinical trial.gov and EudraCT -requirements

In addition, a summary table will be provided for serious adverse events by SOC and PT per treatment group.

15.4 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events

15.4.1 Deaths

Adverse events leading to death will be presented following statistics described in section 15.1.1.

15.5 Adverse Event of Special Interest

The term Adverse Events of Special Interest represents a broader than usual category of events for which specific attention will be paid during the review of the results.

The following statistics will be presented:

- Summary: Patient-year, number of unique event, number of subjects with at least one event, crude incidence and 95% CI per treatment group. All these statistics will be repeated for AE leading to death and serious AE.

In addition, summary table will be repeated by

- CLARITY only
 - CLARITY/CLARITY EXTENSION
 - ORACLE MS
 - ONWARD
- By PT: Number of patients with the AE and crude incidence (%) per treatment group and total will be presented.

15.5.1 AESI= Infections

Reporting will be regrouped into the 7 following AESI categories.

- AESI = Infections and Infestations

AESI = Infections and infestations is defined by any event belonging to the MedDRA SOC = Infections and Infestations.

- AESI = Severe Infections

AESI = Severe Infections is a custom grouping defined by any serious or severe event belonging to the MedDRA SOC = Infections and Infestations.

Data Handling

[REDACTED]

[REDACTED]

Adverse events collected under the New Diagnosis pages (PREMIERE eCRF only) does not have characteristics for severity being collected. However, AEs collected under the category “Other **severe** infections” will be considered for the definition of the AESI = Severe Infections.

- AESI = Herpetic infections

AESI = Herpetic infections is a custom grouping defined by any events from MedDRA HLT = Herpes viral infections.

- AESI = Opportunistic infections

The medical concept “opportunistic infections (including tuberculosis and PML)” is a custom grouping based on medical assessment. It includes MedDRA Preferred Terms (PTs) associated to viral, protozoal and bacterial infections as well as PTs associated to fungal infections with the exclusion of mucocutaneous and cutaneous fungal infections. Infections as provided by the US Centers of Disease Control (1993 revision) and in the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, <http://aidsinfo.nih.gov/guidelines> are included. PTs pertaining to the HLT ‘Herpes viral infections’ are not included.

This definition will be shortened in the tables footnote to read:

AESI = Opportunistic Infections is based on respective lists available in the context of HIV infections. It includes MedDRA preferred terms (PTs) associated to viral, fungal, protozoal and bacterial infections. PTs pertaining to the HLT ‘Herpes viral infections’ are not included.

The MedDRA terms that will be selected are listed in Appendix 18.3.

- AESI = Herpes zoster infections

AESI = Herpes zoster infections is a custom grouping defined by PTs with the term 'herpes zoster'.

The PTs that will be selected are listed in Appendix 18.4.

- AESI = PML

AESI = PML is a custom grouping defined by any events from MedDRA HLT = Polyomavirus infection.

- AESI = Tuberculosis

AESI = Tuberculosis is a custom grouping defined by any events from MedDRA HLT = Tuberculous infections.

15.5.2 AESI = Malignancies

The AESI Malignancies is a custom query using the following process:

All PTs from MedDRA SMQ (SMQ code 20000091) labelled “Malignant or unspecified tumours” are identified (see Appendix 18.5). For this SMQ, there are no broad terms available. The obtained list is reviewed, and an adjudicated decision is made with documented justifications which events qualify as malignancies. These classifications are documented with reasons in Appendix 18.6 and read into the programs for calculations.

15.6 Handling of Missing or Partial AE Dates (onset, resolution date)

Incomplete AE-related dates will be handled in a 'worst case' manner to ensure no under-estimation of the duration of adverse events:

Onset date of an AE

- If the onset date of an AE is missing completely, or missing partially, but the onset month and year (or the onset year) is equal to Registry Day 1, then the onset date will be replaced by the minimum of Registry Day 1 and AE resolution date. Therefore, the period used for defining TEAEs is not underestimated.
- In all other cases, the missing onset day or missing onset month will be replaced by 1/January, ensuring that no adverse event duration is under-estimated.

Stop date of an AE

- Incomplete stop dates will be replaced by the last day of the month (if day is missing), and December (if the month is missing), unless resulting in a date later than the date of subject's death. In the latter case, the date of death will be used to impute the incomplete stop date.
- In all other cases, (for example where the day and month are missing) the incomplete stop date will not be imputed.

15.7 Clinical Laboratory Evaluation

Please refer to section 15.1.4.

15.8 Vital Signs

Not Applicable.

15.9 Other Safety or Tolerability Evaluations

Not Applicable.

16 Analyses of Other Endpoints

Not Applicable.

17 References

1. Clinical Study Report. EMR700568-012 Prospective observational long-term safety Registry of Multiple sclerosis patients who have participated in cladribine clinical studies (PREMIERE). Merck KGaA, Darmstadt, Germany and in USA: EMD Serono, Inc., Rockland MA, USA. May 2 2016
2. Clinical Study Report. EMR700568-012 Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE). Merck Serono SA – Geneva An affiliate of Merck KGaA, Darmstadt, Germany, 29 quai des Bergues, 1201 Geneva / Switzerland. February 5 2018
3. Clopper, C.J., and Pearson, E.S. The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial”, (1934), “*Biometrika* 26, 404–41
4. Jiming Fang Institute for Clinical Evaluative Sciences, Canada, 2011, Using SAS® Procedures FREQ, GENMOD, LOGISTIC, and PHREG to Estimate Adjusted Relative Risks – A Case Study, *Statistics and Data analysis, SAS Global Forum* 2011.
5. Agresti, A., and Coull, B. (1998). Approximate is better than 'exact' for interval estimation of binomial proportions. *The American Statistician*, 52, 119-126.
6. Miettinen O, Nurminen M. Comparative analysis of two rates. *Statistics in Medicine* 1985; 4:213 –226
7. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), Published August 9, 2006, (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae3.pdf)

18 Appendices

18.1 Pregnancy and neonatal topics (SMQ 20000185)

Name	Code	Level
11-beta-hydroxylase deficiency	10000002	PT
17,20-desmolase deficiency	10000013	PT
17-alpha-hydroxylase deficiency	10000014	PT
18q minus syndrome	10068533	PT
20,22-desmolase deficiency	10000020	PT
21-hydroxylase deficiency	10000021	PT
2-Hydroxyglutaric aciduria	10078971	PT
3-hydroxyacetyl-coenzyme A dehydrogenase deficiency	10072273	PT
5-alpha-reductase deficiency	10000029	PT
Aase syndrome	10063429	PT
Abdominal transposition	10000098	PT
Abdominal wall anomaly	10000101	PT
Abnormal palmar/plantar creases	10000162	PT
ABO haemolytic disease of newborn	10000205	PT
Acardia	10075721	PT
Accessory auricle	10000361	PT
Accessory breast	10049786	PT
Accessory carpal bone	10000362	PT
Accessory kidney	10048781	PT
Accessory liver lobe	10052752	PT
Accessory muscle	10000364	PT
Accessory navicular syndrome	10062626	PT
Accessory salivary gland	10000368	PT
Accessory spleen	10068059	PT
Acetylcholinesterase deficiency	10071435	PT
Achromotrichia congenital	10049864	PT
Acral peeling skin syndrome	10078538	PT
Acrodermatitis enteropathica	10000596	PT
Acrodysostosis	10079856	PT
Acrokeratosis verruciformis	10069445	PT
Activated PI3 kinase delta syndrome	10078281	PT
Adactyly	10049207	PT
Adams-Oliver syndrome	10079369	PT
Adenine phosphoribosyl transferase deficiency	10072609	PT
Adenomatous polyposis coli	10056981	PT
Adrenal insufficiency neonatal	10001368	PT
Adrenogenital syndrome	10061630	PT

Adrenoleukodystrophy	10051260	PT
Adult polyglucosan body disease	10077946	PT
Aglossia	10001501	PT
Aicardi's syndrome	10054935	PT
Alagille syndrome	10053870	PT
Albinism	10001557	PT
Albright's disease	10052032	PT
Alkaptonuria	10001689	PT
Allan-Herndon-Dudley syndrome	10078821	PT
Alpers' disease	10062943	PT
Alpha-1 anti-trypsin deficiency	10001806	PT
Alport's syndrome	10001843	PT
Alstroem syndrome	10068783	PT
Alternating hemiplegia of childhood	10077948	PT
Alveolar capillary dysplasia	10077023	PT
Amblyopia congenital	10001908	PT
Amegakaryocytic thrombocytopenia	10076744	PT
Aminoaciduria	10001939	PT
Amniotic band syndrome	10064100	PT
Amyotrophic lateral sclerosis gene carrier	10052653	PT
Anal atresia	10002120	PT
Androgen insensitivity syndrome	10056292	PT
Anencephaly	10002320	PT
Angelman's syndrome	10049004	PT
Angiotensin converting enzyme inhibitor foetopathy	10051098	PT
Aniridia	10002532	PT
Ankyloglossia congenital	10049244	PT
Annular pancreas	10071757	PT
Anodontia	10002583	PT
Anomalous arrangement of pancreaticobiliary duct	10064902	PT
Anomalous pulmonary venous connection	10058079	PT
Anomaly of external ear congenital	10062339	PT
Anomaly of middle ear congenital	10060957	PT
Anomaly of orbit, congenital	10002633	PT
Anophthalmos	10002640	PT
Anorchism	10002641	PT
Anorectal agenesis	10056271	PT
Anotia	10002654	PT
Anterior chamber cleavage syndrome	10059199	PT
Anterior displaced anus	10071651	PT
Antithrombin III deficiency	10002832	PT
Aorta hypoplasia	10049209	PT
Aortic valve atresia	10066801	PT
Aorticopulmonary septal defect	10063732	PT
Apert's syndrome	10002943	PT

Aphakia congenital	10002947	PT
Aplasia	10002961	PT
Aplasia cutis congenita	10002963	PT
Apparent mineralocorticoid excess	10080229	PT
Arachnodactyly	10063847	PT
Arcuate foramen	10067850	PT
Arginase deficiency	10062695	PT
Argininosuccinate lyase deficiency	10058299	PT
Argininosuccinate synthetase deficiency	10058298	PT
Arnold-Chiari malformation	10003101	PT
Arrhythmogenic right ventricular dysplasia	10058093	PT
Arterial tortuosity syndrome	10080250	PT
Arteriovenous malformation	10003193	PT
Ash leaf macule	10076367	PT
Aspartate-glutamate-transporter deficiency	10079140	PT
Aspartylglucosaminuria	10068220	PT
Asphyxiating thoracic dystrophy	10057621	PT
Asplenia	10053622	PT
Asymptomatic gene carrier	10061662	PT
Ataxia telangiectasia	10003594	PT
Atrial septal defect	10003664	PT
Atrioventricular node dispersion	10077893	PT
Atrioventricular septal defect	10063836	PT
Auditory neuropathy spectrum disorder	10072198	PT
Autoimmune lymphoproliferative syndrome	10069521	PT
Autosomal chromosome anomaly	10060975	PT
Azygos lobe	10069490	PT
Baltic myoclonic epilepsy	10054895	PT
Bannayan-Riley-Ruvalcaba syndrome	10080314	PT
Baraitser Rodeck Garner syndrome	10076038	PT
Barakat syndrome	10075281	PT
Barth syndrome	10078537	PT
Bartter's syndrome	10050839	PT
Basal cell naevus syndrome	10062804	PT
Becker's muscular dystrophy	10059117	PT
Beckwith-Wiedemann syndrome	10050344	PT
Benign congenital hypotonia	10051900	PT
Benign familial haematuria	10060876	PT
Benign familial neonatal convulsions	10067866	PT
Benign familial pemphigus	10004265	PT
Berdon's syndrome	10064596	PT
Beta ketothiolase deficiency	10067728	PT
Bicuspid aortic valve	10004552	PT
Bicuspid pulmonary valve	10063730	PT
Biliary hamartoma	10074610	PT

Biotinidase deficiency	10071434	PT
Birth mark	10004950	PT
Birt-Hogg-Dube syndrome	10067736	PT
Bladder agenesis	10056655	PT
Blau syndrome	10071755	PT
Blepharophimosis congenital	10049241	PT
Blindness congenital	10005176	PT
Bloch-Sulzberger syndrome	10077624	PT
Blood incompatibility haemolytic anaemia of newborn	10056369	PT
Bloom syndrome	10073032	PT
Brachycephaly	10053682	PT
Brachydactyly	10072883	PT
Brain malformation	10048409	PT
Branchial cleft sinus	10006162	PT
Branchial cyst	10006164	PT
Branchiogenic syndrome	10058169	PT
Branchio-oto-renal syndrome	10071135	PT
Breast malformation	10006271	PT
Bronchogenic cyst	10064585	PT
Bruton's agammaglobulinaemia	10060360	PT
Bulbospinal muscular atrophy congenital	10068597	PT
Buried penis syndrome	10067131	PT
Camptodactyly congenital	10049028	PT
Camptomelia	10078297	PT
Canavan disease	10067608	PT
Cancer gene carrier	10052648	PT
CANDLE syndrome	10073960	PT
Carbamoyl phosphate synthetase deficiency	10058297	PT
Carbohydrate metabolism disorder	10061023	PT
Carcinogenic effect in offspring	10007268	PT
Cardiac lymphangioma	10055010	PT
Cardiac malposition	10007585	PT
Cardiac septal defect	10064021	PT
Carney complex	10076601	PT
Carnitine palmitoyltransferase deficiency	10050215	PT
Carnitine-acylcarnitine translocase deficiency	10078729	PT
Carpus curvus	10007700	PT
Cartilage-hair hypoplasia	10069596	PT
Cataract congenital	10007747	PT
Caudal regression syndrome	10059387	PT
Central core disease	10057620	PT
Central nervous system dermoid tumour	10007942	PT
Cerebellar dysplasia	10072942	PT
Cerebellar hypoplasia	10008033	PT
Cerebral arteriovenous malformation haemorrhagic	10008086	PT

Cerebral atrophy congenital	10052236	PT
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	10065551	PT
Cerebral dysgenesis	10056467	PT
Cerebral palsy	10008129	PT
Cerebrohepatorenal syndrome	10053684	PT
Cerebrovascular arteriovenous malformation	10056371	PT
Cervical auricle	10008227	PT
Cervical rib	10008299	PT
CHARGE syndrome	10064063	PT
Chediak-Higashi syndrome	10008415	PT
Chiari network	10069393	PT
Chimerism	10068051	PT
Choanal atresia	10008587	PT
Choanal stenosis	10074053	PT
Cholangiectasis congenital	10053630	PT
Choledochal cyst	10008625	PT
Chondrodystrophy	10008723	PT
Chondroectodermal dysplasia	10008724	PT
Chordee	10008746	PT
Chorioretinal degeneration congenital	10008763	PT
Choroidal coloboma	10057402	PT
Chromosomal deletion	10061764	PT
Chromosomal mutation	10061765	PT
Chronic granulomatous disease	10008906	PT
Chronic infantile neurological cutaneous and articular syndrome	10064568	PT
Citrate transporter deficiency	10077947	PT
Cleft lip	10009259	PT
Cleft lip and palate	10009260	PT
Cleft palate	10009269	PT
Cleft uvula	10053507	PT
Cleidocranial dysostosis	10075994	PT
Clinodactyly	10058668	PT
Cloacal exstrophy	10067424	PT
Coagulation factor mutation	10065442	PT
Coarctation of the aorta	10009807	PT
Cobb syndrome	10068841	PT
Cockayne's syndrome	10009835	PT
Cohen syndrome	10049066	PT
Collodion baby	10009926	PT
Coloboma	10009934	PT
Colour blindness	10010050	PT
Combined immunodeficiency	10010099	PT
Complement deficiency disease	10075551	PT
Congenital abdominal hernia	10067183	PT

Congenital absence of bile ducts	10010317	PT
Congenital absence of cranial vault	10010318	PT
Congenital absence of vertebra	10010320	PT
Congenital acrochordon	10050730	PT
Congenital adrenal gland hypoplasia	10049057	PT
Congenital amputation	10079701	PT
Congenital anaemia	10010329	PT
Congenital androgen deficiency	10063469	PT
Congenital anomalies of ear ossicles	10010341	PT
Congenital anomaly	10010356	PT
Congenital anomaly in offspring	10063726	PT
Congenital anomaly of adrenal gland	10062341	PT
Congenital anomaly of inner ear	10062340	PT
Congenital anosmia	10079876	PT
Congenital aortic anomaly	10061052	PT
Congenital aortic atresia	10010368	PT
Congenital aortic dilatation	10058150	PT
Congenital aortic stenosis	10010369	PT
Congenital aortic valve incompetence	10010370	PT
Congenital aortic valve stenosis	10010371	PT
Congenital aplastic anaemia	10053138	PT
Congenital aqueductal stenosis	10066084	PT
Congenital arterial malformation	10062325	PT
Congenital arteriovenous fistula	10010374	PT
Congenital astigmatism	10074992	PT
Congenital aural fistula	10054215	PT
Congenital benign neoplasm	10073493	PT
Congenital bladder anomaly	10061053	PT
Congenital bladder diverticulum	10010381	PT
Congenital bladder neck obstruction	10010382	PT
Congenital bowing of long bones	10054064	PT
Congenital brain damage	10010390	PT
Congenital bronchiectasis	10010391	PT
Congenital bronchomalacia	10010392	PT
Congenital calyceal diverticulum	10057510	PT
Congenital cardiovascular anomaly	10061054	PT
Congenital carnitine deficiency	10062698	PT
Congenital central diabetes insipidus	10073008	PT
Congenital central hypoventilation syndrome	10066131	PT
Congenital central nervous system anomaly	10010411	PT
Congenital cerebellar agenesis	10048784	PT
Congenital cerebral cyst	10054954	PT
Congenital cerebral haemangioma	10048924	PT
Congenital cerebrovascular anomaly	10062327	PT
Congenital choroid plexus cyst	10048785	PT

Congenital choroidal anomaly	10057886	PT
Congenital chylothorax	10078770	PT
Congenital clavicular agenesis	10010416	PT
Congenital claw toe	10010417	PT
Congenital coagulopathy	10063563	PT
Congenital condyloma	10066944	PT
Congenital corneal anomaly	10061059	PT
Congenital coronary artery malformation	10061060	PT
Congenital cranial nerve paralysis	10069774	PT
Congenital cutis laxa	10057042	PT
Congenital cyst	10062328	PT
Congenital cystic disease of liver	10010427	PT
Congenital cystic kidney disease	10010428	PT
Congenital cystic lung	10010429	PT
Congenital cytomegalovirus infection	10010430	PT
Congenital deformity of clavicle	10010434	PT
Congenital dermal sinus	10048728	PT
Congenital diaphragmatic anomaly	10061061	PT
Congenital diaphragmatic eventration	10010438	PT
Congenital diaphragmatic hernia	10010439	PT
Congenital disorder of glycosylation	10075892	PT
Congenital dysfibrinogenaemia	10051123	PT
Congenital dyskeratosis	10062759	PT
Congenital ectodermal dysplasia	10010452	PT
Congenital ectopic bladder	10010453	PT
Congenital ectopic pancreas	10056987	PT
Congenital elevation of scapula	10010455	PT
Congenital emphysema	10010456	PT
Congenital endocrine anomaly	10062329	PT
Congenital epiblepharon	10056531	PT
Congenital epiglottal anomaly	10062330	PT
Congenital Eustachian tube anomaly	10062331	PT
Congenital eye disorder	10059159	PT
Congenital eye naevus	10051050	PT
Congenital eyelid malformation	10061146	PT
Congenital facial nerve hypoplasia	10049449	PT
Congenital fallopian tube anomaly	10061062	PT
Congenital fibrosarcoma	10065859	PT
Congenital flaccid paralysis	10010474	PT
Congenital flat feet	10010475	PT
Congenital floppy infant	10053153	PT
Congenital foot malformation	10062332	PT
Congenital gastric anomaly	10061063	PT
Congenital gastrointestinal vessel anomaly	10062342	PT
Congenital generalised lipodystrophy	10053547	PT

Congenital genital malformation	10062333	PT
Congenital genital malformation female	10010481	PT
Congenital genital malformation male	10059492	PT
Congenital genitourinary abnormality	10062334	PT
Congenital great vessel anomaly	10061080	PT
Congenital haematological disorder	10072107	PT
Congenital hair disorder	10061064	PT
Congenital hand malformation	10062335	PT
Congenital hearing disorder	10010493	PT
Congenital heart valve disorder	10064086	PT
Congenital heart valve incompetence	10077594	PT
Congenital hemiparesis	10071359	PT
Congenital hepatic fibrosis	10056533	PT
Congenital hepatitis B infection	10010496	PT
Congenital hepatobiliary anomaly	10061065	PT
Congenital hepatomegaly	10051130	PT
Congenital herpes simplex infection	10019949	PT
Congenital hiatus hernia	10010501	PT
Congenital high airway obstruction syndrome	10074187	PT
Congenital HIV infection	10010504	PT
Congenital Horner's syndrome	10074554	PT
Congenital hydrocele renalis	10051147	PT
Congenital hydrocephalus	10010506	PT
Congenital hydronephrosis	10050975	PT
Congenital hypercoagulation	10070954	PT
Congenital hyperextension of knee	10048954	PT
Congenital hyperextension of spine	10048953	PT
Congenital hyperthyroidism	10062264	PT
Congenital hypertrichosis	10010507	PT
Congenital hypogammaglobulinaemia	10060747	PT
Congenital hypoparathyroidism	10051315	PT
Congenital hypoplasia of depressor angularis oris muscle	10080879	PT
Congenital hypothyroidism	10010510	PT
Congenital infection	10062343	PT
Congenital inguinal hernia	10068321	PT
Congenital intestinal malformation	10061067	PT
Congenital intestinal obstruction	10073207	PT
Congenital intrinsic factor deficiency	10070440	PT
Congenital iris anomaly	10057411	PT
Congenital jaw malformation	10062336	PT
Congenital joint malformation	10062337	PT
Congenital knee deformity	10061068	PT
Congenital knee dislocation	10010520	PT
Congenital kyphoscoliosis	10048890	PT
Congenital labia pudendi adhesions	10050268	PT

Congenital lacrimal gland anomaly	10010523	PT
Congenital lacrimal passage anomaly	10062338	PT
Congenital large intestinal atresia	10010526	PT
Congenital laryngeal stridor	10010527	PT
Congenital lenticonus	10064660	PT
Congenital limb hyperextension	10049011	PT
Congenital lip fistula	10010532	PT
Congenital lymphoedema	10010535	PT
Congenital malaria	10010538	PT
Congenital malignant neoplasm	10073492	PT
Congenital megacolon	10010539	PT
Congenital megaureter	10010540	PT
Congenital melanocytic naevus	10072036	PT
Congenital melanosis	10010541	PT
Congenital methaemoglobinaemia	10010543	PT
Congenital midline defect	10079687	PT
Congenital mitochondrial cytopathy	10057954	PT
Congenital mitral valve incompetence	10010547	PT
Congenital mitral valve stenosis	10010548	PT
Congenital monorchidism	10069505	PT
Congenital multiplex arthrogryposis	10051643	PT
Congenital muscle absence	10010550	PT
Congenital musculoskeletal anomaly	10062344	PT
Congenital myopathy	10062547	PT
Congenital myopia	10069153	PT
Congenital naevus	10067248	PT
Congenital nail disorder	10010557	PT
Congenital neoplasm	10078557	PT
Congenital nephrogenic diabetes insipidus	10068304	PT
Congenital nephrotic syndrome	10060737	PT
Congenital neurological degeneration	10010558	PT
Congenital neurological disorder	10062345	PT
Congenital neuropathy	10062346	PT
Congenital night blindness	10010559	PT
Congenital nipple anomaly	10080356	PT
Congenital nipple inversion	10080355	PT
Congenital nose malformation	10062347	PT
Congenital nystagmus	10010562	PT
Congenital oculomotor apraxia	10053877	PT
Congenital oesophageal anomaly	10061069	PT
Congenital oesophageal stenosis	10010564	PT
Congenital oesophageal web	10010565	PT
Congenital optic nerve anomaly	10061528	PT
Congenital oral malformation	10061070	PT
Congenital osteodystrophy	10010582	PT

Congenital ovarian anomaly	10061071	PT
Congenital oxalosis	10068593	PT
Congenital pancreatic anomaly	10061072	PT
Congenital perforated nasal septum	10010588	PT
Congenital pharyngeal anomaly	10061073	PT
Congenital pigmentation disorder	10010593	PT
Congenital pneumonia	10010594	PT
Congenital poikiloderma	10052465	PT
Congenital pseudarthrosis	10061573	PT
Congenital pulmonary artery anomaly	10061074	PT
Congenital pulmonary hypertension	10050701	PT
Congenital pulmonary valve atresia	10052644	PT
Congenital pulmonary valve disorder	10061075	PT
Congenital pyelocaliectasis	10049938	PT
Congenital renal cyst	10010607	PT
Congenital renal disorder	10066875	PT
Congenital retinoblastoma	10073470	PT
Congenital rubella infection	10010619	PT
Congenital salivary gland anomaly	10010620	PT
Congenital scleral disorder	10061530	PT
Congenital scoliosis	10050694	PT
Congenital scrotal hypertrophy	10048800	PT
Congenital skin dimples	10072978	PT
Congenital skin disorder	10067769	PT
Congenital small intestinal atresia	10010626	PT
Congenital spinal cord anomaly	10061076	PT
Congenital spinal fusion	10010629	PT
Congenital spinal stenosis	10077379	PT
Congenital spondylolisthesis	10010633	PT
Congenital spondylolysis	10010634	PT
Congenital syphilis	10010641	PT
Congenital syphilitic encephalitis	10010643	PT
Congenital syphilitic meningitis	10010644	PT
Congenital syphilitic osteochondritis	10054002	PT
Congenital teratoma	10052012	PT
Congenital thrombocyte disorder	10058896	PT
Congenital thrombocytopenia	10077833	PT
Congenital thymus absence	10048801	PT
Congenital thyroid disorder	10076602	PT
Congenital tongue anomaly	10061077	PT
Congenital torticollis	10010650	PT
Congenital toxoplasmosis	10010652	PT
Congenital tracheomalacia	10010654	PT
Congenital trichomegaly	10073654	PT
Congenital tricuspid valve atresia	10049767	PT

Congenital tricuspid valve incompetence	10067887	PT
Congenital tricuspid valve stenosis	10010656	PT
Congenital tuberculosis	10010657	PT
Congenital umbilical hernia	10010658	PT
Congenital ureteric anomaly	10061078	PT
Congenital ureterocele	10056434	PT
Congenital ureterovesical junction anomaly	10068133	PT
Congenital urethral anomaly	10062349	PT
Congenital urinary tract obstruction	10010663	PT
Congenital uterine anomaly	10061079	PT
Congenital vaginal cyst	10063457	PT
Congenital varicella infection	10010668	PT
Congenital varicocele	10074459	PT
Congenital vas deferens absence	10010670	PT
Congenital vesicoureteric reflux	10010672	PT
Congenital visual acuity reduced	10059157	PT
Congenital vitreous anomaly	10061085	PT
Congenital white blood cell disorder	10061086	PT
Congenital Zika syndrome	10081044	PT
Conjoined twins	10010688	PT
Conjunctivitis gonococcal neonatal	10010749	PT
Constricted ear deformity	10071233	PT
Cor biloculare	10010967	PT
Cor triatriatum	10010972	PT
Corneal dystrophy	10011005	PT
Corneal opacity congenital	10011037	PT
Cornelia de Lange syndrome	10077707	PT
Corrected transposition of great vessels	10011120	PT
Cortical dysplasia	10070666	PT
Costello syndrome	10067380	PT
Cowden's disease	10051906	PT
Craniofacial deformity	10074180	PT
Craniofacial dysostosis	10066946	PT
Craniolacunia	10072116	PT
Craniorachischisis	10011321	PT
Craniosynostosis	10049889	PT
Craniotabes	10065419	PT
Cri du Chat syndrome	10011385	PT
Crigler-Najjar syndrome	10011386	PT
Cryopyrin associated periodic syndrome	10068850	PT
Cryptophthalmos	10011497	PT
Cryptorchism	10011498	PT
Currarino syndrome	10079857	PT
Cutaneous visceral angiomatosis with thrombocytopenia	10069098	PT
Cyclopia	10057648	PT

Cystathionine beta-synthase deficiency	10071093	PT
Cystic angiomatosis	10079371	PT
Cystic eyeball, congenital	10011761	PT
Cystic fibrosis	10011762	PT
Cystic fibrosis carrier	10052656	PT
Cystic fibrosis gastrointestinal disease	10079428	PT
Cystic fibrosis hepatic disease	10068289	PT
Cystic fibrosis lung	10011763	PT
Cystic fibrosis pancreatic	10011766	PT
Cystic fibrosis related diabetes	10068271	PT
Cystic lymphangioma	10058949	PT
Cystinosis	10011777	PT
Cystinuria	10011778	PT
Cytogenetic abnormality	10067477	PT
Dacryostenosis congenital	10011850	PT
Dandy-Walker syndrome	10048411	PT
Deaf mutism	10011875	PT
Deafness congenital	10011882	PT
Deficiency of the interleukin-1 receptor antagonist	10072224	PT
Deficiency of the interleukin-36 receptor antagonist	10079451	PT
Delayed foetal renal development	10079753	PT
Delta-beta thalassaemia	10012236	PT
Dentatorubral-pallidolusian atrophy	10075298	PT
Dentinogenesis imperfecta	10054013	PT
Dentofacial anomaly	10012331	PT
Dent's disease	10069199	PT
Denys-Drash syndrome	10070179	PT
Dermatofibrosis lenticularis disseminata	10056878	PT
Dermatoglyphic anomaly	10061455	PT
Dermoid cyst	10012522	PT
Developmental glaucoma	10012565	PT
Developmental hip dysplasia	10073767	PT
Dextrocardia	10012592	PT
Diabetic foetopathy	10059116	PT
Diaphragmatic aplasia	10012711	PT
Diastematomyelia	10012750	PT
Diencephalic syndrome of infancy	10012774	PT
Diethylstilboestrol syndrome	10012780	PT
DiGeorge's syndrome	10012979	PT
Dihydropyrimidine dehydrogenase deficiency	10052622	PT
Dilatation intrahepatic duct congenital	10013003	PT
Disorder of sex development	10070597	PT
Distichiasis	10066128	PT
Diverticulitis Meckel's	10013542	PT
Diverticulum of pharynx, congenital	10013568	PT

DNA mismatch repair protein gene mutation	10078672	PT
Dolichocolon	10063917	PT
DOOR syndrome	10080835	PT
Dopa-responsive dystonia	10080034	PT
Double cortex syndrome	10073490	PT
Double heterozygous sickling disorders	10013609	PT
Double outlet left ventricle	10080133	PT
Double outlet right ventricle	10013611	PT
Double ureter	10013613	PT
Dowling-Degos disease	10068651	PT
Duane's syndrome	10013799	PT
Dubin-Johnson syndrome	10013800	PT
Dubowitz syndrome	10059589	PT
Duchenne muscular dystrophy	10013801	PT
Duchenne muscular dystrophy gene carrier	10052655	PT
Ductus arteriosus premature closure	10049996	PT
Ductus arteriosus stenosis foetal	10013808	PT
Ductus venosus agenesis	10068665	PT
Duodenal atresia	10013812	PT
Duplex appendix	10078212	PT
Dyke-Davidoff-Masson syndrome	10080312	PT
Dyschondrosteosis	10071437	PT
Dyschromatosis	10080785	PT
Dysgnathia	10074336	PT
Dysmorphism	10066054	PT
Dysmyelination	10067601	PT
Dysplastic naevus syndrome	10013960	PT
Eagle Barrett syndrome	10051025	PT
Ear malformation	10014016	PT
Early onset familial Alzheimer's disease	10078036	PT
Early onset primary dystonia	10076668	PT
Ebstein's anomaly	10014075	PT
Ectopia cordis	10014144	PT
Ectopic kidney	10063044	PT
Ectopic ovary	10074217	PT
Ectopic posterior pituitary gland	10077557	PT
Ectopic thyroid	10069503	PT
Ectopic ureter	10014172	PT
Ectrodactyly	10079827	PT
Ehlers-Danlos syndrome	10014316	PT
Elliptocytosis hereditary	10014490	PT
Ellis-van Creveld syndrome	10076418	PT
Emanuel syndrome	10079203	PT
Encephalocele	10014617	PT
Encephalocutaneous angiomatosis	10057653	PT

Endocardial fibroelastosis	10014663	PT
Enteric duplication	10076653	PT
Entropion congenital	10014923	PT
Epidermal naevus	10014985	PT
Epidermal naevus syndrome	10077952	PT
Epidermolysis	10053177	PT
Epidermolysis bullosa	10014989	PT
Epilepsy congenital	10015039	PT
Epispadias	10015088	PT
Erythroblastosis foetalis	10015251	PT
Erythrokeratoderma variabilis	10049048	PT
Essential fructosuria	10015487	PT
Exomphalos	10015677	PT
Exophthalmos congenital	10050696	PT
External auditory canal atresia	10054875	PT
Extrarenal pelvis	10072727	PT
Eye anterior chamber congenital anomaly	10061051	PT
Eyelid ptosis congenital	10015996	PT
Fabry's disease	10016016	PT
Faciodigitogenital dysplasia	10067141	PT
Facioscapulohumeral muscular dystrophy	10064087	PT
Factor I deficiency	10016075	PT
Factor II deficiency	10016076	PT
Factor II mutation	10065003	PT
Factor III deficiency	10052473	PT
Factor IX deficiency	10016077	PT
Factor V deficiency	10048930	PT
Factor V Leiden carrier	10075652	PT
Factor V Leiden mutation	10058279	PT
Factor VII deficiency	10016079	PT
Factor VIII deficiency	10016080	PT
Factor X deficiency	10052474	PT
Factor XI deficiency	10016082	PT
Factor XII deficiency	10051806	PT
Factor XIII deficiency	10016083	PT
Fallot's pentalogy	10059205	PT
Fallot's tetralogy	10016193	PT
Fallot's trilogy	10064011	PT
Familial acromegaly	10080509	PT
Familial amyloidosis	10016202	PT
Familial amyotrophic lateral sclerosis	10077024	PT
Familial cold autoinflammatory syndrome	10064570	PT
Familial haemophagocytic lymphohistiocytosis	10070904	PT
Familial hemiplegic migraine	10067039	PT
Familial high density lipoprotein deficiency	10079119	PT

Familial hypertriglyceridaemia	10059183	PT
Familial hypocalciuric hypercalcaemia	10068698	PT
Familial infantile bilateral striatal necrosis	10077450	PT
Familial isolated hyperparathyroidism	10080773	PT
Familial mediterranean fever	10016207	PT
Familial medullary thyroid cancer	10073153	PT
Familial periodic paralysis	10016208	PT
Familial polycythaemia	10016209	PT
Familial renal glycosuria	10073689	PT
Familial scaphocephaly syndrome	10072229	PT
Familial tremor	10016212	PT
Fanconi syndrome	10016219	PT
Fatal familial insomnia	10072077	PT
Fatty acid oxidation disorder	10077951	PT
Femoral anteversion	10064516	PT
Femoral retroversion	10064514	PT
Femur-fibula-ulna complex	10068448	PT
Fibrodysplasia ossificans progressiva	10068715	PT
Fibrous dysplasia of bone	10016664	PT
Fibrous dysplasia of jaw	10070535	PT
Fibula agenesis	10054882	PT
Fissure of tongue, congenital	10016715	PT
Floating-Harbor syndrome	10079943	PT
Foetal alcohol syndrome	10016845	PT
Foetal anticonvulsant syndrome	10066485	PT
Foetal chromosome abnormality	10064041	PT
Foetal cystic hygroma	10052011	PT
Foetal malformation	10060919	PT
Foetal megacystis	10073660	PT
Foetal methotrexate syndrome	10071183	PT
Foetal retinoid syndrome	10073720	PT
Foetal warfarin syndrome	10051445	PT
Foramen magnum stenosis	10064157	PT
Fragile X carrier	10052657	PT
Fragile X syndrome	10017324	PT
Fraser syndrome	10080219	PT
Frasier syndrome	10080313	PT
Freeman-Sheldon syndrome	10073655	PT
Frenulum breve	10072007	PT
Friedreich's ataxia	10017374	PT
Fryns syndrome	10075223	PT
Galactosaemia	10017604	PT
Gallbladder agenesis	10079018	PT
Gallbladder anomaly congenital	10061163	PT
Gastrointestinal arteriovenous malformation	10017932	PT

Gastrointestinal disorder congenital	10061973	PT
Gastrointestinal malformation	10061596	PT
Gastroschisis	10018046	PT
Gaucher's disease	10018048	PT
Gaucher's disease type I	10075697	PT
Gaucher's disease type II	10075698	PT
Gaucher's disease type III	10075699	PT
Gene mutation	10064571	PT
Generalised resistance to thyroid hormone	10018096	PT
Genitalia external ambiguous	10018183	PT
Gilbert's syndrome	10018267	PT
Gitelman's syndrome	10062906	PT
Glucose transporter type 1 deficiency syndrome	10078727	PT
Glucose-6-phosphate dehydrogenase deficiency	10018444	PT
Glucose-galactose malabsorption	10066388	PT
Glutathione synthetase deficiency	10079364	PT
Glycogen storage disease type I	10018464	PT
Glycogen storage disease type II	10053185	PT
Glycogen storage disease type III	10053250	PT
Glycogen storage disease type IV	10053249	PT
Glycogen storage disease type V	10018462	PT
Glycogen storage disease type VI	10053240	PT
Glycogen storage disease type VII	10053241	PT
Glycogen storage disease type VIII	10053242	PT
Glycogen storage disorder	10061990	PT
Gnathoschisis	10068845	PT
GNE myopathy	10077945	PT
Goitre congenital	10018499	PT
Gollop-Wolfgang complex	10079731	PT
Gonadal dysgenesis	10018504	PT
Gorham's disease	10071283	PT
Gray matter heterotopia	10080533	PT
Greig's syndrome	10053878	PT
Haemangioma congenital	10018818	PT
Haemangioma of retina	10018822	PT
Haemochromatosis trait	10073217	PT
Haemoglobin C disease	10018883	PT
Haemoglobin C trait	10055021	PT
Haemoglobin D disease	10055019	PT
Haemoglobin D trait	10055020	PT
Haemoglobin E disease	10053215	PT
Haemoglobin E trait	10063740	PT
Haemoglobin E-thalassaemia disease	10062917	PT
Haemoglobinopathy	10060892	PT
Haemophilia	10061992	PT

Haemophilia A with anti factor VIII	10056492	PT
Haemophilia A without inhibitors	10056493	PT
Haemophilia B with anti factor IX	10056494	PT
Haemophilia B without inhibitors	10056495	PT
Haemophilia carrier	10051658	PT
Haemorrhagic arteriovenous malformation	10064595	PT
Hamartoma	10061193	PT
Hamartoma vascular	10019106	PT
Hand-foot-genital syndrome	10072361	PT
Harlequin foetus	10019163	PT
Hartnup disease	10019165	PT
Heart block congenital	10019263	PT
Heart disease congenital	10019273	PT
Hemihypertrophy	10019463	PT
Hemimegalencephaly	10078100	PT
Hemivertebra	10019477	PT
Hepatic arteriovenous malformation	10019633	PT
Hepatic hamartoma	10079685	PT
Hepato-lenticular degeneration	10019819	PT
Hereditary angioedema	10019860	PT
Hereditary angioedema with C1 esterase inhibitor deficiency	10080955	PT
Hereditary angioedema with normal C1 esterase inhibitor	10080953	PT
Hereditary areflexic dystasia	10063449	PT
Hereditary cerebral degeneration	10061204	PT
Hereditary choroidal dystrophy	10019864	PT
Hereditary disorder	10061205	PT
Hereditary fructose intolerance	10019878	PT
Hereditary haemochromatosis	10057873	PT
Hereditary haemolytic anaemia	10060893	PT
Hereditary haemorrhagic telangiectasia	10019883	PT
Hereditary hypophosphataemic rickets	10077943	PT
Hereditary leiomyomatosis renal cell carcinoma	10067944	PT
Hereditary motor and sensory neuropathy	10077306	PT
Hereditary motor neurone disease	10071328	PT
Hereditary multiple osteochondromas	10079019	PT
Hereditary neuropathic amyloidosis	10019889	PT
Hereditary neuropathy with liability to pressure palsies	10069382	PT
Hereditary non-polyposis colorectal cancer syndrome	10051922	PT
Hereditary optic atrophy	10019895	PT
Hereditary palmoplantar keratoderma	10072537	PT
Hereditary pancreatitis	10056976	PT
Hereditary papillary renal carcinoma	10067943	PT
Hereditary renal microhaematuria	10080385	PT
Hereditary retinal dystrophy	10019899	PT
Hereditary sideroblastic anaemia	10019902	PT

Hereditary spastic paraplegia	10019903	PT
Hereditary spherocytosis	10019904	PT
Hereditary stomatocytosis	10053589	PT
Hermansky-Pudlak syndrome	10071775	PT
Hermaphroditism	10019906	PT
Hernia congenital	10019912	PT
Heterochromia iridis	10066799	PT
Heterotaxia	10067265	PT
Hexokinase deficiency anaemia	10020022	PT
High arched palate	10020046	PT
Hollow visceral myopathy	10060811	PT
Holoprosencephaly	10056304	PT
Holt-Oram syndrome	10050469	PT
Homocystinaemia	10048707	PT
Homocystinuria	10020365	PT
Hooded prepuce	10072135	PT
Huntington's disease	10070668	PT
Hydranencephaly	10073472	PT
Hydrocele	10020488	PT
Hydroxyprolinaemia	10053148	PT
Hyper IgD syndrome	10072010	PT
Hyper IgE syndrome	10051040	PT
Hyper IgM syndrome	10066130	PT
Hyperexplexia	10058271	PT
Hyperglycinaemia	10080883	PT
Hyperinsulinism syndrome	10077858	PT
Hypermethioninaemia	10051245	PT
Hypermethioniuria	10051231	PT
Hyperprolinaemia	10058509	PT
Hypersplenism congenital	10049282	PT
Hypertelorism of orbit	10020771	PT
Hypertrophic cardiomyopathy	10020871	PT
Hypocalvaria	10073670	PT
Hypochondroplasia	10020967	PT
Hypodontia	10055001	PT
Hypomelanosis of Ito	10075301	PT
Hypophosphatasia	10049933	PT
Hypopituitarism foetal	10021068	PT
Hypoplastic left heart syndrome	10021076	PT
Hypoplastic nasal cartilage	10074970	PT
Hypoplastic right heart syndrome	10064962	PT
Hypospadias	10021093	PT
Hypotelorism of orbit	10057855	PT
Hypothalamic hamartoma	10078217	PT
Hypoxanthine-guanine phosphoribosyl transferase deficiency	10075774	PT

Ichthyosis	10021198	PT
Ileal atresia	10021298	PT
Immunodeficiency congenital	10021450	PT
Imperforate hymen	10021529	PT
Imperforate oesophagus	10021530	PT
Inborn error in primary bile acid synthesis	10070882	PT
Inborn error of bilirubin metabolism	10062017	PT
Inborn error of lipid metabolism	10072272	PT
Inborn error of metabolism	10062018	PT
Infantile cortical hyperostosis	10073206	PT
Infantile genetic agranulocytosis	10052210	PT
Infantile septic granulomatosis	10048708	PT
Inherited cardiac conduction disorder	10070294	PT
Iniencephaly	10022034	PT
Interferon gamma receptor deficiency	10057605	PT
Interruption of aortic arch	10022599	PT
Intestinal atresia	10062022	PT
Intestinal malrotation	10064024	PT
Intestinal neuronal dysplasia	10073659	PT
Intestinal transposition	10022712	PT
Intracranial arterial fenestration	10077285	PT
Intracranial lipoma	10072288	PT
IPEX syndrome	10080631	PT
Iris coloboma	10052642	PT
Johanson-Blizzard syndrome	10074947	PT
Joubert syndrome	10078574	PT
Juvenile Paget's disease	10078977	PT
Kabuki make-up syndrome	10063935	PT
Kaufman-McKusick syndrome	10052312	PT
Kearns-Sayre syndrome	10048804	PT
Kenny-Caffey syndrome	10073228	PT
Keratitis-ichthyosis-deafness syndrome	10048786	PT
Keratolysis exfoliativa congenital	10052290	PT
Keratosis follicular	10023369	PT
Kidney duplex	10023416	PT
Kidney malformation	10023430	PT
Kidney malrotation	10067877	PT
Kimmerle's anomaly	10076416	PT
Kinematic imbalances due to suboccipital strain	10062992	PT
Kleefstra syndrome	10079365	PT
Klinefelter's syndrome	10023463	PT
Klippel-Feil syndrome	10023464	PT
Klippel-Trenaunay syndrome	10051452	PT
Krabbe's disease	10023492	PT
Kyphosis congenital	10048576	PT

Labial tie	10076772	PT
Lacrimal punctum agenesis	10023636	PT
Laevocardia	10071015	PT
Lafora's myoclonic epilepsy	10054030	PT
Lamin A/C gene mutation	10075979	PT
Langer-Giedion syndrome	10050638	PT
Laron syndrome	10075492	PT
Larsen syndrome	10073856	PT
Laryngeal cleft	10069115	PT
Laryngeal web	10023871	PT
Laryngocele	10023885	PT
Laryngomalacia	10060786	PT
Laryngo-onycho-cutaneous syndrome	10062987	PT
Laurence-Moon-Bardet-Biedl syndrome	10056715	PT
LDLR mutation	10075640	PT
Leber's congenital amaurosis	10070667	PT
Lecithin-cholesterol acyltransferase deficiency	10077917	PT
Left ventricle outflow tract obstruction	10065930	PT
Left ventricular false tendon	10079017	PT
Left-to-right cardiac shunt	10077834	PT
Lens abnormality, congenital	10024202	PT
Leukodystrophy	10024381	PT
Lichen spinulosus	10024436	PT
Liddle's syndrome	10052313	PT
Li-Fraumeni syndrome	10066795	PT
Limb hypoplasia congenital	10048575	PT
Limb malformation	10024500	PT
Limb reduction defect	10024503	PT
Lipid proteinosis	10051661	PT
Lipidosis	10024585	PT
Lipodermoid tumour	10073484	PT
Lipomeningocele	10050084	PT
Lissencephaly	10048911	PT
Long QT syndrome congenital	10057926	PT
Long-chain acyl-coenzyme A dehydrogenase deficiency	10072653	PT
Low set ears	10024929	PT
Lown-Ganong-Levine syndrome	10024984	PT
Lowry-Wood syndrome	10062600	PT
Lumbarisation	10063410	PT
Lymphangiectasia intestinal congenital	10054722	PT
Lysinuric protein intolerance	10058300	PT
Lysosomal acid lipase deficiency	10077267	PT
Macrocephaly	10050183	PT
Macrocheilia	10025378	PT
Macrocornea	10059253	PT

Macroductyly	10025386	PT
Macrogenia	10025387	PT
Macroglossia	10025391	PT
Macrogathia	10052658	PT
Macrostomia	10025395	PT
Macrotia	10025396	PT
Macular dystrophy congenital	10025412	PT
Majeed's syndrome	10072223	PT
Malformation biliary	10025523	PT
Malformation venous	10025532	PT
Mandibulofacial dysostosis	10051456	PT
Maple syrup disease	10026817	PT
Marcus Gunn syndrome	10064583	PT
Marfan's syndrome	10026829	PT
Maxillonasal dysplasia	10075843	PT
Mayer-Rokitansky-Kuster-Hauser syndrome	10065148	PT
Medium-chain acyl-coenzyme A dehydrogenase deficiency	10072654	PT
Meier-Gorlin syndrome	10070612	PT
MELAS syndrome	10053872	PT
Melkersson-Rosenthal syndrome	10027166	PT
Membranous lipodystrophy	10065127	PT
Meningocele	10027266	PT
Meningomyelocele	10027287	PT
Menkes' syndrome	10027294	PT
Mesoblastic nephroma	10070665	PT
Mesonephric duct cyst	10027405	PT
Metabolic myopathy	10068836	PT
Metachromatic leukodystrophy	10067609	PT
Metaphyseal dysplasia	10066147	PT
Metatarsus primus varus	10027489	PT
Methylenetetrahydrofolate reductase deficiency	10070309	PT
Methylenetetrahydrofolate reductase gene mutation	10074753	PT
Methylmalonic aciduria	10059521	PT
Mevalonate kinase deficiency	10072221	PT
Mevalonic aciduria	10072219	PT
Microcephaly	10027534	PT
Microcheilia	10027535	PT
Microcolon	10073456	PT
Microcornea	10057414	PT
Microencephaly	10068320	PT
Microgenia	10027541	PT
Microglossia	10027542	PT
Micrognathia	10027543	PT
Microorchidism	10080650	PT
Micropenis	10071706	PT

Microphthalmos	10027548	PT
Microstomia	10027553	PT
Microtia	10027555	PT
Microvillous inclusion disease	10068494	PT
Mismatch repair cancer syndrome	10077888	PT
Mitochondrial DNA deletion	10051403	PT
Mitochondrial DNA depletion	10059396	PT
Mitochondrial DNA duplication	10052640	PT
Mitochondrial DNA mutation	10052641	PT
Mitochondrial encephalomyopathy	10058799	PT
Mitochondrial enzyme deficiency	10067729	PT
Mitochondrial hepatopathy	10062938	PT
Mitochondrial myopathy	10027710	PT
Mitochondrial neurogastrointestinal encephalopathy	10065271	PT
Mitral valve atresia	10066800	PT
Mitral valve hypoplasia	10049211	PT
Mittendorf dot	10076031	PT
MLASA syndrome	10078801	PT
Mobile caecum syndrome	10074307	PT
Moebius II syndrome	10027802	PT
Molybdenum cofactor deficiency	10069687	PT
Monopodia	10049214	PT
Morning glory syndrome	10027974	PT
Morton's syndrome	10079320	PT
Mosaicism	10068052	PT
Mount-Reback syndrome	10065658	PT
Muckle-Wells syndrome	10064569	PT
Mucopolipidosis	10072939	PT
Mucopolipidosis type I	10072927	PT
Mucopolipidosis type II	10072928	PT
Mucopolipidosis type III	10072929	PT
Mucopolipidosis type IV	10072930	PT
Mucopolysaccharidosis	10028093	PT
Mucopolysaccharidosis I	10056886	PT
Mucopolysaccharidosis II	10056889	PT
Mucopolysaccharidosis III	10056890	PT
Mucopolysaccharidosis IV	10028095	PT
Mucopolysaccharidosis V	10056891	PT
Mucopolysaccharidosis VI	10056892	PT
Mucopolysaccharidosis VII	10056893	PT
Muir-Torre syndrome	10063042	PT
Multiple carboxylase deficiency	10028176	PT
Multiple cardiac defects	10028178	PT
Multiple congenital abnormalities	10028182	PT
Multiple cutaneous and uterine leiomyomatosis	10077859	PT

Multiple endocrine neoplasia	10051747	PT
Multiple endocrine neoplasia Type 1	10073150	PT
Multiple endocrine neoplasia Type 2	10073149	PT
Multiple endocrine neoplasia Type 2A	10073148	PT
Multiple endocrine neoplasia Type 2B	10073151	PT
Multiple epiphyseal dysplasia	10028197	PT
Multiple gastrointestinal atresias	10028210	PT
Multiple lentiginos syndrome	10062901	PT
Muscular dystrophy	10028356	PT
Mutagenic effect	10028400	PT
Myeloperoxidase deficiency	10074767	PT
MYH9-related disease	10079437	PT
Myocardial bridging	10052289	PT
Myoclonic epilepsy and ragged-red fibres	10069825	PT
Myotonia congenita	10028655	PT
Myotonic dystrophy	10068871	PT
N-acetylglutamate synthase deficiency	10071092	PT
Naevus anaemicus	10069365	PT
Naevus flammeus	10067193	PT
Naevus spider congenital	10050896	PT
Nail aplasia	10079732	PT
Nail-patella syndrome	10063431	PT
Nasopharyngeal atresia	10069701	PT
Neonatal alloimmune thrombocytopenia	10075149	PT
Neonatal haemochromatosis	10078355	PT
Neonatal leukaemia	10028958	PT
Neonatal lupus erythematosus	10057887	PT
Netherton's syndrome	10062909	PT
Neural tube defect	10052046	PT
Neurofibromatosis	10029268	PT
Neuronal ceroid lipofuscinosis	10074607	PT
Neuronal migration disorder	10076677	PT
Neuropathy, ataxia, retinitis pigmentosa syndrome	10062940	PT
Niemann-Pick disease	10029403	PT
Nijmegen breakage syndrome	10067857	PT
Non-compaction cardiomyopathy	10079253	PT
Noonan syndrome	10029748	PT
Norrie's disease	10069760	PT
Ocular albinism	10065276	PT
Oculoauriculovertebral dysplasia	10051934	PT
Oculocerebrorenal syndrome	10051707	PT
Oculodentodigital dysplasia	10063691	PT
Oculopharyngeal dystrophy	10052181	PT
Odontogenic cyst	10063413	PT
Oesophageal atresia	10030146	PT

Oesophageal cyst	10079063	PT
Olfacto genital dysplasia	10053142	PT
Olfactory nerve agenesis	10072941	PT
Olmsted syndrome	10068842	PT
Omenn syndrome	10069097	PT
Opitz-G/BBB syndrome	10079435	PT
Optic disc pit	10079967	PT
Optic nerve hypoplasia	10062942	PT
Oral-facial-digital syndrome type II	10078419	PT
Ornithine transcarbamoylase deficiency	10052450	PT
Oroticaciduria congenital	10052773	PT
Os trigonum	10069805	PT
Osteogenesis imperfecta	10031243	PT
Osteopathia striata	10073776	PT
Osteopetrosis	10031280	PT
Osteopoikilosis	10031281	PT
Osteoporosis-pseudoglioma syndrome	10052452	PT
Ota's naevus	10051713	PT
Otocephaly	10058118	PT
Ovarian agenesis	10033120	PT
Ovarian hypoplasia	10079495	PT
Oxycephaly	10080833	PT
Pachydermoperiostosis	10051686	PT
Pachygyria	10048910	PT
Pachyonychia congenita	10080088	PT
Pallister-Killian syndrome	10080297	PT
Pancreas divisum	10069419	PT
Parachute mitral valve	10064192	PT
Paranasal sinus aplasia	10074401	PT
Parkes-Weber syndrome	10075554	PT
Patent ductus arteriosus	10034130	PT
Pearson's syndrome	10062941	PT
Pectus carinatum	10034203	PT
Pectus excavatum	10034204	PT
Pelizaeus-Merzbacher disease	10067610	PT
Pelvic kidney	10034259	PT
Pendred syndrome	10080398	PT
Penile torsion	10070235	PT
Penoscrotal fusion	10064951	PT
Penoscrotal transposition	10067287	PT
Periodontal congenital anomaly	10057476	PT
Perry syndrome	10079207	PT
Persistent cloaca	10069442	PT
Persistent foetal circulation	10034708	PT
Persistent left superior vena cava	10064193	PT

Persistent pupillary membrane	10070872	PT
Persistent urogenital sinus	10059800	PT
Peutz-Jeghers syndrome	10034764	PT
PHACES syndrome	10068032	PT
Phakomatosis	10048734	PT
Phalangeal agenesis	10054879	PT
Phalangeal hypoplasia	10049212	PT
Phenylketonuria	10034872	PT
Phimosis	10034878	PT
Phyosterolaemia	10063985	PT
Pierre Robin syndrome	10035009	PT
Pilonidal cyst congenital	10054019	PT
Plagiocephaly	10048586	PT
Platelet glycoprotein gene mutation	10071024	PT
Platonychia	10072590	PT
Platybasia	10057115	PT
Platyspondylia	10068629	PT
Poland's syndrome	10036007	PT
Polycystic liver disease	10048834	PT
Polydactyly	10036063	PT
Polymicrogyria	10073489	PT
Popliteal pterygium syndrome	10079892	PT
Porencephaly	10036172	PT
Porokeratosis	10036175	PT
Porphyria	10036181	PT
Porphyria acute	10036182	PT
Porphyria non-acute	10036186	PT
Porphyrin metabolism disorder	10061356	PT
Porphyrinuria	10036193	PT
Portal venous system anomaly	10076609	PT
Postauricular fistula	10036329	PT
Posterior segment of eye anomaly congenital	10053202	PT
Potter's syndrome	10036462	PT
Prader-Willi syndrome	10036476	PT
Preauricular cyst	10036509	PT
Preduodenal portal vein	10059798	PT
Preternatural anus	10064917	PT
Primary cerebellar degeneration	10036686	PT
Primary ciliary dyskinesia	10069713	PT
Primary familial brain calcification	10078822	PT
Primary familial hypomagnesaemia	10076626	PT
Primary hypercholesterolaemia	10077965	PT
Primary immunodeficiency syndrome	10064859	PT
Primary insulin like growth factor-1 deficiency	10071079	PT
Progeria	10036794	PT

Progressive cerebellar degeneration	10036801	PT
Progressive external ophthalmoplegia	10036802	PT
Progressive familial intrahepatic cholestasis	10076033	PT
Prominent epicanthal folds	10065273	PT
Protein C deficiency	10051298	PT
Protein S deficiency	10051292	PT
Proteus syndrome	10074067	PT
Protuberant ear	10071232	PT
Proximal focal femoral deficiency	10078473	PT
Pseudocholinesterase deficiency	10062674	PT
Pseudohermaphroditism	10037122	PT
Pseudohermaphroditism female	10037123	PT
Pseudohermaphroditism male	10037124	PT
Pseudohypoadosteronism	10080593	PT
Pseudohypoparathyroidism	10037126	PT
Pseudotruncus arteriosus	10050053	PT
Pseudoxanthoma elasticum	10037150	PT
Pterygium colli	10051972	PT
Pulmonary aplasia	10037322	PT
Pulmonary arteriovenous fistula	10037332	PT
Pulmonary artery atresia	10037337	PT
Pulmonary artery stenosis congenital	10037339	PT
Pulmonary hypoplasia	10037407	PT
Pulmonary lymphangiectasia	10073661	PT
Pulmonary malformation	10037419	PT
Pulmonary sequestration	10059160	PT
Pulmonary valve stenosis congenital	10037451	PT
Pyloric stenosis	10037621	PT
Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome	10072222	PT
Pyruvate carboxylase deficiency	10077944	PT
Pyruvate kinase deficiency anaemia	10037682	PT
Radioulnar synostosis	10037798	PT
Rathke's cleft cyst	10058969	PT
Rectal atresia	10038031	PT
Red blood cell enzymes abnormal	10049191	PT
Refsum's disease	10038275	PT
Renal aplasia	10064655	PT
Renal arteriovenous malformation	10038368	PT
Renal dysplasia	10038433	PT
Renal fusion anomaly	10068033	PT
Renal hypoplasia	10049102	PT
Renal malposition	10072019	PT
Renal vessel congenital anomaly	10038552	PT
Reproductive tract hypoplasia, male	10057858	PT
Respiratory tract malformation	10038733	PT

Retinal anomaly congenital	10038821	PT
Retinal arteriovenous malformation	10038824	PT
Retinal coloboma	10052643	PT
Retinitis pigmentosa	10038914	PT
Retinopathy congenital	10050706	PT
Retinoschisis congenital	10038938	PT
Rett syndrome	10077709	PT
Rhesus haemolytic disease of newborn	10039037	PT
Rib hypoplasia	10048893	PT
Rib synostosis	10076624	PT
Right aortic arch	10067407	PT
Right ventricle outflow tract obstruction	10064195	PT
Right ventricular false tendon	10080132	PT
Right-to-left cardiac shunt	10076605	PT
Riley-Day syndrome	10039179	PT
Rippling muscle disease	10069417	PT
Rotor's syndrome	10039234	PT
Rubinstein-Taybi syndrome	10039281	PT
Sacral hypoplasia	10056659	PT
Sacralisation	10064932	PT
Sarcosinaemia	10059299	PT
Scaphocephaly	10049426	PT
Schimke immunoosseous dysplasia	10048699	PT
Schinz-Giedion syndrome	10063540	PT
Schizencephaly	10073487	PT
Scimitar syndrome	10051951	PT
Sclerolyosis	10070504	PT
Sebaceous naevus	10039785	PT
Sensory neuropathy hereditary	10040037	PT
Septate hymen	10068484	PT
Septo-optic dysplasia	10067159	PT
Septum pellucidum agenesis	10062267	PT
Sertoli-cell-only syndrome	10066833	PT
Severe myoclonic epilepsy of infancy	10073677	PT
Sex chromosome abnormality	10061513	PT
Shawl scrotum	10080319	PT
Shone complex	10066802	PT
Short-chain acyl-coenzyme A dehydrogenase deficiency	10072655	PT
Shwachman-Diamond syndrome	10067940	PT
Sickle cell anaemia	10040641	PT
Sickle cell disease	10040644	PT
Sickle cell trait	10040650	PT
Silver-Russell syndrome	10062282	PT
Single umbilical artery	10049807	PT
Sirenomelia	10072457	PT

Sjogren-Larsson syndrome	10048676	PT
Skeletal dysplasia	10072610	PT
Skin hypoplasia	10040869	PT
Skin malformation	10040888	PT
Skull malformation	10062348	PT
Smith-Lemli-Opitz syndrome	10078573	PT
Sotos' syndrome	10064387	PT
Special senses congenital anomaly	10041420	PT
Spherophakia	10041513	PT
Spina bifida	10041524	PT
Spina bifida cystica	10071011	PT
Spina bifida occulta	10041525	PT
Spinal muscular atrophy	10041582	PT
Spinal vessel congenital anomaly	10041603	PT
Spine malformation	10041611	PT
Spinocerebellar ataxia	10057660	PT
Spleen malformation	10062350	PT
Splenic hamartoma	10076586	PT
Spondyloepiphyseal dysplasia	10062920	PT
Stargardt's disease	10062766	PT
Steatocystoma multiplex	10048905	PT
Stickler's syndrome	10063402	PT
Sticky platelet syndrome	10068788	PT
Strabismus congenital	10042161	PT
Sturge-Weber syndrome	10042265	PT
Sucrase-isomaltase deficiency	10066387	PT
Supernumerary nipple	10042571	PT
Supernumerary vertebra	10077919	PT
Syndactyly	10042778	PT
Synostosis	10042856	PT
Syringomyelia	10042928	PT
Talipes	10043101	PT
Tangier disease	10051875	PT
Tay-Sachs disease	10043147	PT
Telangiectasia congenital	10061575	PT
Teratogenicity	10043275	PT
Testicular dysplasia	10059271	PT
Testotoxicosis	10063654	PT
Tetrahydrobiopterin deficiency	10069116	PT
Thalassaemia	10043388	PT
Thalassaemia alpha	10043390	PT
Thalassaemia beta	10043391	PT
Thalassaemia sickle cell	10043395	PT
Thalidomide embryopathy	10071249	PT
Thanatophoric dwarfism	10049808	PT

Thrombocytopenia-absent radius syndrome	10071719	PT
Thymus hypoplasia	10052645	PT
Thyroglossal cyst	10051320	PT
Thyroglossal fistula	10062601	PT
Thyroid hemiagenesis	10077609	PT
Thyroid malformation	10062125	PT
Tibial agenesis	10079730	PT
Tibial torsion	10064515	PT
Tilted disc syndrome	10079368	PT
Timothy syndrome	10079205	PT
Tooth discolouration congenital	10044033	PT
Tooth hypoplasia	10044041	PT
Tooth malformation hereditary	10044047	PT
Tornwaldt cyst	10078492	PT
Tourette's disorder	10044126	PT
Tracheal atresia	10054955	PT
Tracheal web	10077940	PT
Tracheo-oesophageal fistula	10044310	PT
Transitional vertebrae	10074306	PT
Transposition of the great vessels	10044443	PT
Trichorhinophalangeal syndrome	10051956	PT
Trifunctional protein deficiency	10077949	PT
Trimethylaminuria	10068233	PT
Triple A syndrome	10073592	PT
Trisomy 11	10044685	PT
Trisomy 12	10063092	PT
Trisomy 13	10044686	PT
Trisomy 14	10071762	PT
Trisomy 15	10062757	PT
Trisomy 17	10053925	PT
Trisomy 18	10053884	PT
Trisomy 21	10044688	PT
Trisomy 22	10044689	PT
Trisomy 4p	10080079	PT
Trisomy 8	10053871	PT
Trisomy 9	10071547	PT
Truncus arteriosus persistent	10044703	PT
Tuberous sclerosis complex	10080584	PT
Tumour necrosis factor receptor-associated periodic syndrome	10067774	PT
Turner's syndrome	10045181	PT
Twin reversed arterial perfusion sequence malformation	10073455	PT
Type I hyperlipidaemia	10060749	PT
Type II hyperlipidaemia	10045254	PT
Type IIa hyperlipidaemia	10045261	PT
Type IIb hyperlipidaemia	10045263	PT

Type III hyperlipidaemia	10060751	PT
Type IV hyperlipidaemia	10060753	PT
Type V hyperlipidaemia	10060755	PT
Tyrosinaemia	10063443	PT
Uhl's anomaly	10048951	PT
Umbilical artery hypoplasia	10045445	PT
Umbilical malformation	10045469	PT
Univentricular heart	10045545	PT
Urachal abnormality	10066125	PT
Urea cycle disorder	10080020	PT
Ureteric atresia	10078351	PT
Urethral atresia	10064895	PT
Urethral valves	10046479	PT
Urinary tract malformation	10046580	PT
Usher's syndrome	10063396	PT
Uterine aplasia	10067704	PT
Uterine cervix hypoplasia	10063120	PT
Uterine hypoplasia	10063146	PT
Uvula aplasia	10053506	PT
VACTERL syndrome	10066022	PT
Vaginal atresia	10046879	PT
Vaginal hypoplasia	10053843	PT
Vaginal septum	10064513	PT
Vascular malformation	10074979	PT
Vein of Galen aneurysmal malformation	10077889	PT
Velo-cardio-facial syndrome	10066430	PT
Venolymphatic malformation	10079880	PT
Venous angioma of brain	10053485	PT
Ventricular hypoplasia	10047296	PT
Ventricular septal defect	10047298	PT
Vertebral artery hypoplasia	10066907	PT
Vertical talus	10066242	PT
Very long-chain acyl-coenzyme A dehydrogenase deficiency	10072656	PT
Vestibulocerebellar syndrome	10080748	PT
Virilism foetal	10047487	PT
Vitello-intestinal duct remnant	10066969	PT
Von Hippel-Lindau disease	10047716	PT
Von Willebrand's disease	10047715	PT
Von Willebrand's disease gene carrier	10080844	PT
Waardenburg syndrome	10069203	PT
Wagner's disease	10063383	PT
Weill-Marchesani syndrome	10064963	PT
Welander distal myopathy	10078052	PT
Werner's syndrome	10049429	PT
Wildervanck syndrome	10069402	PT

Williams syndrome	10049644	PT
Winchester syndrome	10078901	PT
Wiskott-Aldrich syndrome	10047992	PT
Wolff-Parkinson-White syndrome congenital	10049291	PT
Wolf-Hirschhorn syndrome	10050361	PT
Wolfram syndrome	10078338	PT
Wyburn Mason's syndrome	10048661	PT
Xeroderma pigmentosum	10048220	PT
X-linked chromosomal disorder	10056554	PT
X-linked lymphoproliferative syndrome	10068348	PT
XXX syndrome	10076910	PT
XXXY syndrome	10048228	PT
XXYY syndrome	10048230	PT
XYY syndrome	10056894	PT
Y-linked chromosomal disorder	10056555	PT
Young's syndrome	10063689	PT
Zika virus associated birth defect	10081047	PT
Zika virus associated microencephaly	10081048	PT
Zika virus associated ocular birth defect	10081045	PT
Alpha 1 foetoprotein amniotic fluid abnormal	10001776	PT
Alpha 1 foetoprotein amniotic fluid decreased	10060746	PT
Alpha 1 foetoprotein amniotic fluid increased	10001778	PT
Amniocentesis abnormal	10001959	PT
Amniorrhexis	10051641	PT
Amniorrhoea	10066470	PT
Amnioscopy abnormal	10001965	PT
Amniotic cavity disorder	10060936	PT
Amniotic cavity infection	10060937	PT
Amniotic fluid erythropoietin level increased	10064845	PT
Amniotic fluid index abnormal	10067079	PT
Amniotic fluid volume decreased	10063356	PT
Amniotic fluid volume increased	10063357	PT
Amniotic infection syndrome of Blane	10051407	PT
Anaesthetic complication foetal	10052850	PT
Angiotensin converting enzyme inhibitor foetopathy	10051098	PT
Baseline foetal heart rate variability disorder	10074638	PT
Biopsy chorionic villous abnormal	10048537	PT
Biopsy foetal abnormal	10058370	PT
Bradycardia foetal	10006094	PT
Cerebral haemorrhage foetal	10050157	PT
Cerebral infarction foetal	10008119	PT
Chronic villitis of unknown etiology	10072271	PT
Cordocentesis	10066447	PT
Diabetic foetopathy	10059116	PT
Diethylstilboestrol syndrome	10012780	PT

Discordant twin	10069150	PT
Ductus arteriosus stenosis foetal	10013808	PT
Erythroblastosis foetalis	10015251	PT
Foetal acidosis	10050347	PT
Foetal alcohol syndrome	10016845	PT
Foetal anaemia	10077577	PT
Foetal anticonvulsant syndrome	10066485	PT
Foetal arrhythmia	10016847	PT
Foetal biophysical profile score abnormal	10078124	PT
Foetal biophysical profile score equivocal	10078123	PT
Foetal cardiac disorder	10052088	PT
Foetal cerebrovascular disorder	10053601	PT
Foetal chromosome abnormality	10064041	PT
Foetal compartment fluid collection	10077628	PT
Foetal cystic hygroma	10052011	PT
Foetal damage	10016852	PT
Foetal disorder	10061157	PT
Foetal distress syndrome	10016855	PT
Foetal gastrointestinal tract imaging abnormal	10077579	PT
Foetal growth abnormality	10077582	PT
Foetal growth restriction	10070531	PT
Foetal heart rate abnormal	10051139	PT
Foetal heart rate acceleration abnormality	10074642	PT
Foetal heart rate deceleration abnormality	10074636	PT
Foetal heart rate decreased	10051136	PT
Foetal heart rate disorder	10061158	PT
Foetal heart rate increased	10051138	PT
Foetal heart rate indeterminate	10079882	PT
Foetal hypokinesia	10068461	PT
Foetal macrosomia	10053700	PT
Foetal malformation	10060919	PT
Foetal malnutrition	10016862	PT
Foetal megacystis	10073660	PT
Foetal methotrexate syndrome	10071183	PT
Foetal monitoring abnormal	10071507	PT
Foetal movement disorder	10077576	PT
Foetal musculoskeletal imaging abnormal	10077580	PT
Foetal non-stress test abnormal	10071516	PT
Foetal placental thrombosis	10072240	PT
Foetal renal imaging abnormal	10077581	PT
Foetal renal impairment	10078987	PT
Foetal retinoid syndrome	10073720	PT
Foetal surgery	10080563	PT
Foetal tachyarrhythmia	10077575	PT
Foetal therapeutic procedure	10057294	PT

Foetal warfarin syndrome	10051445	PT
Foetal-maternal haemorrhage	10016871	PT
Gestational age test abnormal	10072479	PT
Haemorrhage foetal	10061191	PT
Hydrops foetalis	10020529	PT
Hypocalvaria	10073670	PT
Hypopituitarism foetal	10021068	PT
Intrauterine infection	10056254	PT
Maternal condition affecting foetus	10057673	PT
Maternal death affecting foetus	10026912	PT
Maternal drugs affecting foetus	10026923	PT
Maternal hypertension affecting foetus	10026924	PT
Meconium in amniotic fluid	10051133	PT
Meconium increased	10027059	PT
Meconium peritonitis	10058113	PT
Meconium stain	10057028	PT
Mirror syndrome	10068875	PT
Nonreassuring foetal heart rate pattern	10074641	PT
Oligohydramnios	10030289	PT
Omphalorrhexis	10064270	PT
Paternal drugs affecting foetus	10050425	PT
Polyhydramnios	10036079	PT
Prenatal screening test abnormal	10069151	PT
Radiation injury affecting foetus	10053602	PT
Sinusoidal foetal heart rate pattern	10074643	PT
Tachycardia foetal	10043074	PT
Thalidomide embryopathy	10071249	PT
Twin reversed arterial perfusion sequence malformation	10073455	PT
Ultrasound antenatal screen abnormal	10045400	PT
Ultrasound foetal abnormal	10077578	PT
Umbilical cord abnormality	10048596	PT
Umbilical cord around neck	10045447	PT
Umbilical cord compression	10045451	PT
Umbilical cord cyst	10079122	PT
Umbilical cord haemorrhage	10064534	PT
Umbilical cord occlusion	10076714	PT
Umbilical cord prolapse	10045452	PT
Umbilical cord short	10045453	PT
Umbilical cord thrombosis	10071652	PT
Umbilical cord vascular disorder	10045454	PT
Vesicoamniotic shunt	10068236	PT
Virilism foetal	10047487	PT
Alpha 1 foetoprotein abnormal	10001773	PT
Alpha 1 foetoprotein decreased	10001780	PT
Alpha 1 foetoprotein increased	10001781	PT

Breast milk discolouration	10058665	PT
Breast milk odour abnormal	10080335	PT
Galactocele	10017590	PT
Galactostasis	10060710	PT
Lactation disorder	10061261	PT
Lactation inhibition therapy	10069058	PT
Lactation puerperal increased	10023671	PT
Lactation stimulation therapy	10079806	PT
Mastitis	10026883	PT
Mastitis bacterial	10065212	PT
Mastitis fungal	10065211	PT
Mastitis postpartum	10026889	PT
Neonatal insufficient breast milk syndrome	10072188	PT
Nipple infection	10029419	PT
Nipple inflammation	10064043	PT
Retracted nipple	10038944	PT
Suppressed lactation	10042576	PT
Viral mastitis	10074560	PT
Exposure via breast milk	10080751	PT
Intoxication by breast feeding	10049999	PT
Acne infantile	10000507	PT
Adrenocortical insufficiency neonatal	10001391	PT
Agitation neonatal	10001500	PT
Alveolar capillary dysplasia	10077023	PT
Anaemia neonatal	10002068	PT
Anaesthetic complication neonatal	10052851	PT
Aorticopulmonary window repair	10066834	PT
Apgar score abnormal	10056850	PT
Apgar score low	10002944	PT
Arrhythmia neonatal	10003124	PT
Arterial switch operation	10066129	PT
Atelectasis neonatal	10003599	PT
Atrial septal defect repair	10003667	PT
Atrial switch operation	10068964	PT
Balloon atrial septostomy	10064200	PT
Birth trauma	10004954	PT
Blood loss anaemia neonatal	10005644	PT
Bradycardia neonatal	10056471	PT
Breast engorgement in newborn	10006241	PT
Bronchopulmonary dysplasia	10006475	PT
Caput succedaneum	10056311	PT
Cardiac arrest neonatal	10007516	PT
Cardiomyopathy neonatal	10050111	PT
Cardio-respiratory arrest neonatal	10007618	PT
Cephalhaematoma	10008014	PT

Cerebral haemorrhage neonatal	10008112	PT
Circulatory failure neonatal	10009196	PT
Cleft lip repair	10056999	PT
Cleft palate repair	10009272	PT
Coagulation disorder neonatal	10009732	PT
Collodion baby	10009926	PT
Coma neonatal	10059497	PT
Convulsion neonatal	10010911	PT
Coxsackie viral disease of the newborn	10011260	PT
Cranial nerve injury secondary to birth trauma	10011308	PT
Cranial sutures widening	10058604	PT
Craniosynostosis	10049889	PT
Cyanosis neonatal	10011705	PT
Death neonatal	10011912	PT
Delayed closure of cranial sutures	10054008	PT
Delayed fontanelle closure	10054034	PT
Developmental hip dysplasia	10073767	PT
Diarrhoea infectious neonatal	10012744	PT
Diarrhoea neonatal	10012743	PT
Discordant twin	10069150	PT
Disseminated intravascular coagulation in newborn	10013443	PT
Disturbance of thermoregulation of newborn	10074158	PT
Drug withdrawal syndrome neonatal	10013756	PT
Dry lung syndrome	10074163	PT
Dyskinesia neonatal	10013922	PT
Early infantile epileptic encephalopathy with burst-suppression	10071545	PT
Eczema infantile	10014198	PT
Encephalopathy neonatal	10014633	PT
Endocardial cushion defect repair	10014657	PT
Epileptic encephalopathy	10077380	PT
Erythema toxicum neonatorum	10056274	PT
Facial nerve injury due to birth trauma	10016056	PT
Familial infantile bilateral striatal necrosis	10077450	PT
Feeding intolerance	10076042	PT
Fever neonatal	10016562	PT
Fixed bowel loop	10074216	PT
Floppy infant	10051004	PT
Fontanelle bulging	10016945	PT
Fontanelle depressed	10053214	PT
Fracture of clavicle due to birth trauma	10017107	PT
Fryns syndrome	10075223	PT
Funisitis	10064502	PT
Gangrene neonatal	10017717	PT
Gaspings syndrome	10069162	PT
Granulocytopenia neonatal	10018688	PT

Grey syndrome neonatal	10018723	PT
Group B streptococcus neonatal sepsis	10053588	PT
Haemolysis neonatal	10050190	PT
Haemorrhage neonatal	10061993	PT
Haemorrhagic disease of newborn	10019008	PT
Head circumference abnormal	10060043	PT
Hepatitis neonatal	10019785	PT
Hepatocellular damage neonatal	10019834	PT
Hepatosplenomegaly neonatal	10019848	PT
Herpes simplex virus conjunctivitis neonatal	10049458	PT
Hygroma colli	10050249	PT
Hyperbilirubinaemia neonatal	10020580	PT
Hyperkinesia neonatal	10020652	PT
Hypertension neonatal	10049781	PT
Hypertonia neonatal	10048615	PT
Hypoglycaemia neonatal	10020994	PT
Hypokinesia neonatal	10021022	PT
Hypoplastic nasal cartilage	10074970	PT
Hypothermia neonatal	10050080	PT
Hypotonia neonatal	10021119	PT
Hypoventilation neonatal	10021134	PT
Immature larynx	10048855	PT
Immature respiratory system	10021412	PT
Inclusion conjunctivitis neonatal	10053991	PT
Incubator therapy	10056613	PT
Infantile apnoea	10077321	PT
Infantile asthma	10049585	PT
Infantile back arching	10077276	PT
Infantile colic	10021746	PT
Infantile haemangioma	10075378	PT
Infantile scurvy	10021749	PT
Infantile spasms	10021750	PT
Infantile spitting up	10063338	PT
Infantile vomiting	10075315	PT
Injury to brachial plexus due to birth trauma	10022158	PT
Injury to spinal cord secondary to birth trauma	10022343	PT
Intoxication by breast feeding	10049999	PT
Intraventricular haemorrhage neonatal	10022841	PT
Isoimmune haemolytic disease	10023052	PT
Jaundice neonatal	10023138	PT
Johanson-Blizzard syndrome	10074947	PT
Junctional ectopic tachycardia	10074640	PT
Kernicterus	10023376	PT
Large for dates baby	10023789	PT
Late metabolic acidosis of newborn	10024004	PT

Lenticulostriatal vasculopathy	10073774	PT
Leukopenia neonatal	10050504	PT
Low birth weight baby	10067508	PT
Lymphocytopenia neonatal	10025279	PT
Meconium abnormal	10051132	PT
Meconium aspiration syndrome	10076496	PT
Meconium cyst	10074182	PT
Meconium ileus	10027058	PT
Meconium increased	10027059	PT
Meconium peritonitis	10058113	PT
Meconium plug syndrome	10057075	PT
Meconium stain	10057028	PT
Melaena neonatal	10049777	PT
Meningitis neonatal	10058780	PT
Meningoencephalitis herpes simplex neonatal	10053586	PT
Myasthenia gravis neonatal	10028419	PT
Necrotising enterocolitis neonatal	10055667	PT
Neonatal alloimmune thrombocytopenia	10075149	PT
Neonatal alveolar aeration excessive	10028918	PT
Neonatal anoxia	10028921	PT
Neonatal anuria	10049778	PT
Neonatal asphyxia	10028923	PT
Neonatal aspiration	10059033	PT
Neonatal behavioural syndrome	10072605	PT
Neonatal candida infection	10028924	PT
Neonatal cardiac failure	10049780	PT
Neonatal cholestasis	10056528	PT
Neonatal complications of substance abuse	10061862	PT
Neonatal deafness	10080897	PT
Neonatal diabetes mellitus	10028933	PT
Neonatal disorder	10028934	PT
Neonatal exchange blood transfusion	10028937	PT
Neonatal gastrointestinal disorder	10076388	PT
Neonatal gastrointestinal haemorrhage	10074159	PT
Neonatal haemochromatosis	10078355	PT
Neonatal hepatomegaly	10049995	PT
Neonatal hypoacusis	10080902	PT
Neonatal hypocalcaemia	10079306	PT
Neonatal hyponatraemia	10049222	PT
Neonatal hypoparathyroidism	10056974	PT
Neonatal hypotension	10049223	PT
Neonatal hypoxia	10050081	PT
Neonatal infection	10061308	PT
Neonatal infective mastitis	10028950	PT
Neonatal intestinal dilatation	10058934	PT

Neonatal intestinal obstruction	10028951	PT
Neonatal intestinal perforation	10074160	PT
Neonatal mucocutaneous herpes simplex	10053587	PT
Neonatal multi-organ failure	10050401	PT
Neonatal neuroblastoma	10049793	PT
Neonatal oversedation	10050395	PT
Neonatal pneumonia	10053584	PT
Neonatal respiratory acidosis	10028966	PT
Neonatal respiratory alkalosis	10028967	PT
Neonatal respiratory arrest	10028968	PT
Neonatal respiratory depression	10028970	PT
Neonatal respiratory distress	10028973	PT
Neonatal respiratory distress syndrome	10028974	PT
Neonatal respiratory distress syndrome prophylaxis	10054933	PT
Neonatal respiratory failure	10028975	PT
Neonatal tachycardia	10049775	PT
Neonatal tachypnoea	10057183	PT
Neonatal testicular torsion	10075380	PT
Neonatal tetany	10057037	PT
Neonatal thyrotoxicosis	10028976	PT
Neonatal toxicity	10078986	PT
Neonatal warming therapy	10056585	PT
Neuroendocrine cell hyperplasia of infancy	10072968	PT
Neutropenia neonatal	10029358	PT
Norwood procedure	10068098	PT
Oedema neonatal	10061317	PT
Omphalitis	10030306	PT
Ophthalmia neonatorum	10030861	PT
Overfeeding of infant	10059260	PT
Parenteral nutrition associated liver disease	10074151	PT
Patent ductus arteriosus repair	10034131	PT
Perinatal brain damage	10056392	PT
Perinatal HBV infection	10075233	PT
Perinatal HIV infection	10071049	PT
Perinatal stroke	10073945	PT
Peripheral oedema neonatal	10049779	PT
Periventricular haemorrhage neonatal	10076706	PT
Periventricular leukomalacia	10052594	PT
Polycythaemia neonatorum	10060476	PT
Poor feeding infant	10075316	PT
Poor sucking reflex	10058605	PT
Poor weight gain neonatal	10050086	PT
Posthaemorrhagic hydrocephalus	10079859	PT
Postmature baby	10036392	PT
Premature baby	10036590	PT

Primary familial hypomagnesaemia	10076626	PT
Pulmonary air leakage	10067826	PT
Pulmonary dysmaturity syndrome	10053766	PT
Pulmonary lymphangiectasia	10073661	PT
Pulmonary oedema neonatal	10050459	PT
Purpura neonatal	10037557	PT
Pyloromyotomy	10037626	PT
Rash neonatal	10037871	PT
Renal failure neonatal	10038447	PT
Renal impairment neonatal	10049776	PT
Repair of imperforate rectum	10038570	PT
Respiratory disorder neonatal	10061484	PT
Respiratory tract haemorrhage neonatal	10038728	PT
Retinopathy of prematurity	10038933	PT
Rhesus incompatibility	10063676	PT
Sepsis neonatal	10040049	PT
Small for dates baby	10041092	PT
Somnolence neonatal	10041350	PT
Sporadic infantile bilateral striatal necrosis	10077451	PT
Subarachnoid haemorrhage neonatal	10042317	PT
Subdural haemorrhage neonatal	10042365	PT
Subgaleal haematoma	10069510	PT
Sudden infant death syndrome	10042440	PT
Systemic-pulmonary artery shunt	10052717	PT
Tetanus neonatorum	10043378	PT
Tetralogy of Fallot repair	10067017	PT
Thrombocytopenia neonatal	10043557	PT
Thrombophlebitis neonatal	10043586	PT
Transient hypogammaglobulinaemia of infancy	10044388	PT
Transient hypothyroxinaemia of prematurity	10075901	PT
Transient neonatal pustular melanosis	10072688	PT
Transient tachypnoea of the newborn	10044403	PT
Tremor neonatal	10044575	PT
Umbilical discharge	10072595	PT
Umbilical granuloma	10067731	PT
Umbilical sepsis	10045470	PT
Urinary tract infection neonatal	10046573	PT
Venous thrombosis neonatal	10064602	PT
Ventricular septal defect repair	10047301	PT
Vision abnormal neonatal	10047511	PT
Weight decrease neonatal	10047894	PT
ABO incompatibility	10000206	PT
Alloimmunisation	10060935	PT
Apparent life threatening event	10065044	PT
Breast milk substitute intolerance	10072187	PT

Extraocular retinoblastoma	10015831	PT
Failure to thrive	10016165	PT
Growth failure	10071095	PT
Maternal exposure during delivery	10071407	PT
Neuroblastoma	10029260	PT
Thymus enlargement	10065588	PT
Alpha 1 foetoprotein amniotic fluid normal	10001779	PT
Amniocentesis normal	10001963	PT
Amnioscopy normal	10001966	PT
Biopsy foetal normal	10058398	PT
Birth weight normal	10078661	PT
Caesarean delivery on maternal request	10076983	PT
Cervical dilatation	10079273	PT
Chloasma	10008570	PT
Delivery	10067647	PT
False negative pregnancy test	10063476	PT
First trimester pregnancy	10052395	PT
Foetal heart rate normal	10051140	PT
Human chorionic gonadotropin increased	10071332	PT
Human chorionic gonadotropin positive	10071335	PT
Labour pain	10059204	PT
Live birth	10049550	PT
Multigravida	10028160	PT
Multiparous	10028163	PT
Newborn head moulding	10077984	PT
Normal foetus	10049081	PT
Normal labour	10029767	PT
Normal newborn	10029769	PT
Nulliparous	10029827	PT
Parity	10033997	PT
Planning to become pregnant	10076056	PT
Postpartum state	10048738	PT
Pregnancy	10036556	PT
Pregnancy after post coital contraception	10063671	PT
Pregnancy of partner	10050192	PT
Pregnancy on contraceptive	10067667	PT
Pregnancy on oral contraceptive	10036567	PT
Pregnancy test positive	10036575	PT
Pregnancy test urine positive	10036578	PT
Pregnancy with contraceptive device	10063130	PT
Pregnancy with contraceptive patch	10067082	PT
Pregnancy with implant contraceptive	10063122	PT
Pregnancy with injectable contraceptive	10053394	PT
Prenatal care	10052859	PT
Primigravida	10036757	PT

Primiparous	10036758	PT
Second trimester pregnancy	10052396	PT
Term baby	10080681	PT
Term birth	10072953	PT
Third trimester pregnancy	10052397	PT
Ultrasound antenatal screen normal	10045401	PT
Unintended pregnancy	10045542	PT
Unwanted pregnancy	10046267	PT
Uterine contractions during pregnancy	10049975	PT
Alpha 1 foetoprotein normal	10001782	PT
Breast engorgement	10006240	PT
Abnormal labour	10000153	PT
Abnormal labour affecting foetus	10000154	PT
Acute fatty liver of pregnancy	10000746	PT
Afterbirth pain	10049589	PT
Amniocentesis abnormal	10001959	PT
Amniorrhexis	10051641	PT
Amniorrhoea	10066470	PT
Amnioscopy abnormal	10001965	PT
Amniotic cavity disorder	10060936	PT
Amniotic cavity infection	10060937	PT
Amniotic fluid erythropoietin level increased	10064845	PT
Amniotic fluid index abnormal	10067079	PT
Amniotic fluid index decreased	10075866	PT
Amniotic fluid index increased	10075867	PT
Amniotic fluid volume decreased	10063356	PT
Amniotic fluid volume increased	10063357	PT
Amniotic infection syndrome of Blane	10051407	PT
Amniotic membrane rupture test positive	10078834	PT
Anaemia of pregnancy	10066468	PT
Anaphylactoid syndrome of pregnancy	10067010	PT
Angiotensin II receptor type 1 antibody positive	10079737	PT
Arrested labour	10003118	PT
Artificial rupture of membranes	10003440	PT
Assisted delivery	10061661	PT
Bacteriuria in pregnancy	10004058	PT
Benign hydatidiform mole	10004272	PT
Bimanual uterine compression	10080950	PT
Biopsy chorionic villous abnormal	10048537	PT
Blood type incompatibility	10078985	PT
Breech delivery	10006346	PT
Breech presentation	10006356	PT
Brief psychotic disorder, with postpartum onset	10006362	PT
Brow presentation	10052848	PT
Caesarean section	10006924	PT

Cephalo-pelvic disproportion	10008020	PT
Cervical incompetence	10008267	PT
Cervix cerclage procedure	10054992	PT
Cervix dystocia	10054939	PT
Chloasma	10008570	PT
Cholestasis of pregnancy	10049055	PT
Chorioamniotic separation	10080381	PT
Chronic villitis of unknown etiology	10072271	PT
Complication of delivery	10061781	PT
Complication of pregnancy	10061452	PT
Decidual cast	10068735	PT
Delayed delivery	10012186	PT
Delivery outside health facility	10072446	PT
Diabetes complicating pregnancy	10012596	PT
Discordant twin	10069150	PT
Drug dependence, antepartum	10013675	PT
Drug dependence, postpartum	10013676	PT
Drug use disorder, antepartum	10079382	PT
Drug use disorder, postpartum	10079383	PT
Eclampsia	10014129	PT
Ectopic pregnancy	10014166	PT
Ectopic pregnancy termination	10014168	PT
Ectopic pregnancy with contraceptive device	10074497	PT
Elderly primigravida	10014349	PT
Endometritis bacterial	10074861	PT
Endometritis decidual	10014792	PT
Exposure during pregnancy	10073513	PT
Exposure via father	10071403	PT
External cephalic version	10070636	PT
Face presentation	10016035	PT
Failed induction of labour	10016123	PT
Failed trial of labour	10016142	PT
False labour	10016194	PT
Foetal arm prolapse	10016846	PT
Foetal exposure during delivery	10071409	PT
Foetal exposure during pregnancy	10071404	PT
Foetal exposure timing unspecified	10071405	PT
Foetal malposition	10016863	PT
Foetal malpresentation	10058013	PT
Foetal monitoring abnormal	10071507	PT
Foetal placental thrombosis	10072240	PT
Gestational diabetes	10018209	PT
Gestational hypertension	10070538	PT
Gestational oedema	10063412	PT
Gestational trophoblastic detachment	10049469	PT

Glucose tolerance impaired in pregnancy	10018430	PT
Glycosuria during pregnancy	10018475	PT
Haemorrhage in pregnancy	10018981	PT
HELLP syndrome	10049058	PT
Herpes gestationis	10019939	PT
Heterotopic pregnancy	10064228	PT
High foetal head	10020065	PT
High risk pregnancy	10052744	PT
Hyperemesis gravidarum	10020614	PT
Hyperreactio luteinalis	10074866	PT
Impetigo herpetiformis	10021534	PT
Incoordinate uterine action	10021648	PT
Induced labour	10021718	PT
Inferior vena cava syndrome	10070911	PT
Intrapartum haemorrhage	10067703	PT
Intrauterine infection	10056254	PT
Kleihauer-Betke test positive	10072577	PT
Labour augmentation	10079807	PT
Labour complication	10061050	PT
Labour induction	10052856	PT
Labour stimulation	10052855	PT
Large for dates baby	10023789	PT
Lochial infection	10066103	PT
Locked twins	10024787	PT
Lymphocytic hypophysitis	10063685	PT
Malignant hydatidiform mole	10025598	PT
Malignant neoplasm of placenta	10026350	PT
Mastitis postpartum	10026889	PT
Maternal alcohol use	10065158	PT
Maternal cancer in pregnancy	10079877	PT
Maternal death during childbirth	10066376	PT
Maternal distress during labour	10056391	PT
Maternal exposure before pregnancy	10071406	PT
Maternal exposure during pregnancy	10071408	PT
Maternal exposure timing unspecified	10071415	PT
Maternal therapy to enhance foetal lung maturity	10058340	PT
Metastases to placenta	10049725	PT
Mirror syndrome	10068875	PT
Missed labour	10059107	PT
Multiple pregnancy	10028243	PT
Oblique presentation	10052849	PT
Obstetric infection	10053636	PT
Obstetric procedure complication	10061315	PT
Obstetrical pulmonary embolism	10029925	PT
Obstructed labour	10029934	PT

Oligohydramnios	10030289	PT
Omphalorrhexis	10064270	PT
Paternal exposure before pregnancy	10080093	PT
Paternal exposure during pregnancy	10080091	PT
Paternal exposure timing unspecified	10080092	PT
Pelvic haematoma obstetric	10034248	PT
Perineal repair breakdown	10034528	PT
Peripartum cardiomyopathy	10049430	PT
Peripartum haemorrhage	10072693	PT
Placenta accreta	10062936	PT
Placenta praevia	10035119	PT
Placenta praevia haemorrhage	10035121	PT
Placental chorioangioma	10056718	PT
Placental disorder	10035132	PT
Placental dysplasia	10054810	PT
Placental hypertrophy	10068326	PT
Placental infarction	10064620	PT
Placental insufficiency	10035138	PT
Placental necrosis	10035139	PT
Placental neoplasm	10061349	PT
Placental polyp	10035142	PT
Placental transfusion syndrome	10035146	PT
Polyhydramnios	10036079	PT
Polymorphic eruption of pregnancy	10066100	PT
Postpartum disorder	10061469	PT
Postpartum haemorrhage	10036417	PT
Postpartum hypopituitarism	10036297	PT
Postpartum neurosis	10036419	PT
Postpartum sepsis	10036422	PT
Postpartum stress disorder	10056394	PT
Postpartum thrombosis	10077022	PT
Postpartum uterine subinvolution	10036423	PT
Postpartum venous thrombosis	10036300	PT
Precipitate labour	10036519	PT
Pre-eclampsia	10036485	PT
Pregnancy in habitual aborter	10036562	PT
Pregnancy of unknown location	10072811	PT
Pregnancy with advanced maternal age	10036582	PT
Pregnancy with young maternal age	10069615	PT
Premature delivery	10036595	PT
Premature labour	10036600	PT
Premature rupture of membranes	10036603	PT
Premature separation of placenta	10036608	PT
Prenatal screening test abnormal	10069151	PT
Preterm premature rupture of membranes	10073024	PT

Previous caesarean section	10036656	PT
Prolonged labour	10036872	PT
Prolonged pregnancy	10036877	PT
Prolonged rupture of membranes	10073027	PT
Prophylaxis against Rh isoimmunisation	10066359	PT
Prophylaxis of abortion	10065000	PT
Puerperal infection	10072652	PT
Puerperal pyrexia	10037294	PT
Renal disorder in pregnancy	10056505	PT
Retained placenta operation	10078243	PT
Retained placenta or membranes	10038758	PT
Retained products of conception	10038773	PT
Retroplacental haematoma	10054798	PT
Rhesus incompatibility	10063676	PT
Risk of future pregnancy miscarriage	10078342	PT
Rubella in pregnancy	10039264	PT
Ruptured ectopic pregnancy	10048407	PT
Short interpregnancy interval	10079272	PT
Shortened cervix	10067726	PT
Shoulder dystocia	10040613	PT
Silent thyroiditis	10079012	PT
Small size placenta	10072038	PT
Subchorionic haematoma	10072596	PT
Third stage postpartum haemorrhage	10043449	PT
Threatened labour	10043508	PT
Threatened uterine rupture	10080427	PT
Thyroid dysfunction in pregnancy	10056525	PT
Transverse presentation	10044456	PT
Traumatic delivery	10044520	PT
Tubal rupture	10067553	PT
Twin pregnancy	10045188	PT
Ultrasound antenatal screen abnormal	10045400	PT
Umbilical cord abnormality	10048596	PT
Umbilical cord around neck	10045447	PT
Umbilical cord compression	10045451	PT
Umbilical cord cyst	10079122	PT
Umbilical cord haemorrhage	10064534	PT
Umbilical cord prolapse	10045452	PT
Umbilical cord short	10045453	PT
Umbilical cord thrombosis	10071652	PT
Umbilical cord vascular disorder	10045454	PT
Unstable foetal lie	10046255	PT
Uterine adhesions	10074333	PT
Uterine cervix stenosis	10067732	PT
Uterine compression sutures	10078738	PT

Uterine contractions abnormal	10061400	PT
Uterine contractions during pregnancy	10049975	PT
Uterine dehiscence	10070301	PT
Uterine hyperstimulation	10066288	PT
Uterine hypertonus	10046790	PT
Uterine hypotonus	10046792	PT
Uterine inversion	10046796	PT
Uterine irritability	10079224	PT
Uterine malposition	10046800	PT
Uterine rupture	10046820	PT
Uterine tachysystole	10080022	PT
Vasa praevia	10047036	PT
Venous thrombosis in pregnancy	10067030	PT
Vomiting in pregnancy	10047704	PT
Antiphospholipid syndrome	10002817	PT
Induction of cervix ripening	10073175	PT
Perineal haematoma	10034520	PT
Perineal injury	10073329	PT
Pituitary infarction	10035092	PT
Postponement of preterm delivery	10073177	PT
Reversible cerebral vasoconstriction syndrome	10073240	PT
Uterine scar	10074527	PT
Uterine scar diverticulum	10076608	PT
Varicose veins vaginal	10066002	PT
Vulvovaginal injury	10071212	PT
Abnormal product of conception	10060927	PT
Aborted pregnancy	10000209	PT
Abortion	10000210	PT
Abortion complete	10061614	PT
Abortion complete complicated	10000212	PT
Abortion complicated	10061615	PT
Abortion early	10052846	PT
Abortion incomplete	10000217	PT
Abortion incomplete complicated	10000218	PT
Abortion induced	10000220	PT
Abortion induced complete	10060928	PT
Abortion induced complete complicated	10000221	PT
Abortion induced complicated	10000223	PT
Abortion induced incomplete	10053984	PT
Abortion induced incomplete complicated	10000225	PT
Abortion infected	10000228	PT
Abortion late	10052847	PT
Abortion missed	10000230	PT
Abortion of ectopic pregnancy	10066266	PT
Abortion spontaneous	10000234	PT

Abortion spontaneous complete	10061616	PT
Abortion spontaneous complete complicated	10000236	PT
Abortion spontaneous complicated	10000238	PT
Abortion spontaneous incomplete	10061617	PT
Abortion spontaneous incomplete complicated	10000239	PT
Abortion threatened	10000242	PT
Anembryonic gestation	10079814	PT
Biochemical pregnancy	10063639	PT
Ectopic pregnancy termination	10014168	PT
Evacuation of retained products of conception	10015550	PT
Foetal death	10055690	PT
Foeticide	10075033	PT
Habitual abortion	10062935	PT
Imminent abortion	10051459	PT
Induced abortion failed	10053191	PT
Induced abortion haemorrhage	10052844	PT
Induced abortion infection	10052845	PT
Molar abortion	10065942	PT
Mycoplasmal postabortal fever	10028479	PT
Post abortion complication	10036244	PT
Post abortion haemorrhage	10036246	PT
Post abortion infection	10061467	PT
Premature baby death	10076700	PT
Prophylaxis of abortion	10065000	PT
Retained products of conception	10038773	PT
Risk of future pregnancy miscarriage	10078342	PT
Selective abortion	10067499	PT
Stillbirth	10042062	PT
Twin reversed arterial perfusion sequence malformation	10073455	PT
Vanishing twin syndrome	10071398	PT

18.2 Adverse Events Related to Pregnancy

Events pertaining to PTs from MedDRA SMQ “Pregnancy and neonatal topics” with rationales for exclusion in the AEs related to pregnancy.

Unique Subject Identifier	Reported Term for the Clinical Event	Analysis Preferred Term Code	Analysis Preferred Term	Start Date/Time of Clinical Event	End Date/Time of Adverse Event	Severity/Intensity	Causality	Outcome of Event	Relationship to Non-Study Treatment	Action Taken with Study Treatment	Serious Event	AE related to pregnancy ?	Reason for exclusion
PPD													

PPD



PPD



PPD



PPD



PPD



PPD



PPD



18.3 AESI: Opportunistic Infections

Name	Code	Level	Action
Immunodeficiency disorders NEC	10052739	HLT	Include
Adenoviral infections	10001258	HLT	Include
Allescheria infections	10001753	HLT	Include
Aspergillus infections	10003486	HLT	Include
Atypical mycobacterial infections	10003754	HLT	Include
Blastomyces infections	10005096	HLT	Include
Candida infections	10007134	HLT	Include
Coccidioides infections	10009824	HLT	Include
Cryptococcal infections	10011486	HLT	Include
Cryptosporidia infections	10011499	HLT	Include
Cytomegaloviral infections	10011827	HLT	Include
Fungal infections NEC	10017536	HLT	Include
Histoplasma infections	10020140	HLT	Include
Legionella infections	10024179	HLT	Include
Listeria infections	10024639	HLT	Include
Paracoccidioides infections	10033767	HLT	Include
Pneumocystis infections	10035660	HLT	Include
Pseudallescheria infections	10037104	HLT	Include
Rhinosporidia infections	10039103	HLT	Include
Bartonella infections	10044583	HLT	Include
Toxoplasma infections	10057179	HLT	Include
Tuberculous infections	10044756	HLT	Include
Acinetobacter bacteraemia	10064965	PT	Include
Acinetobacter infection	10051894	PT	Include
Encephalitis protozoal	10061118	PT	Include
Gastrointestinal protozoal infection	10061175	PT	Include
Infection in an immunocompromised host	10021818	PT	Include
Microsporidia infection	10053982	PT	Include
Pelvic inflammatory disease mycoplasmal	10034256	PT	Include
Secondary immunodeficiency	10054979	PT	Include
Trichophytic granuloma	10053419	PT	Include
Vulvovaginal mycotic infection	10064899	PT	Exclude
Balanitis candida	10004074	PT	Exclude
Candida nappy rash	10007135	PT	Exclude
Fungal paronychia	10017540	PT	Exclude
Fungal skin infection	10017543	PT	Exclude
Genital candidiasis	10018143	PT	Exclude
Isosporiasis	10023076	PT	Include
Mucocutaneous candidiasis	10028080	PT	Exclude
Nail candida	10028688	PT	Exclude
Neonatal candida infection	10028924	PT	Exclude
Onychomycosis	10030338	PT	Exclude

████████████████████
████████████████████

████████████████████
████████████████████

Name	Code	Level	Action
Oral candidiasis	10030963	PT	Exclude
Vulvovaginal candidiasis	10047784	PT	Exclude
Microsporium infection	10054121	PT	Include
Skin candida	10054152	PT	Exclude
Salmonella sepsis	10058878	PT	Include
Oral fungal infection	10061324	PT	Exclude
Progressive vaccinia	10069582	PT	Include
Polyoma virus infection	10057200	HLT	Include

[REDACTED]
[REDACTED]

[REDACTED]

18.4 AESI Herpes Zoster

Name	Code	Level
Herpes zoster	10019974	PT
Ophthalmic herpes zoster	10030865	PT
Herpes zoster infection neurological	10061208	PT
Herpes zoster oticus	10063491	PT
Herpes zoster disseminated	10065038	PT
Genital herpes zoster	10072210	PT
Herpes zoster pharyngitis	10074245	PT
Herpes zoster meningoencephalitis	10074248	PT
Herpes zoster meningomyelitis	10074251	PT
Herpes zoster necrotising retinopathy	10074253	PT
Herpes zoster meningitis	10074259	PT
Herpes zoster cutaneous disseminated	10074297	PT
Herpes zoster meningoradiculitis	10079327	PT

18.5 Malignant or Unspecified Tumours (SMQ 20000091)

Name	Code	Level
5q minus syndrome	10068532	PT
Acute bilineal leukaemia	10080323	PT
Acute biphenotypic leukaemia	10067399	PT
Acute leukaemia	10000830	PT
Acute leukaemia in remission	10060930	PT
Acute lymphocytic leukaemia	10000846	PT
Acute lymphocytic leukaemia (in remission)	10000847	PT
Acute lymphocytic leukaemia recurrent	10063620	PT
Acute lymphocytic leukaemia refractory	10076866	PT
Acute megakaryocytic leukaemia	10000860	PT
Acute megakaryocytic leukaemia (in remission)	10057194	PT
Acute monocytic leukaemia	10000871	PT
Acute monocytic leukaemia (in remission)	10000872	PT
Acute myeloid leukaemia	10000880	PT
Acute myeloid leukaemia (in remission)	10000881	PT
Acute myeloid leukaemia recurrent	10059034	PT
Acute myelomonocytic leukaemia	10000890	PT
Acute promyelocytic leukaemia	10001019	PT
Acute undifferentiated leukaemia	10073479	PT
Adult T-cell lymphoma/leukaemia	10001413	PT
Adult T-cell lymphoma/leukaemia recurrent	10001416	PT
Adult T-cell lymphoma/leukaemia refractory	10001417	PT
Adult T-cell lymphoma/leukaemia stage I	10001418	PT
Adult T-cell lymphoma/leukaemia stage II	10001419	PT
Adult T-cell lymphoma/leukaemia stage III	10001420	PT
Adult T-cell lymphoma/leukaemia stage IV	10001421	PT
Aleukaemic leukaemia	10001660	PT
Anaplastic large cell lymphoma T- and null-cell types	10002227	PT
Anaplastic large cell lymphoma T- and null-cell types recurrent	10002229	PT
Anaplastic large cell lymphoma T- and null-cell types refractory	10002230	PT
Anaplastic large cell lymphoma T- and null-cell types stage I	10002231	PT
Anaplastic large cell lymphoma T- and null-cell types stage II	10002232	PT
Anaplastic large cell lymphoma T- and null-cell types stage III	10002233	PT
Anaplastic large cell lymphoma T- and null-cell types stage IV	10002234	PT
Anaplastic large-cell lymphoma	10073478	PT
Angiocentric lymphoma	10002411	PT
Angiocentric lymphoma recurrent	10002414	PT
Angiocentric lymphoma refractory	10002415	PT
Angiocentric lymphoma stage I	10002416	PT
Angiocentric lymphoma stage II	10002417	PT
Angiocentric lymphoma stage III	10002418	PT

Name	Code	Level
Angiocentric lymphoma stage IV	10002419	PT
Angioimmunoblastic T-cell lymphoma	10002449	PT
Angioimmunoblastic T-cell lymphoma recurrent	10002452	PT
Angioimmunoblastic T-cell lymphoma refractory	10002453	PT
Angioimmunoblastic T-cell lymphoma stage I	10002454	PT
Angioimmunoblastic T-cell lymphoma stage II	10002455	PT
Angioimmunoblastic T-cell lymphoma stage III	10002456	PT
Angioimmunoblastic T-cell lymphoma stage IV	10002457	PT
B precursor type acute leukaemia	10003890	PT
B-cell lymphoma	10003899	PT
B-cell lymphoma recurrent	10003902	PT
B-cell lymphoma refractory	10003903	PT
B-cell lymphoma stage I	10003904	PT
B-cell lymphoma stage II	10003905	PT
B-cell lymphoma stage III	10003906	PT
B-cell lymphoma stage IV	10003907	PT
B-cell prolymphocytic leukaemia	10073480	PT
B-cell small lymphocytic lymphoma	10003908	PT
B-cell small lymphocytic lymphoma recurrent	10003911	PT
B-cell small lymphocytic lymphoma refractory	10003912	PT
B-cell small lymphocytic lymphoma stage I	10003913	PT
B-cell small lymphocytic lymphoma stage II	10003914	PT
B-cell small lymphocytic lymphoma stage III	10003915	PT
B-cell small lymphocytic lymphoma stage IV	10003916	PT
B-cell type acute leukaemia	10003917	PT
B-cell unclassifiable lymphoma high grade	10003922	PT
B-cell unclassifiable lymphoma low grade	10003923	PT
Blast cell crisis	10053747	PT
Blast crisis in myelogenous leukaemia	10050282	PT
Blastic plasmacytoid dendritic cell neoplasia	10075460	PT
Bone marrow leukaemic cell infiltration	10049557	PT
Bone marrow tumour cell infiltration	10049556	PT
Burkitt's leukaemia	10067184	PT
Burkitt's lymphoma	10006595	PT
Burkitt's lymphoma recurrent	10006598	PT
Burkitt's lymphoma refractory	10006599	PT
Burkitt's lymphoma stage I	10006600	PT
Burkitt's lymphoma stage II	10006601	PT
Burkitt's lymphoma stage III	10006602	PT
Burkitt's lymphoma stage IV	10006603	PT
Central nervous system leukaemia	10066231	PT
Central nervous system lymphoma	10007953	PT
Chloroma	10008583	PT
Chloroma (in remission)	10008584	PT

Name	Code	Level
Chronic eosinophilic leukaemia	10065854	PT
Chronic leukaemia	10008943	PT
Chronic leukaemia in remission	10061042	PT
Chronic lymphocytic leukaemia	10008958	PT
Chronic lymphocytic leukaemia (in remission)	10008959	PT
Chronic lymphocytic leukaemia recurrent	10008961	PT
Chronic lymphocytic leukaemia refractory	10008962	PT
Chronic lymphocytic leukaemia stage 0	10008963	PT
Chronic lymphocytic leukaemia stage 1	10008964	PT
Chronic lymphocytic leukaemia stage 2	10008965	PT
Chronic lymphocytic leukaemia stage 3	10008966	PT
Chronic lymphocytic leukaemia stage 4	10008967	PT
Chronic lymphocytic leukaemia transformation	10058717	PT
Chronic myeloid leukaemia	10009013	PT
Chronic myeloid leukaemia (in remission)	10009014	PT
Chronic myeloid leukaemia recurrent	10075081	PT
Chronic myeloid leukaemia transformation	10068232	PT
Chronic myelomonocytic leukaemia	10009018	PT
Chronic myelomonocytic leukaemia (in remission)	10009019	PT
Composite lymphoma	10073957	PT
Cutaneous lymphoma	10079945	PT
Diffuse large B-cell lymphoma	10012818	PT
Diffuse large B-cell lymphoma recurrent	10012821	PT
Diffuse large B-cell lymphoma refractory	10012822	PT
Diffuse large B-cell lymphoma stage I	10012823	PT
Diffuse large B-cell lymphoma stage II	10012824	PT
Diffuse large B-cell lymphoma stage III	10012825	PT
Diffuse large B-cell lymphoma stage IV	10012826	PT
Disseminated large cell lymphoma	10054951	PT
Double hit lymphoma	10080202	PT
Enteropathy-associated T-cell lymphoma	10073481	PT
Eosinophilic leukaemia	10014958	PT
Epstein-Barr virus associated lymphoma	10071441	PT
Erythraemic myelosis (in remission)	10015246	PT
Erythroleukaemia	10015281	PT
Extranodal marginal zone B-cell lymphoma (MALT type)	10061850	PT
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent	10015823	PT
Extranodal marginal zone B-cell lymphoma (MALT type) refractory	10015824	PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage I	10015825	PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage II	10015826	PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage III	10015827	PT
Extranodal marginal zone B-cell lymphoma (MALT type) stage IV	10015828	PT
Follicle centre lymphoma diffuse small cell lymphoma	10061957	PT
Follicle centre lymphoma diffuse small cell lymphoma recurrent	10016897	PT

Name	Code	Level
Follicle centre lymphoma diffuse small cell lymphoma refractory	10016898	PT
Follicle centre lymphoma diffuse small cell lymphoma stage I	10016899	PT
Follicle centre lymphoma diffuse small cell lymphoma stage II	10016900	PT
Follicle centre lymphoma diffuse small cell lymphoma stage III	10016901	PT
Follicle centre lymphoma diffuse small cell lymphoma stage IV	10016902	PT
Follicle centre lymphoma, follicular grade I, II, III	10061170	PT
Follicle centre lymphoma, follicular grade I, II, III recurrent	10016905	PT
Follicle centre lymphoma, follicular grade I, II, III refractory	10016906	PT
Follicle centre lymphoma, follicular grade I, II, III stage I	10016907	PT
Follicle centre lymphoma, follicular grade I, II, III stage II	10016908	PT
Follicle centre lymphoma, follicular grade I, II, III stage III	10016909	PT
Follicle centre lymphoma, follicular grade I, II, III stage IV	10016910	PT
Follicular dendritic cell sarcoma	10075332	PT
Gastrointestinal lymphoma	10017973	PT
Haematological malignancy	10066476	PT
Hairy cell leukaemia	10019053	PT
Hairy cell leukaemia recurrent	10077403	PT
Hepatosplenic T-cell lymphoma	10066957	PT
High grade B-cell lymphoma Burkitt-like lymphoma	10020067	PT
High grade B-cell lymphoma Burkitt-like lymphoma recurrent	10020070	PT
High grade B-cell lymphoma Burkitt-like lymphoma refractory	10020071	PT
High grade B-cell lymphoma Burkitt-like lymphoma stage I	10020072	PT
High grade B-cell lymphoma Burkitt-like lymphoma stage II	10020073	PT
High grade B-cell lymphoma Burkitt-like lymphoma stage III	10020074	PT
High grade B-cell lymphoma Burkitt-like lymphoma stage IV	10020075	PT
High-grade B-cell lymphoma	10080215	PT
Histiocytic medullary reticulosis	10068785	PT
Histiocytic sarcoma	10076876	PT
Hodgkin's disease	10020206	PT
Hodgkin's disease lymphocyte depletion stage I site unspecified	10020208	PT
Hodgkin's disease lymphocyte depletion stage I subdiaphragm	10020209	PT
Hodgkin's disease lymphocyte depletion stage I supradiaphragm	10020210	PT
Hodgkin's disease lymphocyte depletion stage II site unspecified	10020211	PT
Hodgkin's disease lymphocyte depletion stage II subdiaphragm	10020212	PT
Hodgkin's disease lymphocyte depletion stage II supradiaphragm	10020213	PT
Hodgkin's disease lymphocyte depletion type recurrent	10020215	PT
Hodgkin's disease lymphocyte depletion type refractory	10020216	PT
Hodgkin's disease lymphocyte depletion type stage III	10020217	PT
Hodgkin's disease lymphocyte depletion type stage IV	10020218	PT
Hodgkin's disease lymphocyte depletion type stage unspecified	10020219	PT
Hodgkin's disease lymphocyte predominance stage I site unspec	10020220	PT
Hodgkin's disease lymphocyte predominance stage I subdiaphragm	10020221	PT
Hodgkin's disease lymphocyte predominance stage I supradiaphragm	10020222	PT
Hodgkin's disease lymphocyte predominance stage II site unspec	10020223	PT

Name	Code	Level
Hodgkin's disease lymphocyte predominance stage II subdiaphragm	10020224	PT
Hodgkin's disease lymphocyte predominance stage II supradiaphragm	10020225	PT
Hodgkin's disease lymphocyte predominance type recurrent	10020227	PT
Hodgkin's disease lymphocyte predominance type refractory	10020228	PT
Hodgkin's disease lymphocyte predominance type stage III	10020229	PT
Hodgkin's disease lymphocyte predominance type stage IV	10020230	PT
Hodgkin's disease lymphocyte predominance type stage unspecified	10020231	PT
Hodgkin's disease mixed cellularity recurrent	10020233	PT
Hodgkin's disease mixed cellularity refractory	10020234	PT
Hodgkin's disease mixed cellularity stage I site unspecified	10020235	PT
Hodgkin's disease mixed cellularity stage I subdiaphragmatic	10020236	PT
Hodgkin's disease mixed cellularity stage I supradiaphragmatic	10020237	PT
Hodgkin's disease mixed cellularity stage II subdiaphragmatic	10020238	PT
Hodgkin's disease mixed cellularity stage II supradiaphragmatic	10020239	PT
Hodgkin's disease mixed cellularity stage III	10020240	PT
Hodgkin's disease mixed cellularity stage IV	10020241	PT
Hodgkin's disease mixed cellularity stage unspecified	10020242	PT
Hodgkin's disease nodular sclerosis	10020244	PT
Hodgkin's disease nodular sclerosis recurrent	10020245	PT
Hodgkin's disease nodular sclerosis refractory	10020246	PT
Hodgkin's disease nodular sclerosis stage I	10073535	PT
Hodgkin's disease nodular sclerosis stage II	10073534	PT
Hodgkin's disease nodular sclerosis stage III	10020252	PT
Hodgkin's disease nodular sclerosis stage IV	10020253	PT
Hodgkin's disease recurrent	10020266	PT
Hodgkin's disease refractory	10020267	PT
Hodgkin's disease stage I	10020268	PT
Hodgkin's disease stage II	10020269	PT
Hodgkin's disease stage III	10020270	PT
Hodgkin's disease stage IV	10061597	PT
Hodgkin's disease unclassifiable	10020271	PT
Immunoblastic lymphoma	10053574	PT
Intestinal T-cell lymphoma recurrent	10022706	PT
Intestinal T-cell lymphoma refractory	10022707	PT
Intestinal T-cell lymphoma stage I	10022708	PT
Intestinal T-cell lymphoma stage II	10022709	PT
Intestinal T-cell lymphoma stage III	10022710	PT
Intestinal T-cell lymphoma stage IV	10022711	PT
Juvenile chronic myelomonocytic leukaemia	10023249	PT
Leptomeningeal myelomatosis	10078282	PT
Leukaemia	10024288	PT
Leukaemia basophilic	10024293	PT
Leukaemia cutis	10053180	PT
Leukaemia granulocytic	10024299	PT

Name	Code	Level
Leukaemia in remission	10061220	PT
Leukaemia monocytic	10024305	PT
Leukaemia recurrent	10062489	PT
Leukaemic cardiac infiltration	10077563	PT
Leukaemic infiltration	10069360	PT
Leukaemic infiltration extramedullary	10067117	PT
Leukaemic infiltration gingiva	10067431	PT
Leukaemic infiltration hepatic	10058671	PT
Leukaemic infiltration ovary	10075853	PT
Leukaemic infiltration pulmonary	10052368	PT
Leukaemic infiltration renal	10069359	PT
Leukaemic lymphoma	10024325	PT
Leukaemic retinopathy	10059239	PT
Lymphangiosarcoma	10025223	PT
Lymphangiosis carcinomatosa	10053132	PT
Lymphocytic leukaemia	10025270	PT
Lymphocytic lymphoma	10052178	PT
Lymphoid leukaemia (in remission)	10025300	PT
Lymphoma	10025310	PT
Lymphoma AIDS related	10025312	PT
Lymphoma transformation	10064344	PT
Lymphoplasmacytoid lymphoma/immunocytoma	10025342	PT
Lymphoplasmacytoid lymphoma/immunocytoma recurrent	10025345	PT
Lymphoplasmacytoid lymphoma/immunocytoma refractory	10025346	PT
Lymphoplasmacytoid lymphoma/immunocytoma stage I	10025347	PT
Lymphoplasmacytoid lymphoma/immunocytoma stage II	10025348	PT
Lymphoplasmacytoid lymphoma/immunocytoma stage III	10025349	PT
Lymphoplasmacytoid lymphoma/immunocytoma stage IV	10025350	PT
Malignant histiocytosis	10025581	PT
Malignant lymphoid neoplasm	10061240	PT
Malignant lymphoma unclassifiable high grade	10025635	PT
Malignant lymphoma unclassifiable low grade	10025636	PT
Malignant mast cell neoplasm	10025638	PT
Malignant neoplasm of thymus	10026533	PT
Malignant splenic neoplasm	10026702	PT
Mantle cell lymphoma	10061275	PT
Mantle cell lymphoma recurrent	10026800	PT
Mantle cell lymphoma refractory	10026801	PT
Mantle cell lymphoma stage I	10026802	PT
Mantle cell lymphoma stage II	10026803	PT
Mantle cell lymphoma stage III	10026804	PT
Mantle cell lymphoma stage IV	10026805	PT
Marginal zone lymphoma	10076596	PT
Marginal zone lymphoma recurrent	10077533	PT

Name	Code	Level
Marginal zone lymphoma refractory	10077534	PT
Marginal zone lymphoma stage I	10077529	PT
Marginal zone lymphoma stage II	10077530	PT
Marginal zone lymphoma stage III	10077531	PT
Marginal zone lymphoma stage IV	10077532	PT
Mastocytic leukaemia	10056450	PT
Mature B-cell type acute leukaemia	10026945	PT
Metastases to bone marrow	10051662	PT
Metastases to lymph nodes	10027459	PT
Metastases to spleen	10051682	PT
Metastatic lymphoma	10071541	PT
Minimal residual disease	10079987	PT
Monocytic leukaemia in remission	10061295	PT
Mycosis fungoides	10028483	PT
Mycosis fungoides recurrent	10028501	PT
Mycosis fungoides refractory	10028502	PT
Mycosis fungoides stage I	10028503	PT
Mycosis fungoides stage II	10028504	PT
Mycosis fungoides stage III	10028505	PT
Mycosis fungoides stage IV	10028506	PT
Myeloblastoma	10051141	PT
Myeloid leukaemia	10028549	PT
Myeloid leukaemia in remission	10061301	PT
Natural killer-cell leukaemia	10028811	PT
Natural killer-cell lymphoblastic lymphoma	10058975	PT
Neonatal leukaemia	10028958	PT
Nodal marginal zone B-cell lymphoma	10029460	PT
Nodal marginal zone B-cell lymphoma recurrent	10029463	PT
Nodal marginal zone B-cell lymphoma refractory	10029464	PT
Nodal marginal zone B-cell lymphoma stage I	10029465	PT
Nodal marginal zone B-cell lymphoma stage II	10029466	PT
Nodal marginal zone B-cell lymphoma stage III	10029467	PT
Nodal marginal zone B-cell lymphoma stage IV	10029468	PT
Nodular lymphocyte predominant Hodgkin lymphoma	10080201	PT
Non-Hodgkin's lymphoma	10029547	PT
Non-Hodgkin's lymphoma metastatic	10071535	PT
Non-Hodgkin's lymphoma recurrent	10029600	PT
Non-Hodgkin's lymphoma refractory	10029601	PT
Non-Hodgkin's lymphoma stage I	10029602	PT
Non-Hodgkin's lymphoma stage II	10029603	PT
Non-Hodgkin's lymphoma stage III	10029604	PT
Non-Hodgkin's lymphoma stage IV	10029605	PT
Non-Hodgkin's lymphoma transformed recurrent	10061871	PT
Non-Hodgkin's lymphoma unspecified histology aggressive	10063908	PT

Name	Code	Level
Non-Hodgkin's lymphoma unspecified histology aggressive recurrent	10029609	PT
Non-Hodgkin's lymphoma unspecified histology aggressive refractory	10029610	PT
Non-Hodgkin's lymphoma unspecified histology aggressive stage I	10029611	PT
Non-Hodgkin's lymphoma unspecified histology aggressive stage II	10029612	PT
Non-Hodgkin's lymphoma unspecified histology aggressive stage III	10029613	PT
Non-Hodgkin's lymphoma unspecified histology aggressive stage IV	10029614	PT
Non-Hodgkin's lymphoma unspecified histology indolent	10065856	PT
Non-Hodgkin's lymphoma unspecified histology indolent stage I	10029622	PT
Non-Hodgkin's lymphoma unspecified histology indolent stage II	10029623	PT
Non-Hodgkin's lymphoma unspecified histology indolent stage III	10029624	PT
Non-Hodgkin's lymphoma unspecified histology indolent stage IV	10029625	PT
Ocular lymphoma	10075324	PT
Peripheral T-cell lymphoma unspecified	10034623	PT
Peripheral T-cell lymphoma unspecified recurrent	10034625	PT
Peripheral T-cell lymphoma unspecified refractory	10034626	PT
Peripheral T-cell lymphoma unspecified stage I	10034627	PT
Peripheral T-cell lymphoma unspecified stage II	10034628	PT
Peripheral T-cell lymphoma unspecified stage III	10034629	PT
Peripheral T-cell lymphoma unspecified stage IV	10034630	PT
Plasma cell leukaemia	10035222	PT
Plasma cell leukaemia in remission	10060406	PT
Plasma cell myeloma	10035226	PT
Plasma cell myeloma in remission	10073132	PT
Plasma cell myeloma recurrent	10073133	PT
Plasmablastic lymphoma	10065039	PT
Plasmacytoma	10035484	PT
Precursor B-lymphoblastic lymphoma	10036523	PT
Precursor B-lymphoblastic lymphoma recurrent	10060910	PT
Precursor B-lymphoblastic lymphoma refractory	10060911	PT
Precursor B-lymphoblastic lymphoma stage I	10036532	PT
Precursor B-lymphoblastic lymphoma stage II	10036533	PT
Precursor B-lymphoblastic lymphoma stage III	10036534	PT
Precursor B-lymphoblastic lymphoma stage IV	10036535	PT
Precursor T-lymphoblastic lymphoma/leukaemia	10036543	PT
Precursor T-lymphoblastic lymphoma/leukaemia recurrent	10036546	PT
Precursor T-lymphoblastic lymphoma/leukaemia refractory	10036547	PT
Precursor T-lymphoblastic lymphoma/leukaemia stage I	10036548	PT
Precursor T-lymphoblastic lymphoma/leukaemia stage II	10036549	PT
Precursor T-lymphoblastic lymphoma/leukaemia stage III	10036550	PT
Precursor T-lymphoblastic lymphoma/leukaemia stage IV	10036551	PT
Primary breast lymphoma	10081036	PT
Primary cardiac lymphoma	10075993	PT
Primary effusion lymphoma	10065857	PT
Primary gastrointestinal follicular lymphoma	10078972	PT

Name	Code	Level
Primary mediastinal large B-cell lymphoma	10036710	PT
Primary mediastinal large B-cell lymphoma recurrent	10036713	PT
Primary mediastinal large B-cell lymphoma refractory	10036714	PT
Primary mediastinal large B-cell lymphoma stage I	10036715	PT
Primary mediastinal large B-cell lymphoma stage II	10036716	PT
Primary mediastinal large B-cell lymphoma stage III	10036717	PT
Primary mediastinal large B-cell lymphoma stage IV	10036718	PT
Polymphocytic leukaemia	10036888	PT
Richter's syndrome	10058728	PT
Splenic marginal zone lymphoma	10062113	PT
Splenic marginal zone lymphoma recurrent	10041652	PT
Splenic marginal zone lymphoma refractory	10041653	PT
Splenic marginal zone lymphoma stage I	10041654	PT
Splenic marginal zone lymphoma stage II	10041655	PT
Splenic marginal zone lymphoma stage III	10041656	PT
Splenic marginal zone lymphoma stage IV	10041657	PT
T-cell chronic lymphocytic leukaemia	10042970	PT
T-cell lymphoma	10042971	PT
T-cell lymphoma recurrent	10042979	PT
T-cell lymphoma refractory	10042980	PT
T-cell lymphoma stage I	10042981	PT
T-cell lymphoma stage II	10042982	PT
T-cell lymphoma stage III	10042983	PT
T-cell lymphoma stage IV	10042984	PT
T-cell prolymphocytic leukaemia	10042985	PT
T-cell type acute leukaemia	10042987	PT
T-cell unclassifiable lymphoma high grade	10042989	PT
T-cell unclassifiable lymphoma low grade	10042990	PT
Thymic cancer metastatic	10055108	PT
Thymoma malignant	10061031	PT
Thymoma malignant recurrent	10043674	PT
Thyroid B-cell lymphoma	10072613	PT
Transformation to acute myeloid leukaemia	10079107	PT
Triple hit lymphoma	10080200	PT
Waldenstrom's macroglobulinaemia	10047801	PT
Waldenstrom's macroglobulinaemia recurrent	10047804	PT
Waldenstrom's macroglobulinaemia refractory	10047805	PT
Waldenstrom's macroglobulinaemia stage I	10047806	PT
Waldenstrom's macroglobulinaemia stage II	10047807	PT
Waldenstrom's macroglobulinaemia stage III	10047808	PT
Waldenstrom's macroglobulinaemia stage IV	10047809	PT
Abdominal wall neoplasm malignant	10071023	PT
Acinar cell carcinoma of pancreas	10073363	PT
Acinic cell carcinoma of salivary gland	10073369	PT

Name	Code	Level
Acral lentiginous melanoma	10000583	PT
Acral lentiginous melanoma stage I	10000585	PT
Acral lentiginous melanoma stage II	10000586	PT
Acral lentiginous melanoma stage III	10000587	PT
Acral lentiginous melanoma stage IV	10000588	PT
Adenocarcinoma	10001141	PT
Adenocarcinoma gastric	10001150	PT
Adenocarcinoma of appendix	10073359	PT
Adenocarcinoma of colon	10001167	PT
Adenocarcinoma of salivary gland	10068068	PT
Adenocarcinoma of the cervix	10001197	PT
Adenocarcinoma pancreas	10052747	PT
Adenoid cystic carcinoma	10053231	PT
Adenoid cystic carcinoma of external auditory canal	10078057	PT
Adenoid cystic carcinoma of salivary gland	10073370	PT
Adenosquamous carcinoma of the cervix	10001244	PT
Adenosquamous carcinoma of vagina	10073978	PT
Adenosquamous cell carcinoma	10068873	PT
Adenosquamous cell lung cancer	10001245	PT
Adenosquamous cell lung cancer recurrent	10001247	PT
Adenosquamous cell lung cancer stage 0	10001248	PT
Adenosquamous cell lung cancer stage I	10001249	PT
Adenosquamous cell lung cancer stage II	10001250	PT
Adenosquamous cell lung cancer stage III	10001251	PT
Adenosquamous cell lung cancer stage IV	10001254	PT
Adrenal gland cancer	10073152	PT
Adrenal gland cancer metastatic	10055095	PT
Adrenocortical carcinoma	10001388	PT
Aesthesioneuroblastoma	10001433	PT
Alveolar rhabdomyosarcoma	10065867	PT
Alveolar soft part sarcoma	10001882	PT
Alveolar soft part sarcoma metastatic	10001884	PT
Alveolar soft part sarcoma recurrent	10001887	PT
Anal cancer	10061424	PT
Anal cancer metastatic	10055096	PT
Anal cancer recurrent	10002133	PT
Anal cancer stage 0	10002134	PT
Anal cancer stage I	10002135	PT
Anal cancer stage II	10002136	PT
Anal cancer stage III	10002137	PT
Anal cancer stage IV	10002138	PT
Anal squamous cell carcinoma	10073358	PT
Anaplastic astrocytoma	10002224	PT
Anaplastic meningioma	10073127	PT

Name	Code	Level
Anaplastic oligodendroglioma	10073128	PT
Anaplastic thyroid cancer	10002240	PT
Angiocentric glioma	10073129	PT
Angiosarcoma	10002476	PT
Angiosarcoma metastatic	10002477	PT
Angiosarcoma non-metastatic	10057700	PT
Angiosarcoma recurrent	10002480	PT
Apocrine breast carcinoma	10066206	PT
Appendix cancer	10073360	PT
Astrocytoma	10003571	PT
Astrocytoma malignant	10060971	PT
Atypical teratoid/rhabdoid tumour of CNS	10065907	PT
Basal cell carcinoma	10004146	PT
Basosquamous carcinoma	10004178	PT
Basosquamous carcinoma of skin	10004179	PT
Bile duct adenocarcinoma	10004585	PT
Bile duct adenosquamous carcinoma	10004589	PT
Bile duct cancer	10004593	PT
Bile duct cancer recurrent	10004596	PT
Bile duct cancer stage 0	10059384	PT
Bile duct cancer stage I	10059373	PT
Bile duct cancer stage II	10059374	PT
Bile duct cancer stage III	10059375	PT
Bile duct cancer stage IV	10059376	PT
Bile duct squamous cell carcinoma	10004633	PT
Biliary cancer metastatic	10055111	PT
Biphasic mesothelioma	10073062	PT
Bladder adenocarcinoma recurrent	10004986	PT
Bladder adenocarcinoma stage 0	10004987	PT
Bladder adenocarcinoma stage I	10004988	PT
Bladder adenocarcinoma stage II	10004989	PT
Bladder adenocarcinoma stage III	10004990	PT
Bladder adenocarcinoma stage IV	10004991	PT
Bladder adenocarcinoma stage unspecified	10004992	PT
Bladder cancer	10005003	PT
Bladder cancer recurrent	10005005	PT
Bladder cancer stage 0, with cancer in situ	10005006	PT
Bladder cancer stage 0, without cancer in situ	10005007	PT
Bladder cancer stage I, with cancer in situ	10005008	PT
Bladder cancer stage I, without cancer in situ	10005009	PT
Bladder cancer stage II	10005010	PT
Bladder cancer stage III	10005011	PT
Bladder cancer stage IV	10005012	PT
Bladder squamous cell carcinoma recurrent	10005075	PT

Name	Code	Level
Bladder squamous cell carcinoma stage 0	10005076	PT
Bladder squamous cell carcinoma stage I	10005077	PT
Bladder squamous cell carcinoma stage II	10005078	PT
Bladder squamous cell carcinoma stage III	10005079	PT
Bladder squamous cell carcinoma stage IV	10005080	PT
Bladder squamous cell carcinoma stage unspecified	10005081	PT
Bladder transitional cell carcinoma	10005084	PT
Bladder transitional cell carcinoma metastatic	10071664	PT
Bladder transitional cell carcinoma recurrent	10066750	PT
Bladder transitional cell carcinoma stage 0	10066749	PT
Bladder transitional cell carcinoma stage I	10066751	PT
Bladder transitional cell carcinoma stage II	10066753	PT
Bladder transitional cell carcinoma stage III	10066754	PT
Bladder transitional cell carcinoma stage IV	10066752	PT
Bone cancer	10005949	PT
Bone cancer metastatic	10055101	PT
Bone giant cell tumour malignant	10073106	PT
Bone sarcoma	10006007	PT
Bowen's disease	10006059	PT
Brain cancer metastatic	10055093	PT
Brain neoplasm malignant	10006131	PT
Brain sarcoma	10073857	PT
Brain stem glioma	10006143	PT
Breast angiosarcoma	10072813	PT
Breast angiosarcoma metastatic	10072814	PT
Breast cancer	10006187	PT
Breast cancer female	10057654	PT
Breast cancer in situ	10006189	PT
Breast cancer male	10061020	PT
Breast cancer metastatic	10055113	PT
Breast cancer recurrent	10006198	PT
Breast cancer stage I	10006199	PT
Breast cancer stage II	10006200	PT
Breast cancer stage III	10006201	PT
Breast cancer stage IV	10006202	PT
Breast sarcoma	10068582	PT
Breast sarcoma metastatic	10068583	PT
Breast sarcoma recurrent	10068584	PT
Bronchial carcinoma	10006417	PT
Bronchioloalveolar carcinoma	10058354	PT
Buschke-Lowenstein's tumour	10059427	PT
Cancer in remission	10065305	PT
Carcinoid tumour	10007275	PT
Carcinoid tumour of the appendix	10007277	PT

Name	Code	Level
Carcinoid tumour of the caecum	10007278	PT
Carcinoid tumour of the duodenum	10050110	PT
Carcinoid tumour of the gastrointestinal tract	10007279	PT
Carcinoid tumour of the pancreas	10055007	PT
Carcinoid tumour of the prostate	10007280	PT
Carcinoid tumour of the small bowel	10052819	PT
Carcinoid tumour of the stomach	10007281	PT
Carcinoid tumour pulmonary	10007282	PT
Carcinoma ex-pleomorphic adenoma	10077435	PT
Carcinoma in situ	10061450	PT
Carcinoma in situ of eye	10007368	PT
Carcinoma in situ of penis	10007384	PT
Carcinoma in situ of skin	10007390	PT
Carcinoma in situ of trachea	10007401	PT
Cardiac neoplasm malignant	10061025	PT
Central nervous system melanoma	10077160	PT
Central nervous system neuroblastoma	10073130	PT
Cervix cancer metastatic	10055094	PT
Cervix carcinoma	10008342	PT
Cervix carcinoma recurrent	10008344	PT
Cervix carcinoma stage 0	10061809	PT
Cervix carcinoma stage I	10008345	PT
Cervix carcinoma stage II	10008346	PT
Cervix carcinoma stage III	10008347	PT
Cervix carcinoma stage IV	10008348	PT
Cholangiocarcinoma	10008593	PT
Cholangiosarcoma	10077861	PT
Chondrosarcoma	10008734	PT
Chondrosarcoma metastatic	10008736	PT
Chondrosarcoma recurrent	10008738	PT
Chordoma	10008747	PT
Choriocarcinoma	10008757	PT
Choroid melanoma	10008773	PT
Choroid plexus carcinoma	10067478	PT
Chromophobe renal cell carcinoma	10080544	PT
Clear cell carcinoma of cervix	10074909	PT
Clear cell endometrial carcinoma	10009252	PT
Clear cell renal cell carcinoma	10073251	PT
Clear cell sarcoma of soft tissue	10073140	PT
Clear cell sarcoma of the kidney	10009253	PT
CNS germinoma	10065852	PT
Colon cancer	10009944	PT
Colon cancer metastatic	10055114	PT
Colon cancer recurrent	10009952	PT

Name	Code	Level
Colon cancer stage 0	10063523	PT
Colon cancer stage I	10009953	PT
Colon cancer stage II	10009954	PT
Colon cancer stage III	10009955	PT
Colon cancer stage IV	10009956	PT
Colorectal adenocarcinoma	10052360	PT
Colorectal cancer	10061451	PT
Colorectal cancer metastatic	10052358	PT
Colorectal cancer recurrent	10010030	PT
Colorectal cancer stage I	10010032	PT
Colorectal cancer stage II	10010033	PT
Colorectal cancer stage III	10010034	PT
Colorectal cancer stage IV	10010035	PT
Colorectal carcinoma stage 0	10010038	PT
Congenital fibrosarcoma	10065859	PT
Congenital malignant neoplasm	10073492	PT
Congenital retinoblastoma	10073470	PT
Conjunctival melanoma	10066384	PT
Cystadenocarcinoma ovary	10054912	PT
Cystadenocarcinoma pancreas	10065908	PT
Dedifferentiated liposarcoma	10073135	PT
Dermatofibrosarcoma protuberans	10057070	PT
Dermatofibrosarcoma protuberans metastatic	10073574	PT
Desmoplastic melanoma	10072449	PT
Desmoplastic mesothelioma	10073063	PT
Desmoplastic small round cell tumour	10064581	PT
Ductal adenocarcinoma of pancreas	10073364	PT
Ear neoplasm malignant	10055017	PT
Eccrine carcinoma	10069680	PT
Embryonal rhabdomyosarcoma	10065868	PT
Endocrine neoplasm malignant	10061122	PT
Endometrial adenocarcinoma	10014720	PT
Endometrial cancer	10014733	PT
Endometrial cancer metastatic	10014734	PT
Endometrial cancer recurrent	10014736	PT
Endometrial cancer stage 0	10014737	PT
Endometrial cancer stage I	10014738	PT
Endometrial cancer stage II	10014739	PT
Endometrial cancer stage III	10014740	PT
Endometrial cancer stage IV	10014741	PT
Endometrial sarcoma	10057649	PT
Endometrial sarcoma metastatic	10067065	PT
Endometrial sarcoma recurrent	10067064	PT
Endometrial stromal sarcoma	10048397	PT

Name	Code	Level
Endotheliomatosis	10076868	PT
Ependymoma malignant	10014968	PT
Epididymal cancer	10073115	PT
Epiglottic carcinoma	10057438	PT
Epithelioid mesothelioma	10073064	PT
Epithelioid sarcoma	10015099	PT
Epithelioid sarcoma metastatic	10015101	PT
Epithelioid sarcoma recurrent	10015104	PT
Ewing's sarcoma	10015560	PT
Ewing's sarcoma metastatic	10015562	PT
Ewing's sarcoma recurrent	10015564	PT
Extragenadal primary embryonal carcinoma	10015789	PT
Extragenadal primary germ cell tumour	10073055	PT
Extragenadal primary germ cell tumour mixed	10073056	PT
Extragenadal primary germ cell tumour mixed stage I	10015800	PT
Extragenadal primary germ cell tumour mixed stage II	10015801	PT
Extragenadal primary germ cell tumour mixed stage III	10015802	PT
Extragenadal primary malignant teratoma	10061848	PT
Extragenadal primary non-seminoma	10061849	PT
Extragenadal primary non-seminoma stage I	10015805	PT
Extragenadal primary non-seminoma stage II	10015806	PT
Extragenadal primary non-seminoma stage III	10015809	PT
Extragenadal primary non-seminoma stage IV	10015810	PT
Extragenadal primary seminoma (pure)	10073057	PT
Extragenadal primary seminoma (pure) stage I	10015811	PT
Extragenadal primary seminoma (pure) stage II	10015812	PT
Extragenadal primary seminoma (pure) stage III	10015815	PT
Extragenadal primary seminoma (pure) stage IV	10015816	PT
Extramammary Paget's disease	10068223	PT
Extraocular retinoblastoma	10015831	PT
Extra-osseous Ewing's sarcoma	10015759	PT
Extra-osseous Ewing's sarcoma metastatic	10015761	PT
Extra-osseous Ewing's sarcoma recurrent	10015764	PT
Extraskeletal chondrosarcoma metastatic	10015840	PT
Extraskeletal chondrosarcoma recurrent	10015843	PT
Extraskeletal myxoid chondrosarcoma	10073134	PT
Extraskeletal osteosarcoma	10015847	PT
Extraskeletal osteosarcoma metastatic	10015849	PT
Extraskeletal osteosarcoma recurrent	10015852	PT
Fallopian tube cancer	10016180	PT
Fallopian tube cancer metastatic	10016182	PT
Fallopian tube cancer stage I	10016184	PT
Fallopian tube cancer stage II	10016185	PT
Fallopian tube cancer stage III	10016186	PT

Name	Code	Level
Fallopian tube cancer stage IV	10016187	PT
Familial medullary thyroid cancer	10073153	PT
Female reproductive tract carcinoma in situ	10061154	PT
Fibrosarcoma	10016632	PT
Fibrosarcoma metastatic	10016635	PT
Follicular thyroid cancer	10016935	PT
Gallbladder adenocarcinoma	10058286	PT
Gallbladder adenosquamous carcinoma	10073067	PT
Gallbladder cancer	10017614	PT
Gallbladder cancer metastatic	10066879	PT
Gallbladder cancer recurrent	10017619	PT
Gallbladder cancer stage 0	10059316	PT
Gallbladder cancer stage I	10059317	PT
Gallbladder cancer stage II	10058281	PT
Gallbladder cancer stage III	10058282	PT
Gallbladder cancer stage IV	10058283	PT
Gallbladder squamous cell carcinoma	10073068	PT
Ganglioglioma	10017701	PT
Ganglioneuroblastoma	10017708	PT
Gastric cancer	10017758	PT
Gastric cancer recurrent	10017761	PT
Gastric cancer stage 0	10017762	PT
Gastric cancer stage I	10017763	PT
Gastric cancer stage II	10017764	PT
Gastric cancer stage III	10017765	PT
Gastric cancer stage IV	10061967	PT
Gastric sarcoma	10055008	PT
Gastrinoma malignant	10051709	PT
Gastroenteropancreatic neuroendocrine tumour disease	10077559	PT
Gastrointestinal adenocarcinoma	10081003	PT
Gastrointestinal cancer metastatic	10053548	PT
Gastrointestinal carcinoma	10017940	PT
Gastrointestinal carcinoma in situ	10061168	PT
Gastrointestinal melanoma	10077167	PT
Gastrointestinal stromal cancer	10071653	PT
Gastrooesophageal cancer	10062878	PT
Genital cancer male	10073116	PT
Genital cancer male in situ	10073124	PT
Genital neoplasm malignant female	10018160	PT
Genitourinary melanoma	10077166	PT
Germ cell cancer	10061184	PT
Germ cell cancer metastatic	10068971	PT
Gestational trophoblastic tumour	10061988	PT
Gingival cancer	10067807	PT

Name	Code	Level
Glioblastoma	10018336	PT
Glioblastoma multiforme	10018337	PT
Glioma	10018338	PT
Gliomatosis cerebri	10066254	PT
Glioneuronal tumour	10068601	PT
Gliosarcoma	10018340	PT
Glottis carcinoma	10018395	PT
Glucagonoma	10018404	PT
Haemangiopericytoma	10018825	PT
Haemangiopericytoma of meninges	10018826	PT
Head and neck cancer	10067821	PT
Head and neck cancer metastatic	10071540	PT
Head and neck cancer stage I	10071539	PT
Head and neck cancer stage II	10071538	PT
Head and neck cancer stage III	10071537	PT
Head and neck cancer stage IV	10071536	PT
Hepatic angiosarcoma	10067388	PT
Hepatic cancer	10073069	PT
Hepatic cancer metastatic	10055110	PT
Hepatic cancer recurrent	10073070	PT
Hepatic cancer stage I	10059318	PT
Hepatic cancer stage II	10059319	PT
Hepatic cancer stage III	10059324	PT
Hepatic cancer stage IV	10059325	PT
Hepatobiliary cancer	10073073	PT
Hepatobiliary cancer in situ	10073074	PT
Hepatoblastoma	10062001	PT
Hepatoblastoma recurrent	10019823	PT
Hepatocellular carcinoma	10073071	PT
HER-2 positive breast cancer	10065430	PT
HER-2 positive gastric cancer	10066896	PT
Hereditary leiomyomatosis renal cell carcinoma	10067944	PT
Hereditary papillary renal carcinoma	10067943	PT
Hidradenocarcinoma	10073088	PT
Hormone refractory breast cancer	10076935	PT
Hormone-dependent prostate cancer	10071119	PT
Hormone-refractory prostate cancer	10062904	PT
Huerthle cell carcinoma	10066136	PT
Hypopharyngeal cancer	10021042	PT
Hypopharyngeal cancer recurrent	10021044	PT
Hypopharyngeal cancer stage 0	10021045	PT
Hypopharyngeal cancer stage I	10021046	PT
Hypopharyngeal cancer stage II	10021047	PT
Hypopharyngeal cancer stage III	10021048	PT

Name	Code	Level
Hypopharyngeal cancer stage IV	10021049	PT
Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma	10072796	PT
Inflammatory carcinoma of breast recurrent	10021977	PT
Inflammatory carcinoma of breast stage III	10021978	PT
Inflammatory carcinoma of breast stage IV	10021979	PT
Inflammatory carcinoma of the breast	10021980	PT
Inflammatory malignant fibrous histiocytoma	10073142	PT
Inflammatory myofibroblastic tumour	10067917	PT
Intestinal adenocarcinoma	10051925	PT
Intestinal metastasis	10080311	PT
Intracranial germ cell tumour	10073751	PT
Intracranial meningioma malignant	10022770	PT
Intraductal papillary breast neoplasm	10073540	PT
Intraductal papillary-mucinous carcinoma of pancreas	10073365	PT
Intraductal proliferative breast lesion	10073094	PT
Intraocular melanoma	10061252	PT
Invasive breast carcinoma	10075713	PT
Invasive ductal breast carcinoma	10073095	PT
Invasive lobular breast carcinoma	10073096	PT
Invasive papillary breast carcinoma	10073098	PT
Iris melanoma	10073086	PT
Kaposi's sarcoma	10023284	PT
Kaposi's sarcoma AIDS related	10023286	PT
Kaposi's sarcoma classical type	10023288	PT
Keratinising squamous cell carcinoma of nasopharynx	10073324	PT
Keratoacanthoma	10023347	PT
Langerhans cell sarcoma	10078782	PT
Large cell lung cancer	10023774	PT
Large cell lung cancer metastatic	10069730	PT
Large cell lung cancer recurrent	10023775	PT
Large cell lung cancer stage 0	10023776	PT
Large cell lung cancer stage I	10023777	PT
Large cell lung cancer stage II	10023778	PT
Large cell lung cancer stage III	10023779	PT
Large cell lung cancer stage IV	10023780	PT
Laryngeal cancer	10023825	PT
Laryngeal cancer metastatic	10070902	PT
Laryngeal cancer recurrent	10023828	PT
Laryngeal cancer stage 0	10023829	PT
Laryngeal cancer stage I	10023830	PT
Laryngeal cancer stage II	10023831	PT
Laryngeal cancer stage III	10023832	PT
Laryngeal cancer stage IV	10023833	PT

Name	Code	Level
Laryngeal squamous cell carcinoma	10023856	PT
Leiomyosarcoma	10024189	PT
Leiomyosarcoma metastatic	10024191	PT
Leiomyosarcoma recurrent	10024194	PT
Lentigo maligna	10024218	PT
Lentigo maligna recurrent	10024220	PT
Lentigo maligna stage I	10024221	PT
Lentigo maligna stage II	10024222	PT
Lentigo maligna stage III	10024223	PT
Lentigo maligna stage IV	10024224	PT
Leydig cell tumour of the testis	10024407	PT
Linitis plastica	10024520	PT
Lip and/or oral cavity cancer	10061523	PT
Lip and/or oral cavity cancer recurrent	10024535	PT
Lip and/or oral cavity cancer stage 0	10024536	PT
Lip and/or oral cavity cancer stage I	10024537	PT
Lip and/or oral cavity cancer stage II	10024538	PT
Lip and/or oral cavity cancer stage III	10024539	PT
Lip and/or oral cavity cancer stage IV	10024540	PT
Lip neoplasm malignant stage unspecified	10024557	PT
Lip squamous cell carcinoma	10064055	PT
Liposarcoma	10024627	PT
Liposarcoma metastatic	10024629	PT
Liposarcoma recurrent	10024632	PT
Lobular breast carcinoma in situ	10073099	PT
Lung adenocarcinoma	10025031	PT
Lung adenocarcinoma recurrent	10025033	PT
Lung adenocarcinoma stage 0	10025034	PT
Lung adenocarcinoma stage I	10025035	PT
Lung adenocarcinoma stage II	10025036	PT
Lung adenocarcinoma stage III	10025037	PT
Lung adenocarcinoma stage IV	10025038	PT
Lung cancer metastatic	10050017	PT
Lung carcinoma cell type unspecified recurrent	10025065	PT
Lung carcinoma cell type unspecified stage 0	10025066	PT
Lung carcinoma cell type unspecified stage I	10025067	PT
Lung carcinoma cell type unspecified stage II	10025068	PT
Lung carcinoma cell type unspecified stage III	10025069	PT
Lung carcinoma cell type unspecified stage IV	10025070	PT
Lung infiltration malignant	10062041	PT
Lung neoplasm malignant	10058467	PT
Lung squamous cell carcinoma metastatic	10071533	PT
Lung squamous cell carcinoma recurrent	10025120	PT
Lung squamous cell carcinoma stage 0	10025121	PT

Name	Code	Level
Lung squamous cell carcinoma stage I	10025122	PT
Lung squamous cell carcinoma stage II	10025123	PT
Lung squamous cell carcinoma stage III	10025124	PT
Lung squamous cell carcinoma stage IV	10025125	PT
Malignant anorectal neoplasm	10061237	PT
Malignant blue naevus	10072448	PT
Malignant connective tissue neoplasm	10074340	PT
Malignant cranial nerve neoplasm	10061238	PT
Malignant fibrous histiocytoma	10025552	PT
Malignant fibrous histiocytoma metastatic	10025554	PT
Malignant fibrous histiocytoma of bone	10025557	PT
Malignant fibrous histiocytoma recurrent	10025561	PT
Malignant genitourinary tract neoplasm	10074419	PT
Malignant giant cell fibrous histiocytoma	10073141	PT
Malignant glioma	10065443	PT
Malignant haemangiopericytoma	10025566	PT
Malignant haemangiopericytoma metastatic	10025567	PT
Malignant haemangiopericytoma recurrent	10025570	PT
Malignant hydatidiform mole	10025598	PT
Malignant joint neoplasm	10078145	PT
Malignant mediastinal neoplasm	10061241	PT
Malignant melanoma	10025650	PT
Malignant melanoma in situ	10025652	PT
Malignant melanoma of eyelid	10063706	PT
Malignant melanoma of sites other than skin	10025654	PT
Malignant melanoma stage I	10025668	PT
Malignant melanoma stage II	10025669	PT
Malignant melanoma stage III	10025670	PT
Malignant melanoma stage IV	10025671	PT
Malignant meningioma metastatic	10077758	PT
Malignant mesenchymoma	10061526	PT
Malignant mesenchymoma metastatic	10025674	PT
Malignant mesenchymoma recurrent	10025677	PT
Malignant mesenteric neoplasm	10067369	PT
Malignant middle ear neoplasm	10061267	PT
Malignant muscle neoplasm	10062050	PT
Malignant neoplasm of ampulla of Vater	10025697	PT
Malignant neoplasm of auricular cartilage	10057272	PT
Malignant neoplasm of choroid	10025839	PT
Malignant neoplasm of conjunctiva	10025861	PT
Malignant neoplasm of cornea	10025871	PT
Malignant neoplasm of eye	10025910	PT
Malignant neoplasm of eyelid	10063693	PT
Malignant neoplasm of islets of Langerhans	10025997	PT

Name	Code	Level
Malignant neoplasm of lacrimal duct	10026030	PT
Malignant neoplasm of lacrimal gland	10026031	PT
Malignant neoplasm of orbit	10026183	PT
Malignant neoplasm of paraurethral glands	10026326	PT
Malignant neoplasm of placenta	10026350	PT
Malignant neoplasm of pleura	10026351	PT
Malignant neoplasm of pleura metastatic	10072432	PT
Malignant neoplasm of renal pelvis	10026426	PT
Malignant neoplasm of retina	10026432	PT
Malignant neoplasm of seminal vesicle	10068124	PT
Malignant neoplasm of spermatic cord	10026470	PT
Malignant neoplasm of spinal cord	10026472	PT
Malignant neoplasm of thorax	10026532	PT
Malignant neoplasm of unknown primary site	10073059	PT
Malignant neoplasm of uterine adnexa	10026616	PT
Malignant neoplasm papilla of Vater	10077303	PT
Malignant nervous system neoplasm	10061268	PT
Malignant nipple neoplasm	10062051	PT
Malignant nipple neoplasm female	10053129	PT
Malignant nipple neoplasm male	10053128	PT
Malignant oligodendroglioma	10026659	PT
Malignant ovarian cyst	10026662	PT
Malignant palate neoplasm	10026663	PT
Malignant pericardial neoplasm	10054946	PT
Malignant peritoneal neoplasm	10061269	PT
Malignant pituitary tumour	10026672	PT
Malignant polyp	10078695	PT
Malignant respiratory tract neoplasm	10061270	PT
Malignant sweat gland neoplasm	10073087	PT
Malignant transformation	10064912	PT
Malignant urinary tract neoplasm	10061272	PT
Marjolin's ulcer	10076248	PT
Maternal cancer in pregnancy	10079877	PT
Medullary carcinoma of breast	10027095	PT
Medullary thyroid cancer	10027105	PT
Medulloblastoma	10027107	PT
Medulloblastoma recurrent	10066594	PT
Melanoma recurrent	10066600	PT
Meningioma malignant	10027193	PT
Mesothelioma malignant	10027407	PT
Mesothelioma malignant recurrent	10027411	PT
Metaplastic breast carcinoma	10073100	PT
Metastases to abdominal cavity	10027450	PT
Metastases to abdominal wall	10051664	PT

Name	Code	Level
Metastases to adrenals	10027451	PT
Metastases to biliary tract	10062195	PT
Metastases to bladder	10049722	PT
Metastases to bone	10027452	PT
Metastases to breast	10027454	PT
Metastases to central nervous system	10059282	PT
Metastases to chest wall	10051663	PT
Metastases to diaphragm	10051665	PT
Metastases to Eustachian tube	10051666	PT
Metastases to eye	10049724	PT
Metastases to fallopian tube	10049727	PT
Metastases to gallbladder	10051667	PT
Metastases to gastrointestinal tract	10062196	PT
Metastases to heart	10049717	PT
Metastases to kidney	10027455	PT
Metastases to larynx	10051668	PT
Metastases to liver	10027457	PT
Metastases to lung	10027458	PT
Metastases to meninges	10051696	PT
Metastases to mouth	10051669	PT
Metastases to muscle	10049730	PT
Metastases to nasal sinuses	10051670	PT
Metastases to neck	10027460	PT
Metastases to nervous system	10061287	PT
Metastases to oesophagus	10051671	PT
Metastases to ovary	10027462	PT
Metastases to pancreas	10049721	PT
Metastases to pelvis	10070913	PT
Metastases to penis	10051672	PT
Metastases to perineum	10051673	PT
Metastases to peripheral nervous system	10051674	PT
Metastases to peripheral vascular system	10058307	PT
Metastases to peritoneum	10051676	PT
Metastases to pharynx	10051677	PT
Metastases to pituitary gland	10049728	PT
Metastases to placenta	10049725	PT
Metastases to pleura	10027463	PT
Metastases to prostate	10051678	PT
Metastases to rectum	10051679	PT
Metastases to reproductive organ	10061288	PT
Metastases to retroperitoneum	10051680	PT
Metastases to salivary gland	10051681	PT
Metastases to skin	10027465	PT
Metastases to soft tissue	10062197	PT

Name	Code	Level
Metastases to spinal cord	10078267	PT
Metastases to spine	10027468	PT
Metastases to stomach	10049718	PT
Metastases to testicle	10051683	PT
Metastases to the mediastinum	10027469	PT
Metastases to the respiratory system	10061600	PT
Metastases to thorax	10051684	PT
Metastases to thyroid	10049723	PT
Metastases to tonsils	10077476	PT
Metastases to trachea	10051685	PT
Metastases to urinary tract	10056251	PT
Metastases to uterus	10049726	PT
Metastases to vagina	10075555	PT
Metastasis	10062194	PT
Metastatic bronchial carcinoma	10058306	PT
Metastatic carcinoid tumour	10068115	PT
Metastatic carcinoma of the bladder	10057352	PT
Metastatic choriocarcinoma	10071532	PT
Metastatic gastric cancer	10063916	PT
Metastatic glioma	10063157	PT
Metastatic glucagonoma	10075245	PT
Metastatic malignant melanoma	10027480	PT
Metastatic neoplasm	10061289	PT
Metastatic nervous system neoplasm	10077703	PT
Metastatic ocular melanoma	10068117	PT
Metastatic renal cell carcinoma	10050513	PT
Metastatic salivary gland cancer	10066882	PT
Metastatic squamous cell carcinoma	10063569	PT
Metastatic uterine cancer	10068116	PT
Microsatellite instability cancer	10079618	PT
Mismatch repair cancer syndrome	10077888	PT
Mixed adenoneuroendocrine carcinoma	10076748	PT
Mixed hepatocellular cholangiocarcinoma	10027761	PT
Mixed-type liposarcoma	10073136	PT
Mucinous adenocarcinoma of appendix	10073361	PT
Mucinous breast carcinoma	10073101	PT
Mucinous cystadenocarcinoma ovary	10054914	PT
Mucinous endometrial carcinoma	10028076	PT
Mucoepidermoid carcinoma	10057269	PT
Mucoepidermoid carcinoma of salivary gland	10073371	PT
Musculoskeletal cancer	10077675	PT
Myxofibrosarcoma	10066948	PT
Myxoid liposarcoma	10073137	PT
Naevoid melanoma	10079054	PT

Name	Code	Level
Nasal cavity cancer	10028729	PT
Nasal sinus cancer	10028767	PT
Nasopharyngeal cancer	10061306	PT
Nasopharyngeal cancer metastatic	10079104	PT
Nasopharyngeal cancer recurrent	10028787	PT
Nasopharyngeal cancer stage 0	10028788	PT
Nasopharyngeal cancer stage I	10028789	PT
Nasopharyngeal cancer stage II	10028790	PT
Nasopharyngeal cancer stage III	10028791	PT
Nasopharyngeal cancer stage IV	10028792	PT
Neonatal neuroblastoma	10049793	PT
Neoplasm malignant	10028997	PT
Nephroblastoma	10029145	PT
Neuroblastoma	10029260	PT
Neuroblastoma recurrent	10066595	PT
Neuroendocrine breast tumour	10073103	PT
Neuroendocrine carcinoma	10057270	PT
Neuroendocrine carcinoma metastatic	10071542	PT
Neuroendocrine carcinoma of the bladder	10078341	PT
Neuroendocrine carcinoma of the skin	10029266	PT
Neuroendocrine tumour	10052399	PT
Neuroendocrine tumour of the lung	10078174	PT
Neuroendocrine tumour of the lung metastatic	10078175	PT
Neurofibrosarcoma	10061527	PT
Neurofibrosarcoma metastatic	10029274	PT
Neurofibrosarcoma recurrent	10029277	PT
Nodular melanoma	10029488	PT
Nongerminomatous germ cell tumour of the CNS	10065871	PT
Nonkeratinising carcinoma of nasopharynx	10073325	PT
Non-renal cell carcinoma of kidney	10061872	PT
Non-small cell lung cancer	10061873	PT
Non-small cell lung cancer metastatic	10059515	PT
Non-small cell lung cancer recurrent	10029515	PT
Non-small cell lung cancer stage 0	10029516	PT
Non-small cell lung cancer stage I	10029517	PT
Non-small cell lung cancer stage II	10029518	PT
Non-small cell lung cancer stage III	10029519	PT
Non-small cell lung cancer stage IIIA	10029520	PT
Non-small cell lung cancer stage IIIB	10029521	PT
Non-small cell lung cancer stage IV	10029522	PT
NUT midline carcinoma	10078295	PT
Ocular cancer metastatic	10055099	PT
Ocular haemangiopericytoma	10057416	PT
Oesophageal adenocarcinoma	10030137	PT

Name	Code	Level
Oesophageal adenocarcinoma recurrent	10030140	PT
Oesophageal adenocarcinoma stage 0	10030141	PT
Oesophageal adenocarcinoma stage I	10030142	PT
Oesophageal adenocarcinoma stage II	10030143	PT
Oesophageal adenocarcinoma stage III	10030144	PT
Oesophageal adenocarcinoma stage IV	10030145	PT
Oesophageal cancer metastatic	10055102	PT
Oesophageal carcinoma	10030155	PT
Oesophageal carcinoma recurrent	10030159	PT
Oesophageal carcinoma stage 0	10030162	PT
Oesophageal squamous cell carcinoma	10061534	PT
Oesophageal squamous cell carcinoma metastatic	10058527	PT
Oesophageal squamous cell carcinoma recurrent	10030187	PT
Oesophageal squamous cell carcinoma stage 0	10030188	PT
Oesophageal squamous cell carcinoma stage I	10030189	PT
Oesophageal squamous cell carcinoma stage II	10030190	PT
Oesophageal squamous cell carcinoma stage III	10030191	PT
Oesophageal squamous cell carcinoma stage IV	10030192	PT
Oestrogen receptor positive breast cancer	10070577	PT
Oligoastrocytoma	10073131	PT
Oligodendroglioma	10030286	PT
Optic glioma	10073338	PT
Oral cavity cancer metastatic	10055098	PT
Oropharyngeal cancer	10031096	PT
Oropharyngeal cancer recurrent	10031098	PT
Oropharyngeal cancer stage 0	10031099	PT
Oropharyngeal cancer stage I	10031100	PT
Oropharyngeal cancer stage II	10031101	PT
Oropharyngeal cancer stage III	10031102	PT
Oropharyngeal cancer stage IV	10064099	PT
Oropharyngeal lymphoepithelioma	10031104	PT
Oropharyngeal squamous cell carcinoma	10031112	PT
Osteosarcoma	10031291	PT
Osteosarcoma metastatic	10031294	PT
Osteosarcoma recurrent	10031296	PT
Otic cancer metastatic	10055100	PT
Ovarian cancer	10033128	PT
Ovarian cancer metastatic	10057529	PT
Ovarian cancer recurrent	10066697	PT
Ovarian cancer stage I	10070905	PT
Ovarian cancer stage II	10070906	PT
Ovarian cancer stage III	10070907	PT
Ovarian cancer stage IV	10070908	PT
Ovarian clear cell carcinoma	10073268	PT

Name	Code	Level
Ovarian dysgerminoma stage I	10033144	PT
Ovarian dysgerminoma stage II	10033148	PT
Ovarian dysgerminoma stage III	10033152	PT
Ovarian dysgerminoma stage IV	10033156	PT
Ovarian dysgerminoma stage unspecified	10052759	PT
Ovarian embryonal carcinoma	10056266	PT
Ovarian endometrioid carcinoma	10073269	PT
Ovarian epithelial cancer	10061328	PT
Ovarian epithelial cancer metastatic	10033158	PT
Ovarian epithelial cancer recurrent	10033160	PT
Ovarian epithelial cancer stage I	10033161	PT
Ovarian epithelial cancer stage II	10033162	PT
Ovarian epithelial cancer stage III	10033163	PT
Ovarian epithelial cancer stage IV	10033164	PT
Ovarian germ cell cancer	10061893	PT
Ovarian germ cell cancer stage I	10061894	PT
Ovarian germ cell cancer stage II	10061895	PT
Ovarian germ cell cancer stage III	10061896	PT
Ovarian germ cell cancer stage IV	10061897	PT
Ovarian germ cell choriocarcinoma	10073262	PT
Ovarian germ cell choriocarcinoma stage I	10033183	PT
Ovarian germ cell choriocarcinoma stage II	10033187	PT
Ovarian germ cell choriocarcinoma stage III	10033191	PT
Ovarian germ cell choriocarcinoma stage IV	10033195	PT
Ovarian germ cell embryonal carcinoma stage I	10033196	PT
Ovarian germ cell embryonal carcinoma stage II	10033200	PT
Ovarian germ cell embryonal carcinoma stage III	10033204	PT
Ovarian germ cell embryonal carcinoma stage IV	10033208	PT
Ovarian germ cell endodermal sinus tumour	10073263	PT
Ovarian germ cell endodermal sinus tumour stage I	10033218	PT
Ovarian germ cell endodermal sinus tumour stage II	10033219	PT
Ovarian germ cell endodermal sinus tumour stage III	10033220	PT
Ovarian germ cell endodermal sinus tumour stage IV	10033221	PT
Ovarian germ cell polyembryoma	10073264	PT
Ovarian germ cell polyembryoma stage I	10033223	PT
Ovarian germ cell polyembryoma stage II	10033227	PT
Ovarian germ cell polyembryoma stage III	10033231	PT
Ovarian germ cell polyembryoma stage IV	10033235	PT
Ovarian germ cell teratoma	10073265	PT
Ovarian germ cell teratoma stage I	10033237	PT
Ovarian germ cell teratoma stage II	10033241	PT
Ovarian germ cell teratoma stage III	10033245	PT
Ovarian germ cell teratoma stage IV	10033249	PT
Ovarian germ cell tumour mixed	10073259	PT

Name	Code	Level
Ovarian granulosa-theca cell tumour	10057376	PT
Ovarian low malignant potential tumour	10033268	PT
Ovarian stromal cancer	10065858	PT
Paget's disease of nipple	10033364	PT
Paget's disease of penis	10033365	PT
Paget's disease of the vulva	10033369	PT
Pancoast's tumour	10033572	PT
Pancreatic carcinoma	10033609	PT
Pancreatic carcinoma metastatic	10033610	PT
Pancreatic carcinoma recurrent	10033613	PT
Pancreatic carcinoma stage 0	10059320	PT
Pancreatic carcinoma stage I	10059321	PT
Pancreatic carcinoma stage II	10059322	PT
Pancreatic carcinoma stage III	10059323	PT
Pancreatic carcinoma stage IV	10059326	PT
Pancreatic neuroendocrine tumour	10067517	PT
Pancreatic neuroendocrine tumour metastatic	10068909	PT
Pancreatic sarcoma	10055006	PT
Pancreatoblastoma	10073367	PT
Papillary renal cell carcinoma	10078493	PT
Papillary serous endometrial carcinoma	10033700	PT
Papillary thyroid cancer	10033701	PT
Paraganglion neoplasm malignant	10033791	PT
Paranasal sinus and nasal cavity malignant neoplasm	10061909	PT
Paranasal sinus and nasal cavity malignant neoplasm recurrent	10033855	PT
Paranasal sinus and nasal cavity malignant neoplasm stage 0	10033856	PT
Paranasal sinus and nasal cavity malignant neoplasm stage I	10033857	PT
Paranasal sinus and nasal cavity malignant neoplasm stage II	10033858	PT
Paranasal sinus and nasal cavity malignant neoplasm stage III	10033859	PT
Paranasal sinus and nasal cavity malignant neoplasm stage IV	10033860	PT
Parathyroid tumour malignant	10033965	PT
Penile cancer	10034299	PT
Penile squamous cell carcinoma	10059631	PT
Penis carcinoma metastatic	10034329	PT
Penis carcinoma recurrent	10034331	PT
Penis carcinoma stage I	10034332	PT
Penis carcinoma stage II	10034333	PT
Penis carcinoma stage III	10034334	PT
Penis carcinoma stage IV	10034335	PT
Pericardial mesothelioma malignant	10073066	PT
Pericardial mesothelioma malignant recurrent	10034480	PT
Peripheral nerve sheath tumour malignant	10034590	PT
Peripheral neuroepithelioma of bone	10061342	PT
Peripheral neuroepithelioma of bone metastatic	10034603	PT

Name	Code	Level
Peripheral neuroepithelioma of bone recurrent	10034605	PT
Peripheral neuroepithelioma of soft tissue	10057646	PT
Peripheral primitive neuroectodermal bone tumour	10073107	PT
Peripheral primitive neuroectodermal tumour of soft tissue	10073144	PT
Peritoneal carcinoma metastatic	10068974	PT
Peritoneal mesothelioma malignant	10056558	PT
Peritoneal mesothelioma malignant recurrent	10034671	PT
Peritoneal sarcoma	10051949	PT
Phaeochromocytoma malignant	10051710	PT
Pharyngeal cancer	10034811	PT
Pharyngeal cancer metastatic	10055104	PT
Pharyngeal cancer recurrent	10034813	PT
Pharyngeal cancer stage 0	10034814	PT
Pharyngeal cancer stage I	10034815	PT
Pharyngeal cancer stage II	10034816	PT
Pharyngeal cancer stage III	10034817	PT
Pharyngeal cancer stage IV	10034818	PT
Pilomatrix carcinoma	10075614	PT
Pineal germinoma	10035052	PT
Pineal parenchymal neoplasm malignant	10061537	PT
Pinealoblastoma	10050487	PT
Pituitary cancer metastatic	10055106	PT
Pituitary neoplasm malignant recurrent	10057838	PT
Pleomorphic liposarcoma	10073138	PT
Pleomorphic malignant fibrous histiocytoma	10073143	PT
Pleural mesothelioma	10035603	PT
Pleural mesothelioma malignant	10059518	PT
Pleural mesothelioma malignant recurrent	10035607	PT
Pleural sarcoma	10051950	PT
Pleuropulmonary blastoma	10080682	PT
Poorly differentiated thyroid carcinoma	10076603	PT
Porocarcinoma	10063609	PT
Postcricoid cancer	10036334	PT
Primary pulmonary melanoma	10080717	PT
Primitive neuroectodermal tumour	10057846	PT
Primitive neuroectodermal tumour metastatic	10068910	PT
Prostate cancer	10060862	PT
Prostate cancer metastatic	10036909	PT
Prostate cancer recurrent	10036911	PT
Prostate cancer stage 0	10036912	PT
Prostate cancer stage I	10036917	PT
Prostate cancer stage II	10036918	PT
Prostate cancer stage III	10036919	PT
Prostate cancer stage IV	10036920	PT

Name	Code	Level
Pseudosarcoma	10051807	PT
Queyrat erythroplasia	10037732	PT
Rectal adenocarcinoma	10038019	PT
Rectal cancer	10038038	PT
Rectal cancer metastatic	10055097	PT
Rectal cancer recurrent	10038046	PT
Rectal cancer stage 0	10038047	PT
Rectal cancer stage I	10038048	PT
Rectal cancer stage II	10038049	PT
Rectal cancer stage III	10038050	PT
Rectal cancer stage IV	10038051	PT
Rectosigmoid cancer	10038086	PT
Rectosigmoid cancer metastatic	10069728	PT
Rectosigmoid cancer recurrent	10038094	PT
Rectosigmoid cancer stage 0	10038095	PT
Rectosigmoid cancer stage I	10038096	PT
Rectosigmoid cancer stage II	10038097	PT
Rectosigmoid cancer stage III	10038098	PT
Rectosigmoid cancer stage IV	10038099	PT
Recurrent cancer	10038111	PT
Refractory cancer	10070308	PT
Renal cancer	10038389	PT
Renal cancer metastatic	10050018	PT
Renal cancer recurrent	10038390	PT
Renal cancer stage I	10038391	PT
Renal cancer stage II	10038392	PT
Renal cancer stage III	10038393	PT
Renal cancer stage IV	10038394	PT
Renal cell carcinoma	10067946	PT
Renal cell carcinoma recurrent	10038410	PT
Renal cell carcinoma stage I	10038411	PT
Renal cell carcinoma stage II	10038412	PT
Renal cell carcinoma stage III	10038413	PT
Renal cell carcinoma stage IV	10038414	PT
Respiratory tract carcinoma in situ	10038724	PT
Retinal melanoma	10038878	PT
Retinoblastoma	10038916	PT
Retroperitoneal cancer	10038977	PT
Retroperitoneal neoplasm metastatic	10062485	PT
Rhabdoid tumour	10073334	PT
Rhabdoid tumour of the kidney	10039019	PT
Rhabdomyosarcoma	10039022	PT
Rhabdomyosarcoma recurrent	10039027	PT
Round cell liposarcoma	10073139	PT

Name	Code	Level
Salivary gland cancer	10061934	PT
Salivary gland cancer recurrent	10039398	PT
Salivary gland cancer stage 0	10039399	PT
Salivary gland cancer stage I	10039400	PT
Salivary gland cancer stage II	10039401	PT
Salivary gland cancer stage III	10039402	PT
Salivary gland cancer stage IV	10039403	PT
Sarcoma	10039491	PT
Sarcoma metastatic	10068595	PT
Sarcoma of skin	10039495	PT
Sarcoma uterus	10039497	PT
Sarcomatoid carcinoma	10080324	PT
Sarcomatoid mesothelioma	10073065	PT
Sarcomatosis	10039500	PT
Scrotal cancer	10039744	PT
Sebaceous carcinoma	10068784	PT
Second primary malignancy	10039801	PT
Seminoma	10039956	PT
Serous cystadenocarcinoma ovary	10054913	PT
Signet-ring cell carcinoma	10057266	PT
Sinus cancer metastatic	10055105	PT
Skin angiosarcoma	10072891	PT
Skin cancer	10040808	PT
Skin cancer metastatic	10055115	PT
Skin squamous cell carcinoma metastatic	10077314	PT
Small cell carcinoma	10041056	PT
Small cell carcinoma of the cervix	10041057	PT
Small cell lung cancer	10041067	PT
Small cell lung cancer extensive stage	10041068	PT
Small cell lung cancer limited stage	10041069	PT
Small cell lung cancer metastatic	10059514	PT
Small cell lung cancer recurrent	10041070	PT
Small intestine adenocarcinoma	10073373	PT
Small intestine carcinoma	10054184	PT
Small intestine carcinoma metastatic	10041121	PT
Small intestine carcinoma recurrent	10041124	PT
Small intestine carcinoma stage 0	10059368	PT
Small intestine carcinoma stage I	10059369	PT
Small intestine carcinoma stage II	10059370	PT
Small intestine carcinoma stage III	10059371	PT
Small intestine carcinoma stage IV	10059372	PT
Small intestine leiomyosarcoma	10041127	PT
Soft tissue sarcoma	10075333	PT
Solid pseudopapillary tumour of the pancreas	10069345	PT

Name	Code	Level
Spermatocytic seminoma	10073118	PT
Spinal meningioma malignant	10041580	PT
Spindle cell sarcoma	10049067	PT
Squamous cell breast carcinoma	10079307	PT
Squamous cell carcinoma	10041823	PT
Squamous cell carcinoma of head and neck	10060121	PT
Squamous cell carcinoma of lung	10041826	PT
Squamous cell carcinoma of pharynx	10066471	PT
Squamous cell carcinoma of skin	10041834	PT
Squamous cell carcinoma of the cervix	10041848	PT
Squamous cell carcinoma of the hypopharynx	10041849	PT
Squamous cell carcinoma of the oral cavity	10041857	PT
Squamous cell carcinoma of the tongue	10041865	PT
Squamous cell carcinoma of the vagina	10041866	PT
Squamous cell carcinoma of the vulva	10041875	PT
Squamous endometrial carcinoma	10041883	PT
Stewart-Treves syndrome	10059498	PT
Superficial spreading melanoma stage I	10042549	PT
Superficial spreading melanoma stage II	10042550	PT
Superficial spreading melanoma stage III	10042551	PT
Superficial spreading melanoma stage IV	10042552	PT
Superficial spreading melanoma stage unspecified	10042553	PT
Synovial sarcoma	10042863	PT
Synovial sarcoma metastatic	10042864	PT
Synovial sarcoma recurrent	10042867	PT
Testicular cancer metastatic	10055103	PT
Testicular choriocarcinoma	10062122	PT
Testicular choriocarcinoma recurrent	10069812	PT
Testicular choriocarcinoma stage I	10043303	PT
Testicular choriocarcinoma stage II	10043304	PT
Testicular choriocarcinoma stage III	10043305	PT
Testicular embryonal carcinoma	10062123	PT
Testicular embryonal carcinoma stage I	10043309	PT
Testicular embryonal carcinoma stage II	10043310	PT
Testicular embryonal carcinoma stage III	10043311	PT
Testicular germ cell cancer	10061378	PT
Testicular germ cell cancer metastatic	10068694	PT
Testicular germ cell tumour mixed	10073119	PT
Testicular germ cell tumour mixed stage I	10043331	PT
Testicular germ cell tumour mixed stage II	10043332	PT
Testicular germ cell tumour mixed stage III	10043333	PT
Testicular leiomyosarcoma	10057340	PT
Testicular malignant teratoma	10073120	PT
Testicular malignant teratoma stage I	10043339	PT

Name	Code	Level
Testicular malignant teratoma stage II	10043340	PT
Testicular malignant teratoma stage III	10043341	PT
Testicular seminoma (pure)	10062124	PT
Testicular seminoma (pure) stage I	10043350	PT
Testicular seminoma (pure) stage II	10043351	PT
Testicular seminoma (pure) stage III	10043352	PT
Testicular yolk sac tumour	10073121	PT
Testicular yolk sac tumour stage I	10043357	PT
Testicular yolk sac tumour stage II	10043358	PT
Testicular yolk sac tumour stage III	10043359	PT
Testis cancer	10057644	PT
Testis cancer recurrent	10069813	PT
Throat cancer	10043515	PT
Thyroid cancer	10066474	PT
Thyroid cancer metastatic	10055107	PT
Thyroid cancer recurrent	10072162	PT
Thyroid cancer stage 0	10070567	PT
Thyroid cancer stage I	10071027	PT
Thyroid cancer stage II	10071028	PT
Thyroid cancer stage III	10071029	PT
Thyroid cancer stage IV	10071030	PT
Tongue cancer metastatic	10055109	PT
Tongue cancer recurrent	10071251	PT
Tongue carcinoma stage 0	10058429	PT
Tongue carcinoma stage I	10058430	PT
Tongue carcinoma stage II	10058431	PT
Tongue carcinoma stage III	10058432	PT
Tongue carcinoma stage IV	10058433	PT
Tongue neoplasm malignant stage unspecified	10043966	PT
Tonsil cancer	10044002	PT
Tonsil cancer metastatic	10072792	PT
Tracheal cancer	10044285	PT
Transitional cell cancer of renal pelvis and ureter metastatic	10044406	PT
Transitional cell cancer of the renal pelvis and ureter	10044407	PT
Transitional cell cancer of the renal pelvis and ureter localised	10044408	PT
Transitional cell cancer of the renal pelvis and ureter recurrent	10044410	PT
Transitional cell cancer of the renal pelvis and ureter regional	10044411	PT
Transitional cell carcinoma	10044412	PT
Transitional cell carcinoma metastatic	10071080	PT
Transitional cell carcinoma recurrent	10077051	PT
Transitional cell carcinoma urethra	10044426	PT
Trichoblastic carcinoma	10080660	PT
Triple negative breast cancer	10075566	PT
Tubular breast carcinoma	10073104	PT

Name	Code	Level
Tumour budding	10076969	PT
Undifferentiated carcinoma of colon	10073362	PT
Undifferentiated nasopharyngeal carcinoma	10073328	PT
Undifferentiated sarcoma	10045515	PT
Ureteric cancer	10046392	PT
Ureteric cancer local	10046393	PT
Ureteric cancer metastatic	10046394	PT
Ureteric cancer recurrent	10046396	PT
Ureteric cancer regional	10046397	PT
Urethral cancer	10046431	PT
Urethral cancer metastatic	10046433	PT
Urethral cancer recurrent	10046435	PT
Urethral melanoma metastatic	10072793	PT
Urinary bladder sarcoma	10051690	PT
Urinary tract carcinoma in situ	10061396	PT
Uterine cancer	10046766	PT
Uterine carcinoma in situ	10046770	PT
Uterine leiomyosarcoma	10046799	PT
Vaginal adenocarcinoma	10065349	PT
Vaginal cancer	10046885	PT
Vaginal cancer metastatic	10046887	PT
Vaginal cancer recurrent	10046889	PT
Vaginal cancer stage 0	10046890	PT
Vaginal cancer stage I	10046891	PT
Vaginal cancer stage II	10046892	PT
Vaginal cancer stage III	10046893	PT
Vaginal cancer stage IVA	10046894	PT
Vaginal cancer stage IVB	10046895	PT
Vulval cancer	10047741	PT
Vulval cancer metastatic	10047742	PT
Vulval cancer recurrent	10047744	PT
Vulval cancer stage 0	10047745	PT
Vulval cancer stage I	10047746	PT
Vulval cancer stage II	10047747	PT
Vulval cancer stage III	10047748	PT
Vulval cancer stage IV	10047749	PT
Vulvar adenocarcinoma	10063536	PT
Epstein Barr virus positive mucocutaneous ulcer	10079386	PT
Epstein-Barr virus associated lymphoproliferative disorder	10068349	PT
Good syndrome	10079838	PT
Haematopoietic neoplasm	10061187	PT
Langerhans' cell histiocytosis	10069698	PT
Large granular lymphocytosis	10023791	PT
Lymphatic system neoplasm	10062044	PT

Name	Code	Level
Lymphoproliferative disorder	10061232	PT
Lymphoproliferative disorder in remission	10061233	PT
Myeloproliferative neoplasm	10077465	PT
Neoplasm of thymus	10056296	PT
Post transplant lymphoproliferative disorder	10051358	PT
Splenic neoplasm malignancy unspecified	10053190	PT
Thymoma	10043670	PT
Abdominal neoplasm	10060925	PT
Abdominal wall neoplasm	10061610	PT
ACTH-producing pituitary tumour	10000613	PT
Adrenal neoplasm	10061588	PT
Anal neoplasm	10061629	PT
APUDoma	10003069	PT
Astroblastoma	10079366	PT
Atypical fibroxanthoma	10064755	PT
Biliary neoplasm	10004668	PT
Bladder neoplasm	10005056	PT
Bone giant cell tumour	10005969	PT
Bone neoplasm	10005995	PT
Borderline mucinous tumour of ovary	10073266	PT
Borderline ovarian tumour	10006032	PT
Borderline serous tumour of ovary	10073267	PT
Brain neoplasm	10061019	PT
Brain teratoma	10068394	PT
Breast neoplasm	10006279	PT
Brenner tumour	10073258	PT
Bronchial neoplasm	10052245	PT
Cardiac neoplasm unspecified	10051549	PT
Cardiac teratoma	10057456	PT
Carotid body tumour	10007690	PT
Cartilage neoplasm	10061746	PT
Central nervous system neoplasm	10007958	PT
Cerebellar tumour	10061750	PT
Cerebellopontine angle tumour	10069726	PT
Cervix neoplasm	10008354	PT
Chest wall tumour	10072960	PT
Choroid neoplasm	10057405	PT
Colon neoplasm	10061045	PT
Congenital neoplasm	10078557	PT
Congenital teratoma	10052012	PT
Conjunctival neoplasm	10057406	PT
Conjunctival primary acquired melanosis	10066925	PT
Connective tissue neoplasm	10061088	PT
Diaphragm neoplasm	10051932	PT

Name	Code	Level
Duodenal neoplasm	10061825	PT
Dysplastic naevus syndrome	10013960	PT
Ear neoplasm	10055016	PT
Endocrine neoplasm	10061121	PT
Endometrial neoplasm	10014759	PT
Ependymoma	10014967	PT
Epididymal neoplasm	10069101	PT
Extradural neoplasm	10058955	PT
Eyelid tumour	10050497	PT
Fallopian tube neoplasm	10061855	PT
Female reproductive neoplasm	10061153	PT
Gallbladder neoplasm	10073072	PT
Gastric neoplasm	10061968	PT
Gastrinoma	10017852	PT
Gastrointestinal neoplasm	10061174	PT
Gastrointestinal stromal tumour	10051066	PT
Gastrointestinal submucosal tumour	10072581	PT
Genitourinary tract neoplasm	10061183	PT
Germ cell neoplasm	10075292	PT
Granular cell tumour	10060980	PT
Granulosa cell tumour of the testis	10078131	PT
Growth hormone-producing pituitary tumour	10018758	PT
Hepatic neoplasm	10019695	PT
Hepatobiliary neoplasm	10061203	PT
Hormone-secreting ovarian tumour	10020391	PT
Hypopharyngeal neoplasm	10056305	PT
Insulinoma	10022498	PT
Iris neoplasm	10057412	PT
Joint neoplasm	10078144	PT
Lacrimal duct neoplasm	10057408	PT
Laryngeal neoplasm	10023841	PT
Lip neoplasm	10062038	PT
Lung neoplasm	10062042	PT
Male reproductive tract neoplasm	10061236	PT
Maxillofacial sinus neoplasm	10026956	PT
Mediastinum neoplasm	10027086	PT
Meningeal neoplasm	10061282	PT
Mesenteric neoplasm	10072025	PT
Mesothelioma	10027406	PT
Mueller's mixed tumour	10066057	PT
Muscle neoplasm	10070956	PT
Nasal neoplasm	10060768	PT
Neoplasm	10028980	PT
Neoplasm of appendix	10056288	PT

Name	Code	Level
Neoplasm of cornea unspecified malignancy	10052903	PT
Neoplasm of orbit	10061863	PT
Neoplasm prostate	10029096	PT
Neoplasm recurrence	10061864	PT
Neoplasm skin	10029098	PT
Nervous system neoplasm	10061311	PT
Neuroectodermal neoplasm	10056672	PT
Neurogenic tumour	10080963	PT
Neurotensinoma	10029341	PT
Nipple neoplasm	10056286	PT
Non-secretory adenoma of pituitary	10029556	PT
Ocular neoplasm	10052448	PT
Oesophageal neoplasm	10061882	PT
Optic nerve neoplasm	10053645	PT
Oral neoplasm	10061325	PT
Oropharyngeal neoplasm	10057444	PT
Ovarian germ cell tumour	10075812	PT
Ovarian granulosa cell tumour	10073260	PT
Ovarian neoplasm	10061535	PT
Ovarian Sertoli-Leydig cell tumour	10073270	PT
Ovarian theca cell tumour	10073261	PT
Pancreatic neoplasm	10061902	PT
Paraganglion neoplasm	10061332	PT
Paranasal sinus neoplasm	10057448	PT
Parathyroid tumour	10033963	PT
Pelvic neoplasm	10061336	PT
Penile neoplasm	10061913	PT
Pericardial neoplasm	10054945	PT
Peripheral nervous system neoplasm	10062069	PT
Peritoneal neoplasm	10061344	PT
Phaeochromocytoma	10034800	PT
Pharyngeal neoplasm	10062075	PT
Phyllodes tumour	10071776	PT
Pineal neoplasm	10061348	PT
Pinealoma	10035057	PT
Pituitary tumour	10035104	PT
Pituitary tumour recurrent	10057316	PT
Placental neoplasm	10061349	PT
Pleomorphic adenoma	10073372	PT
Pleural neoplasm	10061352	PT
Prolactin-producing pituitary tumour	10036831	PT
Rectal neoplasm	10062099	PT
Renal neoplasm	10061482	PT
Respiratory tract neoplasm	10061486	PT

Name	Code	Level
Retinal neoplasm	10057407	PT
Retro-orbital neoplasm	10038956	PT
Retroperitoneal neoplasm	10056664	PT
Salivary gland neoplasm	10061497	PT
Secretory adenoma of pituitary	10039893	PT
Sertoli cell testicular tumour	10073117	PT
Skin neoplasm bleeding	10060712	PT
Smooth muscle cell neoplasm	10062253	PT
Soft tissue neoplasm	10068771	PT
Somatostatinoma	10041329	PT
Spinal cord neoplasm	10062261	PT
Tendon neoplasm	10061377	PT
Teratoma	10043276	PT
Testicular germ cell tumour	10075811	PT
Testicular neoplasm	10061379	PT
Thyroid neoplasm	10043744	PT
Thyroid stimulating hormone-producing pituitary tumour	10043772	PT
Tongue neoplasm	10062129	PT
Tonsillar neoplasm	10062131	PT
Tracheal neoplasm	10062133	PT
Tumour of ampulla of Vater	10073851	PT
Ureteral neoplasm	10062221	PT
Urethral neoplasm	10062223	PT
Urinary tract neoplasm	10061398	PT
Uterine neoplasm	10046803	PT
Vaginal neoplasm	10062165	PT
Vascular neoplasm	10055031	PT
Vipoma	10047430	PT
Vocal cord neoplasm	10057038	PT
Vulval neoplasm	10062135	PT
Yolk sac tumour site unspecified	10048251	PT
Dysplastic naevus	10062805	PT

18.6 AESI: Malignancies

Events pertaining to PTs from MedDRA SMQ “Malignant or unspecified tumors” with rationales for inclusion/exclusion in the AESIs Malignancies.

Original Study Identifier	Subject Identifier (SUBJID)	Unique Subject Identifier (USUBJID)	Study Identifier for AE Occurrence (STUDYID)	Reported Term (AETERM)	Dictionary-Derived Term (AEDECOD)	Start Date/Time of Adverse Event (AESTDTC)	End Date/Time of Adverse Event (AEENDTC)	Severity/Intensity (AESEV)	Reported Causality (AEREL)	Outcome of Adverse Event (AEOUT)	SMQ Malignant or unspecified tumors	AESI = Malignant tumors	Rationale for exclusion	Data Source
---------------------------	-----------------------------	-------------------------------------	--	------------------------	-----------------------------------	--	--	----------------------------	----------------------------	----------------------------------	-------------------------------------	-------------------------	-------------------------	-------------

PPD

[Redacted]

PPD



PPD



PPD



PPD



PPD



PPD



ELECTRONIC SIGNATURES

Document: emr700568-012-integrated analysis plan-text-final-v1

Signed By	Event Name	Meaning of Signature	Server Date (dd-MMM-yyyy HH:mm 'GMT'Z)
PPD	Task Completed (Approval eSign): Approved	Business Approval	11/22/2018 02:15:01

████████████████████
████████████████████

████████████████████
████████████████████